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Abstract
This thesis describes the study of the synthesis and biological evaluation of
analogues of the kigamicin natural products. Chapter One gives a background to
pancreatic cancer and explains the anti-austerity strategy for new therapeutics. It
then describes the kigamicins and their biological activity, focusing on why they are
thought to be clinically applicable. Other structurally related, tetrahydroxanthone
containing, natural products are also discussed.
Chapter Two focuses on the synthesis of the tetrahydroxanthone nucleus. Existing
methodology is initially utilised, before exploring formation of the
tetrahydroxanthone using milder, metal catalysed routes. Copper and palladium are
both explored for this transformation and an underlying uncatalysed process is
revealed and fully investigated. This methodology is extended to tandem catalysis
for the synthesis of 7-arylated tetrahydroxanthones through combination of this
chemistry with Suzuki-Miyaura couplings. Examples of Sonogashira and Heck
couplings as well as alternative substitution patterns, are also presented.
Chapter Three discusses the attempted synthesis of the fused rings of the
kigamicins. Our efforts towards suitable substrates are detailed.
Chapter Four outlines the anti-austerity assays established to evaluate the potency
and selectivity of analogues synthesised in Chapter Two. Kigamicin C is tested in
this assay to compare with literature values and validate our assay. The potency and
selectivity of our analogues are reported and compared to the natural product. The
anti-austerity effect of kibdelone C and analogues, is investigated for the first time.
Attempted isolation of the natural product is also described.
Chapter Five details the experimental procedures and characterisation data for the
novel compounds produced.
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1.1 Introduction
This thesis is focused on the kigamicin natural products (Figure 1.1) which have
shown potent cytotoxicity against pancreatic cancer, and more specifically my work
has focused on the synthesis and bioactivity of the tetrahydroxanthone core.
Figure 1.1: Kigamicins A-E
A significant focus of this project has been the synthesis of analogues of this
natural product and the assessment of their biological activity. As such, it is
important to begin with an introduction to pancreatic cancer and why the
kigamicins provide such an exciting new avenue of research for treatment of this
disease. This will be followed by a detailed description of the kigamicins and their
biological activity before reviewing other structurally similar natural products.
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1.2 Pancreatic Cancer
1.2.1 Introduction
Pancreatic cancer is the fourth deadliest cancer worldwide, claiming 30,000 lives in
the US and 40,000 lives in Europe every year.1-3 Complete remission from any form
of pancreatic cancer is extremely rare and the prognosis for people with the disease
is dismal with a survival rate of only 24% after one year and only 3-5% after five
years,3 with the median survival being only 6 months.4 One of the key reasons for
such a poor prognosis is the late diagnosis of this disease, which is predominantly
due to lack of symptoms until very late stage in the cancer progression.5 These
symptoms include weight loss, back pain and jaundice which is caused by the
blockage of the bile ducts in the pancreas by the tumour.6,7 It is acknowledged that
metastases occur in the early stages of the cancer5,8 with almost 100% of patients
presenting with metastases during the course of the disease.1 More significantly,
85% of patients have metastases at the time of diagnosis rendering medical
intervention ineffective.9
Increasing age is a key risk factor in the development of pancreatic cancer with the
majority of diagnoses made in people over the age of 65.5,7 Dietary factors have
also been associated with the onset of pancreatic cancer. Larsson et al10 recently
reported that an increased consumption of processed meats could be a risk factor for
pancreatic cancer and an increased consumption of red meat could also be a risk
factor in men. It has been suggested that there is no link between alcohol or coffee
consumption and pancreatic cancer, whereas a decreased risk has been linked to an
increase in vegetable consumption.11-14 Smoking is a major associated risk factor of
pancreatic cancer with a reported 25-29% of pancreatic cancer caused by
smoking.1,11 It has been found that 80% of people with pancreatic cancer have
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diabetes but there remains some controversy in the literature as to whether diabetes
is actually a risk factor for pancreatic cancer or whether pancreatic cancer causes
diabetes.15 Genetic factors are also thought to play a part. A family history of
pancreatic cancer has been associated with onset of this disease with 10% of
pancreatic cancer sufferers reporting at least one other family member with the
disease.16
1.2.2 Current therapeutics
The only curative treatment is surgery, although in the vast majority of cases, at the
time of diagnosis, the cancer has progressed too far for this to be a viable option.
Only 9-15% of people diagnosed are eligible for this surgery.7 Even in those cases
where surgery is undertaken, most patients subsequently relapse with metastases.5
Historically, 5-fluorouracil (Figure 1.2) was the main chemotherapy drug but it
showed little selectivity, targeting DNA replication and therefore many side effects
were suffered, including alopecia, nausea and severe fatigue.17 In 1996,
gemcitabine (Figure 1.2) was launched18 and has subsequently replaced 5-
fluorouracil in many cases. Despite providing only a modest improvement in
median survival time (an additional month), it offers an improvement in quality of
life for patients, reducing levels of pain experienced in the later stages of the
disease.19
Figure 1.2: Structures of 5-fluorouracil20 (6) and gemcitabine21 (7)
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There has been very little progress in the development of new treatments for
pancreatic cancer since the discovery of gemcitabine and consequently gemcitabine
remains the main chemotherapy drug for the treatment of pancreatic cancer. A
substantial number of investigations into the use of combination therapies have
been carried out, including many phase III clinical trials. However, many of these
did not provide a significant elongation of life expectancy or quality of life, and
were therefore not approved for use.22-29 A combination of erlotinib with
gemcitabine has been shown to provide a marginal improvement.30 In 2011, Conroy
et al31 reported studies comparing a new combination therapy FOLFIRINOX (a
cocktail of 5-fluorouracil, oxaliplatin, leucovorin and irinotecan, Figure 1.3) to
gemcitabine. They found that despite a higher incidence of adverse effects, there
was a much higher median survival time (11.1 months compared with 6.8 months
for gemcitabine) and the time before definitive degradation of quality of life was
also extended.
Figure 1.3: FOLFIRINOX; 5-fluorouracil20 (6), leucovorin32 (8),
oxaliplatin33 (9) and irinotecan34 (10)
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Therapy which is gaining more clinical interest is that of high intensity focused
ultrasound (HIFU). This is a non-invasive technique, where ultrasound is focused at
a set depth and area, targeted at the site of the tumour and heated above the
temperature of protein denaturisation. This allows the target tumour tissue to be
thermally destroyed, leaving the surrounding tissue intact.35 This has shown
promise for the treatment of a number of cancers, particularly prostrate cancer.
However, severe side effects have been reported in patients involved in studies for
the use of HIFU on pancreatic cancer. In a study carried out by Han et al in 2011,36
they reviewed the medical records for patients with pancreatic cancer, treated with
HIFU between 2006 and 2008. They reported that 100% of patients suffered pain in
the treated area and oedema. Major complications included fistula formation
between the tumour and duodenum and third degree burns. A study by Hwang et al
in 200937 showed fewer complications with only 3.4% of patients suffering second
degree burns and 6.7% with subcutaneous sclerosis. Despite a lack of side effects,
no patients had a complete response to therapy and only 14.6% had a partial
response, with the remaining patients showing no change or cancer progression.
1.2.3 New anti-austerity approach
Despite small improvements being made in the prognosis for patients with
pancreatic cancer, the overall prognosis and quality of life is still very poor. It is
clear that new drugs and therapies are needed in order for significant advance.
Due to the rapid and uncontrolled growth of tumour cells, their microenvironment is
often characterised as hypoxic and nutrient deficient with a lack of organised
vasculature.38 There are two main ways that these stressed cancer cells can survive;
the first is by angiogenesis, the growth of new vasculature, and the second is by
Chapter 1: Introduction
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acquiring a tolerance to these relatively austere conditions.39 Anti-angiogenesis
therapies have received a lot of attention40-43 however hypovascular tumours are
particularly common in pancreatic cancer, as angiogenesis provides inadequate
vasculature for tumour cells.44,45 In 2000, Esumi et al46 carried out studies, whereby
they exposed pancreatic cancer cell lines to nutrient deprived conditions (no serum,
amino acids or glucose) and observed that there was greater than 50 % cell survival
after 48 h. This suggests that many pancreatic cancer cells have a tolerance to such
austere conditions. Removing a cancer cell’s ability to tolerate these conditions,
would have a dramatic effect on cell survival. If a drug could selectively kill cells
under nutrient deprived conditions, then it would likely be selective to cancer as
normal cells are seldom subjected to these conditions.47 Such an approach to
chemotherapy has been described as ‘anti-austerity’.
Park et al48 published research in 2009 carried out on Ponciri Fructus, an active
component of a herbal medicine source. They tested the extracts using a lactate
dehydrogenase assay against the PANC-1 cell line and observed selective
cytotoxicity for cells under glucose deprived conditions.
Kadota et al39 also used this strategy and screened the methanol extract of red
propolis collected from Brazil against PANC-1 cells. This extract showed 100%
selective cytotoxicity against cells under nutrient deprived conditions and their
research describes the isolation of three new active component compounds (Figure
1.4).
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Figure 1.4: New active compounds isolated form red propolis
Interestingly two new flavones (14 and 15) isolated from extracts of Mexican
propolis also exhibited similar selective cytotoxicity as described by Tezuka et al
(Figure 1.5).49
Figure 1.5: New active flavones
Other natural products exhibiting preferential cytotoxic effects include the
kayeassamins,50 kigamicins,51 panduratins,52 and arctigenin.53 The kigamicins have
been the focus of this project and their significance is highlighted below.
1.3 Kigamicins
1.3.1 Introduction
The kigamicins are a group of five polycyclic natural products differing only in the
length of the oligosaccharide attached to the aglycone (Figure 1.6).
Their discovery, isolation, structure determination and biological activity are
described below. The rings of the natural products have been labelled A-H, and the
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backbone numbered as indicated. This nomenclature and numbering convention
will be used when describing portions of the natural product in later chapters.
Figure 1.6: Structure of the kigamicins
1.3.2 Discovery and isolation
The kigamicins were discovered in 2003 by Kunimoto et al51 by the screening of
over 2000 actinomycete culture media against pancreatic cancer cells. The culture
media were screened in both Dulbecco’s modified Eagles medium (DMEM)
supplemented with foetal bovine serum and nutrient deprived medium (NDM).
Those samples that exhibited potent and selective cytotoxicity in NDM were subject
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to further investigation, as this indicated activity by an anti-austerity mechanism.
One strain of active bacteria was identified as ML630-mF1.
ML630-mF1 was observed growing on various media and the physical properties
probed in great detail. Partial DNA sequencing was also used in order to identify
the bacteria as belonging to the genus Amycolatopsis. The organic phase isolated
from production culture of this organism was purified using column
chromatography. Further reverse phase chromatography and HPLC purification
provided the five kigamicins. From a 12 L culture broth, kigamicin A (25.8 mg),
kigamicin C (31.6 mg), kigamicin D (85.3 mg) and kigamicin E (19.4 mg) were
isolated. Kigamicin B (4.1 mg) was isolated from a separate 3 L broth.
1.3.3 Structure determination and absolute configuration
Having isolated the natural products, Kunimoto and coworkers54 set out to
determine their structure. HRMS was used initially to establish the molecular
formula of these compounds and were determined to be as follows: C34H35NO13,
MW 665 (kigamicin A), C40H45NO15, MW 779 (kigamicin B), C41H47NO16, MW
809 (kigamicin C), C48H59NO19, MW 953 (kigamicin D) and C55H71NO22, MW
1097 (kigamicin E). Their UV absorbances were all very similar and absorption
bands at 227, 253, 306 and 384 nm indicated the presence of a polycyclic xanthone
chromophore. Infra-red helped confirm the presence of hydroxyl, carbonyl and γ-
pyrone moieties.
The 1H NMR, 13C NMR, DEPT, HMQC, HMBC and COSY spectra of all five
structures were the same in all but the oligosaccharide that they contained. The 48
signals in the 13C NMR and DEPT of kigamicin D included 6 methyl, 10
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methylene, 16 methine and 16 quaternary carbons. The 1H NMR showed 5
deuterium exchangeable protons (δ 2.45, 4.53, 5.22, 12.58 and 13.01 ppm) and 
based on their shifts, two of these were established as phenolic protons. The
information obtained from the COSY and HMBC confirmed the structure of the
aglycone with 7 spin systems observed in the COSY as well as some longer range
couplings. Further evidence was provided for the structure of the H ring of the
kigamicins by 1H-15N NMR which revealed coupling from the 15N signal to the
methylene and methyl groups associated with that ring. Evidence from the HMQC
indicated the location of the glycosidic linkage and further support for this was
provided by NOE experiments.
The absolute configuration of the kigamicins was established by Someno et al in
2005.55 The determination of absolute configuration was accomplished using a
combination of x-ray crystallography and degradation studies. A single crystal x-ray
of kigamicin A was achieved and from this the relative stereochemistry deduced.
Hydrolysis of this material by treatment with 1N HCl in THF at room temperature
for 18 h, provided aglycone 17 and amicetose fragment 16 (Scheme 1.1). The
optical rotation of the isolated amicetose ([α]D
22 +42.5° (c 0.7, Me2CO)) agreed
with literature values for D-amicetose ([α]D22 +43.6° (c 1.0, Me2CO)). From these
studies both the relative and absolute configuration of kigamicin A could be
unambiguously established.
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Scheme 1.1: Hydrolysis of kigamicin A
Kigamicins C and D were also hydrolysed into their aglycone and oligosaccharide
components. Crystal structures were obtained of the di and tri-saccharides and the
aglycones were determined to be identical to 17 from hydrolysis of kigamicin A in
all spectroscopic properties. From these studies, the structures of these natural
products have been fully established.
1.3.4 Biological activity
Initial screening by Kunimoto et al in 200351 when they first isolated the
compounds, showed that the kigamicins exhibited both anti-cancer and anti-
microbial properties. All five kigamicins inhibited Gram-positive bacteria including
MRSA but showed no activity against Gram-negative bacteria. Perhaps more
interestingly, the kigamicins all exhibited potent activity against pancreatic cancer
(PANC-1) cells under nutrient deprived conditions; 100-fold more potent than
under normal conditions.
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Lu et al47 reported kigamicin D to have an IC50 of 85 ng/mL in NDM,
demonstrating no activity at all in DMEM at any concentration tested (up to 10
µg/mL). These initial results were observed after 24 h incubation with kigamicin D.
However, the authors also tested the cytotoxic effects of kigamicin over time and
found that at 0.1 µg/mL there was total cell death after only 6 h. The authors
examined which components of the nutrient rich media were responsible for the
inactivity of kigamicin D. They discovered that when glucose was absent,
kigamicin D had a strong cytotoxic effect, whereas in the presence of glucose,
kigamicin D had little or no effect on cell viability.
In order to determine which mode of cell death the kigamicins were inducing, the
authors treated the cells with kigamicin D under nutrient deprived conditions and
then subjected the cells to Annexin V and propidium iodide (PI) staining. The cells
were then analysed using FACS (fluorescence-activated cell sorting) analysis. They
found that the cells had been stained with PI, clearly showing necrosis of the cells.
Evidence for necrosis was also provided by studies carried out by Hata et al56 also
using flow cytometry. Further analysis of these cells showed degradation of the
cytoplasm, whilst the nucleus remained viable, which is another indicator that the
cells were undergoing necrosis.
Lu et al47 carried out experiments in order to determine if kigamicin D displayed in
vivo cytotoxic effects. They implanted a suspension of PANC-1 cells in DMEM,
subcutaneously into the abdominal wall of five week old nude mice. After two
weeks, mice with a tumour of approximately 5 mm in diameter were divided into a
treatment group and a control group. Kigamicin D was dissolved in DMSO at 10
mg/mL and diluted with saline to a concentration of 15 µg/mL. This solution was
Chapter 1: Introduction
___________________________________________________________________________________________________________________
___________________________________________________________________
25
either force-fed intragastrically or injected into the tumour site six days a week.
Tumour size and body weight were measured on a weekly basis. The results
indicated a reduction of the tumour volume by 41% by subcutaneous administration
of kigamicin D and a reduction by 20% by oral administration with no significant
body weight loss. Other pancreatic cancer cell lines were tested (MIA Paca-2 and
Capan-1) and results showed that kigamicin D also significantly inhibited these cell
lines in vivo.
In order to determine whether kigamicin D had any detrimental effects on other
normal cells, the oesophagus, stomach, lungs, liver and spleen were removed from
the mice treated with kigamicin D. No toxic effects on these organs were observed.
Further evidence was provided by Hata et al56 who showed that lymphocytes were
less susceptible to kigamicin than myeloma cells, supporting the hypothesis that
these compounds could be clinically applicable.
In order to further demonstrate kigamicin D as unique from current therapeutics, the
authors decided to test widely used drugs, in parallel to kigamicin D in both DMEM
and NDM. All drugs tested (vincristine, 5-fluorouracil, taxol, doxorubicin, cisplatin
and camptothecin) showed an inverse selectivity; they showed greater cytotoxic
effects under normal conditions and a very weak effect under austere conditions.
This may contribute to poor patient response using therapeutics for the treatment of
pancreatic cancer.
Masuda et al57 examined the effect of kigamicin D on a range of cancer cells and
also on normal cells. They confirmed the potent activity of kigamicin D on
pancreatic cancer cells with selectivity between NDM and DMEM. Normal cells
such as lung fibroblast and prostrate stromal cells were tested alongside the
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pancreatic cancer cells and a similar trend was found; the cells were relatively
unaffected under normal conditions whereas under nutrient deprived conditions,
toxicity was observed. They also carried out studies of human lung and colon
cancer xenografts in nude mice. Surprisingly, contrary to results found in vitro by
Lu et al,47 kigamicin D showed only a very weak effect on these cancers. Thus
kigamicin D appears to have excellent anti-cancer properties but specifically to
pancreatic cancers, perhaps due to the austere microenvironment surrounding the
pancreatic cancer cells.57
1.3.5 Mechanism of action
The PI3K-Akt pathway (Figure 1.7) has been implicated in the development and
progression of human cancers.56,58,59 It has been shown that in cases of pancreatic
cancer, there is a higher frequency of K-Ras and p53 mutations60 both of which are
believed to upregulate the PI3K-Akt pathway. This could contribute to the
diminished apoptosis of these cells resulting in drug resistance. When gemcitabine
was used in combination with known PI3K inhibitors (Wortmannin and
LY294002), there was an observed increase in the cytotoxic effects of
gemcitabine.59 This provides evidence of the involvement of this pathway in the
progression of the cancer.
PI3K (phosphatidylinositol 3’ kinase) is a lipid kinase and is involved in the
phosphorylation of PIP2 (phosphatidylinositol 4,5-bisphosphate) to provide the
signalling messenger, PIP3 (phosphatidylinositol 3,4,5-bisphosphate) which is
responsible for a cascade of events. PIP3 can bind to Akt thus altering the
conformation of it and allowing it to be phosphorylated by PDPK1 (3-
phosphoinositide dependent protein kinase-1). Once activated, pAkt
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(phosphorylated Akt) has a vast number of roles, perhaps its most pivotal being cell
proliferation and motility.58,61 An increase in the activation of Akt also inhibits
apoptosis and promotes survival of the cells.
PI3K Akt
P
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3
P
IP
2
PTEN
pAkt
Cell survival
Inhibition of apoptosis
Cell growth
Cell proliferation and motility
P
IP
2
PDK1
Figure 1.7: PI3K-Akt pathway61,62
PTEN (phosphatase and tensin homolog) is the main negative regulator of this
pathway, dephosphorylating PIP3 to PIP2 thus keeping the amount of activated Akt
to a normal level. Deletion or mutation of PTEN has been shown in a large number
of studies to be involved in the onset or progression of a number of human cancers
including but not limited to lung,63 thyroid,64,65 breast,66 prostrate67, melanoma68
and lymphoid carcinomas.69
There is data to suggest that kigamicin D blocks the PI3K-Akt pathway evidenced
by the inhibition of expression of phophorylated Akt observed in treated cells.
Chapter 1: Introduction
___________________________________________________________________________________________________________________
___________________________________________________________________
28
Lu et al47 carried out studies to analyse the mechanism of action of kigamicin D in
which they stimulated the phosphorylation of Akt in nutrient deprived cells before
adding kigamicin D. They found that there was significant inhibition of Akt
phosphorylation. They also probed the activation of Akt in vivo. Tumours from
nude mice grown over a period of six weeks, both with and without treatment with
kigamicin D, were excised and subjected to analysis. These results mimicked the
results found in vitro, providing support for the hypothesis that kigamicin D inhibits
the activation of Akt.
These results were supported by Hata et al56 who also observed that there was
diminished expression of phosphorylated Akt after treatment with kigamicin under
conditions of nutrient deprivation. However the authors suggested that it inhibits
more than one pathway and is not specific, as they found that kigamicin also
inhibited the phosphorylation of ERK. The authors noted that kigamicin was found
to induce necrosis, whereas typical ERK inhibitors induce cell death by apoptosis
and so perhaps inhibition of ERK phophorylation was not the cause of kigamicin’s
toxicity under nutrient deprived conditions.
1.4 Structurally Related Natural Products
In order to understand which part of the kigamicins is the active pharmacophore, we
must first examine other structurally related natural products with potent biological
activity. There are a number of polycyclic xanthone containing natural products;
their biological activity and syntheses have been studied extensively.70 Focus here
is on those natural products containing the tetrahydroxanthone nucleus structurally
analogous to the kigamicins but less well studied than their xanthone counterparts.
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1.4.1 Secalonic acids
Secalonic acids A-G (18-24) are an example of dimeric structures often described
as ergochromes for which the tetrahydroxanthone forms a monomeric part of its
dimer-like structure (Figure 1.8). The first isolation of the secalonic acids dates
back to 1906.70 The biological effects of the secalonic acids have been studied, and
in particular, secalonic acid D. Unlike the other natural products described in this
chapter, the secalonic acids have been shown to have adverse biological effects. It
has been shown to induce cleft palette in the offspring of exposed mice.71,72 The
compound has also been shown to have teratogenic effects including skeletal,
ophthalmic and visceral malformations in newly born mice and it has been
proposed that it could cause behavioural dysfunction in neonatal mice.73 Ehrlich et
al74 reported that secalonic acid D from the Penicillium oxalium fungus commonly
found to infect corn crops, was present in corn dust from four sampled grain storage
elevators in the US at levels of 0.3 – 4.5 ppm. This research was further developed
by Pussemier et al75 who found secalonic acid D in grain dust exposed workers at
dangerous levels.
Figure 1.8: Structure of the secalonic acids
O
OOH
R2
R1
R3
O
O OH
R5
R6
R4
Me(18) R1 = R2 = R3 = R4 = R5 = R6 =
(19) R1 = R2 = R3 = R4 = R5 = R6 =
(20) R1 = R2 = R3 = R4 = R5 = R6 =
(21) R1 = R2 = R3 = R4 = R5 = R6 =
(22) R1 = R2 = R3 = R4 = R5 = R6 =
(23) R1 = R2 = R3 = R4 = R5 = R6 =
(24) R1 = R2 = R3 = R4 = R5 = R6 =
OH CO2Me CO2Me OH Me
Me OH CO2Me CO2Me OH Me
OH
OH
OH
OH
OH
Me
Me
Me
Me
Me
CO2Me
CO2Me
CO2Me
CO2Me
CO2Me
CO2Me
CO2Me
CO2Me
CO2Me
CO2Me
OH
OH
OH
OH
OH
Me
Me
Me
Me
Me
Chapter 1: Introduction
___________________________________________________________________________________________________________________
___________________________________________________________________
30
Secalonic acid A (18), however, has been found to have neuroprotective effects
from colchine-induced apoptosis present in neurodegenerative diseases.76 Secalonic
acids B (19) and D (21) both exhibit potent cytotoxic activity to the B16 murine
melanoma cell line (2.8 and 0.28 µM respectively).77
To the best of our knowledge, despite much work on the monomeric components of
the secalonic acids, there have been no total syntheses of any of these dimeric
compounds.
1.4.2 Actinoplanones
The isolation and absolute structure determination of actinoplanones A and B
(Figure 1.9) were described in 1988 by Noshino et al.78 The natural product was
isolated from the culture broth of a soil bacterium (Actinoplanes sp. R-304). The
structure was determined using a wide range of spectroscopic methods. The same
authors subsequently set out to isolate further analogues from the same culture
broth.79 Isolation was monitored using cytotoxicity against HeLa cells and the
active fractions were purified using HPLC and preparative TLC. From this
extraction, actinoplanones C-G were isolated and their structures identified. NOE
experiments confirmed the relative configuration and Mosher’s method80 was
employed to determine absolute configuration. Interestingly, the absolute
configuration around the saturated ring is the same as for the kigamicins. The
kigamicins also contain an acetal moiety in the same position in relation to the THX
core and with the same absolute stereochemistry.
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Figure 1.9: Structures of the actinoplanones
The actinoplanones A and B exhibited potent cytotoxicity against HeLa cells (IC50
= 0.04 ng/mL; 5 ng/mL respectively) and actinoplanone C and G also demonstrated
excellent cytotoxic activity (IC50 = <0.04 ng/mL). Antifungal activity was also
reported in the nanomolar range. Due to limited availablility of material, only
actinoplanones A, B and F were screened for antibacterial activity. Actinoplanone
A showed strong activity against both Gram positive and Gram negative bacteria,
whereas actinoplanone B and F were only active against Gram positive bacteria.
1.4.3 Simaomicin α and β 
Simaomicin α and β are interesting natural products isolated in 1990 by Maiese et
al81 from an actinomycete strain of bacteria. The structures were elucidated by
Borders et al82 by a range of NMR techniques and x-ray crystallography.
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Figure 1.10: Structures of simaomicin α (32) and simaomicin β (33)
They have been reported to exhibit a wide range of biological activity. Initial
analysis by Maiese81 showed that they displayed activity against Gram positive
bacteria but not against Gram negative bacteria. They also reported antibiotic in
vitro activity against a range of chicken coccidia, a type of parasite responsible for a
significant economic loss to the poultry industry.83 When tested in vivo, simaomicin
α almost completely prevented lesions at only 1g/ton of medicated feed. Omura et
al84 reported simaomicin α to have extremely high in vitro potency against both
drug resistant and drug sensitive strains of malaria (IC50 = 0.045 ng/mL and 0.0097
ng/mL respectively). They also reported strong cytotoxicity (IC50 = 4 ng/mL)
against the human diploid embryonic cell line MRC-5. In 2009 Sugiyama et al85
investigated the effect of simaomicin α on a variety of cancer cell lines and reported 
IC50 values in the nanomolar range against all tested cell lines.
To the best of our knowledge no synthetic work has been undertaken on this natural
product.
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1.4.4 Sch 42137
Three Sch 42137 compounds were isolated by Cooper et al in 199286 from a culture
broth of Actinoplanes sp. SCC1906 isolated from a Brazilian soil sample.
Figure 1.11: Structure of the Sch 42137 compounds
These compounds are active as antifungal agents with minimum inhibitory
concentrations (MIC): 34, 0.125 µg/mL; 35 and 36, 1-2 µg/mL.
The authors conducted circular dichroism studies to establish the absolute
configuration at C-4. Comparison to actinoplanone and lysolipin whose structures
have been previously defined using CD spectra and single x-ray crystallography,
provided evidence for absolute configuration at this centre. No effort, however, was
made to establish the relative or absolute configuration at C-10 or C-13.
1.4.5 Ascherxanthones A and B
Ascherxanthone A was isolated from a culture of the fungus Aschersonia sp. BCC
8401 in 2005 by Isaka et al.87 Chutrakul et al88 isolated Ascherxanthone B
alongside Ascherxanthone A from the culture broth of Aschersonia luteola sp. BCC
8774 in 2009.
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Figure 1.12: Structure of ascherxanthone A and B
The authors assigned the relative stereochemistry using NOE NMR experiments but
attempts to synthesise Mosher’s esters in order to assign the absolute configuration,
were unsuccessful.
Ascherxanthone A was screened in a range of assays and was found to be a potent
anti-malarial compound (IC50 = 0.2 µg/mL) and also a potent anti-cancer compound
with activity against human epidermoid carcinoma cells (IC50 = 1.70 µg/mL),
human breast cancer cells (IC50 = 1.70 µg/mL) and human lung cancer cells (IC50 =
0.16 µg/mL).
Ascherxanthone B is active against a rice blast fungus, Magnaporthe grisea, with
an IC50 value of 0.58 µg/mL, whereas ascherxanthone A showed no activity in this
assay. Ascherxanthone B also displayed good activity in vivo in a rice plant infected
with this pathogen.
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1.4.6 Kibdelones
The kibdelones (Figure 1.13) were discovered and isolated by Capon et al89 from a
rare Kibdelosporangium sp. MST-108465 soil bacteria. Screening of an organic
extract from the culture broth of these bacteria revealed potent cytotoxic activity.90
Figure 1.13: Structure of the kibdelones
A range of NMR and MS spectroscopic techniques allowed them to determine the
structure of the kibdelones but the absolute stereochemical assignment was not
established until Porco et al completed the total synthesis in 2011 (described
below).91 Comparison of the 1H and 13C NMR, UV and optical rotations ([α]D23 = +
48° synthetic, + 49° natural (c = 0.5, CHCl3)) of synthetic kibdelone C to that
reported for the natural kibdelone, confirmed the absolute stereochemistry as that
depicted (Figure 1.13). Interestingly, the absolute configuration at C-1 and C-4 is
the same in the kibdelones as in the kigamicins and the actinoplanones.
There have been two reported syntheses of this natural product to date. Porco et al91
and Ready et al.92 Both groups opted to construct the natural product in a
convergent manner. Key steps in Porco’s synthesis of fragment 46 were platinum
mediated arylation of 42 and photocycloaddition of the resulting substrate 44.93
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Scheme 1.2: Synthesis of 46
This fragment was then combined with 47 followed by cyclisation using cyanuric
chloride 49 and pyridine in (CH2Cl)2 to afford THX 50 in moderate yield.
Kibdelone C (41) was formed in a further three steps and 59% yield.
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Scheme 1.3: Final steps of Porco’s kibdelone C total synthesis
Ready and coworkers92 elected to begin the synthesis with formation of THX 55 by
lithium-halogen exchange of 52 and addition into aldehyde 51. Subsequent Dess
Martin oxidation, deprotection of three hydroxyl groups, acid catalysed cyclisation
and acetonide formation, provided 55 in 66% yield. The authors speculated that the
cyclisation may occur through oxonium intermediate 54 (Scheme 1.4).
Sonogashira coupling of THX 55 and acetylene 56 combined the two halves of the
natural product. Subsequent hydrogenation, copper catalysed iodination and C–H
arylation provided the fused cyclic core. Kibdelone C (41) was synthesised from 59
in four steps and 20% yield.
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Scheme 1.4: THX formation by Ready et al92
Scheme 1.5: Final steps of Ready’s kibdelone C total synthesis
Initial biological screening of kibdelone C was carried out by Capon et al.89 They
reported strong antibacterial activity against gram positive bacteria (LD99 = 0.13
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nM) and potent nematocidal activity (LD99 = 8.5 nM). They also reported anti-
cancer activity with GI50 values of <0.3 nM against leukaemia and colon, CNS
(central nervous system), melanoma, ovarian, renal, prostrate and breast cancers.
Porco et al93 tested the kibdelones in the NCI 60-cell panel of human cancer cell
lines and found potency in the nanomolar region against both leukaemia and renal
cancer cell lines. This prompted them to investigate the total synthesis (as reported
above). During the course of the total synthesis, they decided to test fragments of
the natural product (60 and 61) in the NCI 60-cell panel in order to compare the
biological activity.
Figure 1.14: Kibdelone analogues for biological screening
The fragments also showed anti-cancer properties, however they reported much
lower potencies (4.5 µM cf. 2.4 nM for the kibdelones). The authors concluded that
the missing tetrahydroxanthone may be important for high potency.
1.4.7 Globosuxanthones A and B
Globosuxanthone B is a tetrahydroxanthone with a highly substituted saturated ring.
It was isolated by Gunatilaka et al in 2006 94 from Chaetomium globosum, a fungal
strain from the rhizosphere of Opuntia leptocaulis, a Christmas cactus.
Globosuxanthone A, the corresponding dihydroxanthone, was also isolated. Both
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were tested for cytotoxic activity and globosuxanthone A was found to have greater
activity against all seven human cancer cell lines screened.
Figure 1.15: Structures of globosuxanthone A (62) and B (63)
1.4.8 Blennolides A, B and C
Blennolides A, B and C were originally isolated from a fungus (Blennoria) from the
Canary Islands, by Krohn et al in 2008.95
Figure 1.16: Structures of blennolides A (64), B (65) and C (66)
After some controversy surrounding the structure of these natural products, they
were assigned as depicted in Figure 1.16 by Nicolaou et al96 by total synthesis of
blennolide C and comparison to data obtained for the original sample isolated by
Krohn.95
Blennolide A and B exhibit anti-algal activity, anti-fungal activity and also activity
against Gram positive and Gram negative bacteria.95
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There are several reported syntheses of blennolide C96-98, only one for blennolide B
and to the best of our knowledge, none for blennolide A. Nicolaou et al96 used a
domino deallylation-oxa-michael reaction as their key step from 69 synthesised by
lithium-halogen exchange of 67 and addition into acyl cyanide 68 followed by
oxidation to give desired diketone 69 (Scheme 1.6).
Scheme 1.6: Key steps in Nicolaou’s synthesis of blennolide C96
Porco et al98 reported the synthesis of both blennolide B and C by vinylogous
addition of siloxyfurans 73 to 72 and subsequent Dieckmann cyclisation, to provide
the natural products in four steps (Scheme 1.7). Blennolide B was made in an
analogous fashion.
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Scheme 1.7: Key steps in Porco’s synthesis of blennolide C
1.4.9 Dicerandrols A, B and C
Dicerandrols A, B and C were isolated from the fungus Phomopsis sp. PSU-D15 by
Rukachaisirikul et al99 in 2008 and also by Clardy et al100 in 2001 from Phomopsis
longicolla which is a fungus of the endangered mint Dicerandra frutescens.
Figure 1.17: Structures of the dicerandrols100
O
O OHOH
O
Me
O
Me
O
R1
O
OOH OH
O
Me
O
Me
O
R2
(76) Dicerandrol A: R1 = H R2 = H
(77) Dicerandrol B: R1 = Ac R2 = H
(78) Dicerandrol C: R1 = Ac R2 = Ac
O
O
CO2Me
O
OTMS
i) 2,6-lutidine
iPr2Si(OTf)2
CH2Cl2
ii)
iii) Et3N
.3HF
O
OH
Me
O
CO2Me
O
H
O
O
OH
Me
O
CO2Me
O
H
O
NiCl2.6H2O
NaBH4
THF/MeOH
O
OH
Me
O
CO2Me
O
H
O
NaH, THF
O
O OH
Me
OH
HO O OMe
O
O OH
Me
OH
HO O OMe
6671
72 73 74
75
75
OH
Chapter 1: Introduction
___________________________________________________________________________________________________________________
___________________________________________________________________
43
The biological activity of these compounds was assessed against Staphylococcus
aureus and Bascillus subtilis bacteria, Geotrichum candidum fungus,
Saccharomyces cerevisae yeast, human colon tumour cell line HCT-116 and human
lung tumour cell line A549. They found that all three compounds showed anti-
bacterial activity but were inactive against the fungus and yeast. They also showed
activity against both cancer cell lines (IC50 = 1.8 – 7.0 µg/mL).
1.5 Conclusions
Despite the improvements in prognosis for many cancers over the last decade, little
such improvement has been realised for patients with pancreatic cancer. This is due
in part, to the ability of the cancer cells to survive under austere conditions and the
inability of the current chemotherapy drugs to demonstrate cytotoxicity under such
conditions.
The new anti-austerity approach to selectively target cancer cells, opens up an
exciting new avenue of research. The kigamicins are exciting lead structures in this
research area and have shown efficacy both in vitro and in vivo with no obvious
toxicity to normal cells. The THX nucleus forms the core of this natural product and
many closely related polycyclic structures displaying potent biological activities,
including cytotoxic activity. Simpler THXs – either monomeric or dimeric –display
a range of interesting biological properties, including against cancer.
Thus, it is tempting to speculate that the THX nucleus of the kigamicins is
responsible, at least in part, for the anti-austerity effects of the kigamicins.
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In this thesis, we have set out to test this hypothesis through the synthesis of
simplified kigamicin analogues that retain the THX nucleus and their evaluation in
anti-austerity assays. Since mild methods for the synthesis of THXs are not
especially well established, this has necessitated the development of innovative new
chemical methods for the synthesis of these oxygen heterocycles.
Chapter 2:
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2.1 Initial Studies and Synthesis of Kigamicin Analogues
2.1.1 Introduction
As discussed in Chapter One, the tetrahydroxanthone (THX) nucleus forms the
central core of many biologically active natural products including the
kigamicins,101 kibdelones,90 actinoplanones,78 simaomicin α,82 globosuxanthone B94
and artopeden A102 (Figure 2.1). As such, it is reasonable to assume that the THX
nucleus may be responsible, at least in part, for the biological activity of these
natural products.
Figure 2.1: Natural products containing the THX core
Clearly, the development of efficient routes to THXs is desirable so that analogues
can be synthesised in order to investigate structure activity relationships. It is also
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important that any such methodology allows for the incorporation of an aryl group
at the 7-position of the THX – a key feature of many of these natural products.
This chapter focuses initially on the synthesis of 7-arylated THXs using existing
methodology before exploring improved metal catalysed routes. Finally, tandem
catalysis is developed utilising the developed metal catalysed strategies in
partnership with conventional cross coupling reactions to facilitate the synthesis of
7-arylated THXs very directly.
2.1.2 Existing methodology for the synthesis of tetrahydroxanthones
Kapil et al 103 reported the synthesis of THXs via the oxidation and alkyl migration
of 2-spirochromanones. This method utilises thallium (III) nitrate or acetate to first
oxidise 2-spirochromanone 80 prior to alkyl migration.104 It is proposed that this
migration is driven by the greater stability of the resulting conjugated THX 83.
Scheme 2.1: Mechanism proposed for THX synthesis via spirochromanones104
THXs have also been synthesised by Marakos et al105 who created small libraries of
compounds for biological screening and SAR studies. Their research was based
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around aminoanthraquinones which exhibit potent anti-tumour properties. However,
they have limited clinical use due to their cardiotoxic side effects. To this end,
Marakos et al sought to create novel analogues including pyrazole-fused
xanthenones 87 and amino derivatives thereof.
This involved the initial synthesis of xanthones and tetrahydroxanthones as
precursors for the more elaborate biologically active molecules described above.
The THX moiety was produced by heating 1,3-cyclohexanedione and salicylic acid
with polyphosphoric acid at 150 °C.
Scheme 2.2: Synthesis of pyrazole-fused xanthenones via THX synthesis105
In 1987, Watanabe and coworkers explored the synthesis of the chromone core of
Khellin, a natural product with antispasmodic and coronary vasodilating properties
(Figure 2.2).106
Figure 2.2: Khellin
To rapidly synthesise analogues for SAR studies, they investigated various routes to
92, from the silyl enol ether 93 or enamine 89 (Scheme 2.3). Their findings revealed
that either precursor was suitable but much greater yields were generally obtained
using the lithium enolate method derived from the silyl enol ether.
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Scheme 2.3: Synthetic routes to chromones
In all these syntheses, the final step to form the xanthone or THX was acid
catalysed dehydration. This method involves the deprotection of the acetate
protecting group and cyclisation in one step by heating the precursor in
concentrated acetic and hydrochloric acid to 100 °C.
Scheme 2.4: Acid catalysed dehydration
To make THXs rapidly, we wanted to explore a convergent synthesis whereby
functionalised A and C rings could be brought together with assembly of ring B.
Scheme 2.5: Convergent synthesis to the THX
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→ –
–
Encouraged by the good to excellent yields achieved in the aforementioned research
by Watanabe et al,106 we sought to establish if this might provide a general route to
THXs.
2.1.3 Tetrahydroxanthone synthesis by acid catalysed dehydration
Initially, we set about the synthesis of known THX 83 (Scheme 2.6). The lithium
enolate 97 was formed directly from cyclohexanone 96 and not from the silyl enol
ether as reported by Watanabe et al.106 This was in order to minimise the number of
steps in the synthesis. Enolate 97 was then added to acid chloride 90 to form 95.
This was not fully purified although an aqueous work-up was performed at this
point to remove remaining diisopropylamine before the acid catalysed dehydration
step.
Scheme 2.6: Synthesis of the THX using acid
Disappointingly this reaction gave low yields (17-22%) compared with that
reported by Watanabe et al (30-90%)106 where enolate 97 was generated from the
silyl enol ether (Scheme 2.3). Since 95 has a very acidic hydrogen, we were
concerned that the product might be deprotonated. In order to improve the yield, the
equivalents of LDA were increased from 1 to 1.5. This led to further side product
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resulting from the addition of diisopropylamine (for LDA formation) to the acid
chloride. The equivalents of acid chloride were increased to 1.5 but this did not
result in an improved yield. The length of time for enolate formation was varied
from 1 to 2 h but this had no effect. The base was changed to LiHMDS to try and
minimise side products but unfortunately had no effect on the yield of reaction. In
view of these results, lithium enolate 97 was generated from the silyl enol ether
following the work of Watanabe106 (Scheme 2.3). However, this resulted in no
improvement to the yield.
We then attempted to introduce a bromine onto the 7-position of the aromatic ring
of the THX in order to enable further elaboration of these compounds via cross
coupling reactions. This was accomplished by treating 5-bromosalicylic acid 98
with acetic anhydride and acetic acid, followed by treatment 99 with thionyl
chloride to give acid chloride 100.
Scheme 2.7: Synthesis of the brominated acid chloride
With bromide 100 in hand, the corresponding THX 102 was synthesised without
problem but the yield for this reaction was comparably poor (22%). However, on
scale up (9 g, 32 mmol), the yield improved to 44%.
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Scheme 2.8: Synthesis of brominated THX
2.1.4 Suzuki-Miyaura couplings
Next, we wished to carry out a series of Suzuki-Miyaura couplings in order to form
7-arylated THXs which might overlay well with the 7-aryl ring of the natural
product. Such cross-coupling reactions have been thoroughly researched and a
plethora of reaction conditions exist for this transformation.107 Initially, we
examined the coupling of bromide 102 with phenyl boronic acid (1 equiv.) using
Pd(PPh3)4 (2 mol %) and 2M Na2CO3 (2 equiv.) in EtOH/toluene (1:1) (0.5 mM).108
This provided 103 in an encouraging 55% yield.
Scheme 2.9: Suzuki-Miyaura reaction
The conditions for the Suzuki-Miyaura reaction were further optimised using
phenyl boronic acid before applying them to other boronic acid substrates (Table
2.1).
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O OLi
LDA, THF
78°C, 1 h–
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– 78 °C  rt
18 h
HCl / AcOH
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As shown in Table 2.1, the yield improved as the equivalents of boronic acid were
increased (entry 5). However, increasing the equivalents of base had the opposite
effect with two equivalents optimal. There was no appreciable difference in yield
between reactions carried out in a microwave and reactions heated to reflux in a
round-bottomed flask but due to shorter reaction times, microwave irradiation was
used for all subsequent reactions.
Entry Boronic
acid equiv.
2M Na2CO3
equiv.
Reaction conditions Yield
(%)
1 1 2 thermal heating
90 °C, 1 h 45 min
55
2 2 2 thermal heating
90 °C, 1 h 45 min
67
3 2 2 microwave irradiation
300 W, 110 °C, 10 min
71
4 2 4 microwave irradiation
300 W, 110 °C, 10 min
52
5 3 2 microwave irradiation
300 W, 110 °C, 10 min
76
Table 2.1: Optimisation of Suzuki-Miyaura Couplings
The best yield obtained for the coupling of phenyl boronic acid with 102 was 76%.
Different boronic acids were then used to test the substrate scope and produce
derivatives 105 and 107. A low yield was obtained for 107, presumably due to the
substituent ortho to the boronic acid (discussed in more detail in Section 2.2).
O
O
Br
O
O
PhB(OH)2
Pd(PPh3)4 (2 mol%)
2M Na2CO3
EtOH/toluene
102 103
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Scheme 2.10: Synthesis of derivatives X and X
The structures of 83, 102, 103 and 105 were all confirmed by 1H and 13C NMR
spectroscopy, high resolution MS and elemental analysis. In the case of 83, the data
matched that reported in the literature.109 A single crystal of compound 105 was
grown from chloroform by slow evaporation and the structure unambiguously
confirmed using single x-ray crystal diffraction (see Appendix I).
Figure 2.3: Crystal structure of compound 105
O
O
Br
O
O
Pd(PPh3)4
2M Na2CO3
EtOH/toluene
O
O
O OMe
HO
O
OMe
(HO)2B
(HO)2B OH
Pd(PPh3)4
2M Na2CO3
EtOH/toluene
74%
11%
105
107
102 106
104
Chapter 2: Synthesis of Tetrahydroxanthones
___________________________________________________________________________________________________________________
___________________________________________________________________
55
2.1.5 Amide couplings
With ester 105 in hand, we wished to make the corresponding amide which would
further overlay kigamicin A, since an amide group is found in this position in the
natural product (Figure 2.1). Initially, reactions between ester 105 and ammonia
were attempted in MeOH and H2O/THF but without success (Scheme 2.11).
Scheme 2.11: Attempted synthesis of amides
Subsequently, the ester was hydrolysed to the carboxylic acid before successfully
undergoing conventional amide coupling. Several different analogues, namely 108
and 110-112 were synthesised in this manner (Scheme 2.12). These included a
morpholine adduct 112, which contains an additional oxygen and saturated ring to
approximate the H ring of the natural product. Moderate to low yields were
obtained for all of the amide couplings shown in Scheme 2.12, although no starting
material or by-products were isolated. Despite this, there was sufficient material
obtained for biological testing and therefore no alternative coupling reagents (such
as DCC, EDC or HATU)110 were investigated.
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Scheme 2.12: Hydrolysis and subsequent amide couplings
2.1.6 Initial library of natural product analogues
A further four analogues 118-119 were synthesised by a placement student, Chua
Chun Kiang, under my supervision, that differed in the nature of the saturated A
ring. An additional ketone group was incorporated into the A ring and the
corresponding alcohol analogues were synthesised by final reduction of these
ketones (Scheme 2.13).
Entry Compound R1 R2 Yield (%)
1 108 H H 47
2 110 H CH3 26
3 111 CH3 CH3 42
4 112 (CH2)2O(CH2)2 53
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Scheme 2.13: Synthesis of analogues
A further analogue 123 was also made by Chua Chun Kiang by hydrolysis and
subsequent amide coupling of ester 121.
Scheme 2.14: Hydrolysis and amide coupling
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The final library of analogues, along with kigamicin C itself (commercially
available111) were then tested for cytotoxicity against PANC-1 cells at the Peninsula
Medical School (see Chapter Four).
2.2 Attempted Synthesis of the Natural Product E Ring
With this methodology in place, we wished to use ortho substituted boronic acids or
esters in the cross couplings such that more complex analogues could be made and
tested for biological activity. If an analogue could be synthesised with functionality
ortho to the aryl-aryl bond, then the synthesis of the saturated E ring could be
attempted (Scheme 2.15). This was thought to be desirable as it would further limit
the number of rotatable bonds, an important concept in medicinal chemistry.112-114
Such a difference in conformational rigidity could have a large impact on the
biological activity. Pentacycle 126 was expected to have a conformation much more
akin to the natural product.
Scheme 2.15: Strategy to the synthesis of more complex analogues
Historically, the use of ortho substituted boronic acids in Suzuki-Miyaura reactions,
often results in much longer reactions times and/or lower yields compared to meta
O
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and para substituted derivatives. This can be attributed to the inherent steric
hindrance which is particularly problematic during the transmetallation step of the
catalytic cycle.115 Boronic acids used in Suzuki-Miyaura couplings can be prone to
competitive hydrolytic deboronation and due to the longer reaction times with ortho
substituted boronic acids, higher quantities of such side-product are often
observed.116,117 Often, pinacol esters are used as they are less susceptible to
hydrolytic deboronation, however this does not entirely solve this problem.116
Baudoin et al118 developed and optimised Suzuki-Miyaura reactions for the
formation of ortho substituted pinacol esters, similar in structure to those required
by us. Based on this work, boronic pinacol ester 128 was synthesised directly from
127 which was commercially available. The yield for this transformation was low,
but provided sufficient quantities of 128 to test the subsequent steps.
Scheme 2.16: Synthesis of a functionalised 7-aryl THX containing a cyano moiety
With 128 in hand, a further Suzuki-Miyaura reaction was undertaken. Strong bases
such as Ba(OH)2 have been shown to give higher yields for sterically encumbered
substrates.107,119 Using Pd(OAc)2 in combination with Ba(OH)2 as a base, 129 was
O
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CN
128, Pd(OAc)2
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dioxane, 100 °C, 1 h
29%
Br
CN
B
CN
O O
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dioxane, 90 °C, 18 h
23%
127 128
102 129
Chapter 2: Synthesis of Tetrahydroxanthones
___________________________________________________________________________________________________________________
___________________________________________________________________
60
obtained in 29% yield. Despite the low yield, enough product was isolated cleanly
to attempt ring closure.
Cyclisation was attempted using trifluoromethanesulphonic acid (TFSA) as similar
cyclisations had been successfully reported in the literature by Nakamura et al.120
They described the development of superacid catalysed cyclisations of
arylcyanopropionates to give various carbocycles and it was hoped that similar
reaction conditions could be applied here.
Scheme 2.17: Cyclisations by Nakamura120
Nitrile 129 was added to ice-cold TFSA and then allowed to slowly warm to room
temperature. After 3 h, there was no product apparent by crude 1H NMR
spectroscopy, only starting material was evident. The reaction was allowed to stir at
room temperature overnight and then since no change was observed, the mixture
was heated to 50 °C for a further 18 h.
Scheme 2.18: Attempted intramolecular cyclisation
Since only 129 was isolated under these forcing reaction conditions, it was
concluded that such nitriles are too unreactive for cyclisation to occur in these
substrates.
O
O
CN O
O
O
TFSA
rt 50 °C
129 130
CN
O
TFSA
R R
130 131
Chapter 2: Synthesis of Tetrahydroxanthones
___________________________________________________________________________________________________________________
___________________________________________________________________
61
To circumvent these problems, we decided to try the cyclisation via a more
conventional Friedel Crafts process. For this, it was necessary to synthesise pinacol
ester 132 containing a masked carboxylic acid moiety. The synthesis of 132
occurred in a much higher yield (63%) relative to its cyano analogue 128 (Scheme
2.16). With the pinacol ester 132 in hand, the subsequent Suzuki-Miyaura reaction
provided 133 in an improved 46% yield.
Scheme 2.19: Synthesis of a functionalised 7-aryl THX containing an ester moiety
Ester 133 was then hydrolysed using lithium hydroxide in a biphasic mixture of
THF and H2O. The reaction mixture was stirred at room temperature overnight and
then subjected to an acidic aqueous work up to facilitate extraction of the acid into
the organic phase. Further silica gel chromatography was not undertaken due to
insolubility issues. However, by crude 1H NMR spectroscopy, the methyl ester peak
was no longer present and there was a broad peak at 10.78 ppm, indicative of a
carboxylic acid hydrogen. There were only minor impurities present and therefore
134 was used without further purification.
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Scheme 2.20: Hydrolysis
Several methods were then attempted to realise cyclisation. The first of these was
another strongly acidic method as reported by Sharma et al for the cyclisation of
135 to 136 in high yield (Scheme 2.21).121
Scheme 2.21: Cyclisation using methanesulphonic acid121
However, 137 was not isolated when these reaction conditions were applied to 134.
Scheme 2.22: Attempted cyclisation
Other reports in the literature for similar reactions include that of DeShong et al122
where the carboxylic acid was first converted to the acid chloride in situ before
intramolecular Friedel Crafts reaction. This was attempted on 134 but as before,
137 was not isolated. This could be because the acid chloride didn’t fully form
before attempting the Friedel Crafts reaction. Due to being a one-pot process, the
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intermediate acid chloride was not isolated or characterised and therefore it was
difficult to ascertain which step was problematic.
The final method attempted followed the work of Feldman et al.123 They found that
treating 138 with BBr3 to remove the methyl groups, facilitated cyclisation to 139
(Scheme 2.23).
Scheme 2.23: Cyclisation using BBr3
These conditions were applied to acid 134 and the reaction mixture was allowed to
stir overnight at room temperature. The crude 1H NMR spectrum showed a trace of
one product forming with a large proportion of starting material remaining.
Disappointingly, the product did not show the disappearance of the aromatic
doublet of H–6 as expected but instead the singlet peak at H–8 which would only
arise if regioisomer 138 had formed (Scheme 2.24).
Scheme 2.24: Attempted cyclisation and possible formation of alternative regioisomer
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The formation of this isomer may arise from preferential coordination of both
carbonyls to the Lewis acid during the cyclisation with loss of a bromide ion.
Alternatively, it is possible that hydrogen bonding between the carboxylic acid
hydrogen and the carbonyl of the THX encourages formation of this isomer (Figure
2.4).
Figure 2.4: Possible hydrogen bonding or Lewis acid coordination
Disappointingly, treatment with further equivalents of BBr3 and longer reaction
times did not drive the reaction to completion. As such, we were unable to isolate
sufficient quantities of 138 to verify its structure. Further work to produce
analogues with an intact E ring was discontinued at this juncture.
2.3 Metal Catalysed Route to Tetrahydroxanthones
2.3.1 Introduction
As described previously, current methods to THXs utilise very strong acids and
harsh reaction conditions. Whilst this provides a rapid route to basic analogues
containing the THX moiety, analogues with greater complexity that mimic the
kigamicins more closely could not be made this way. In these cases, less forcing
conditions would need to be developed. The natural product contains several acid
sensitive functionalities, for example, the hydroxyl groups in the A ring at C-1 and
C-4 which would be sensitive to acid catalysed dehydration and the cyclic acetal (D
ring) would also potentially be sensitive to acid. On this basis, we concluded that it
was necessary to develop a non-acidic route to THXs.
O
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OOBBr
O
O
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H
Br
139 140
BBr3
+
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Figure 2.5: Kigamicin
We reasoned that the THX nucleus could be constructed via a metal-catalysed
process, mediated for example, using copper or palladium. This would involve the
use of a mild base and could provide a facile route which would be much more
tolerant of a range of functional groups making way for the synthesis of libraries of
analogues for biological screening. Such methodology could also be helpful in
relation to the synthesis of the natural product itself. It is envisioned that the
reaction would proceed via insertion of the metal into the aryl halide bond. This
would be followed by the coordination of the enolate, formed after deprotonation,
with the metal and subsequent reductive elimination to form the oxygen–aryl bond
reforming the metal catalyst (Scheme 2.25).
Scheme 2.25: Proposed formation of the THX core via a metal catalysed route
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2.3.2 Synthesis of substrates for investigation of metal catalysed cyclisation
Several different methods were explored for the synthesis of the substrates required
for investigating the metal catalysed THX formation. The first of these, involved
the addition of the lithium enolate of cyclohexanone to the appropriate acid chloride
as shown in Scheme 2.26. This is analogous to the strategy used for synthesising the
earlier precursors such as 83 and 102 for the acid catalysed dehydration method. In
both cases, none of the diketone was observed, only the enol tautomer, presumably
due to the hydrogen bonding between the enol proton and adjacent carbonyl
oxygen. Evidence for this hydrogen bonding is also observed in the 1H NMR where
the highly deshielded enol proton appears at δ 15.82 ppm. It was assigned as enol 
141a instead of enol 141b by NOE NMR experiments. Irradiation of the enol
proton showed enhancement of the alkyl proton signals of C-4 but no effect on the
aromatic protons.
Figure 2.6: Possible enol tautomers
Alongside a 65% yield of 141, a noticeable amount of 143 was observed, formed
from the reaction of the LDA directly with acid chloride 142.
Scheme 2.26: Acylation using LDA and side reaction
OOH
Br
OHO
Br141a 141b
4
Chapter 2: Synthesis of Tetrahydroxanthones
___________________________________________________________________________________________________________________
___________________________________________________________________
67
It was postulated that this could be avoided if the lithium enolate of cyclohexanone
was trapped with TMSCl to give the silyl enol ether as described by Watanabe et
al.106 This could then be isolated and the lithium enolate regenerated using
methyllithium to which the acid chloride could be added in the absence of
diisopropylamine. Without this competing reaction, it was hoped that a higher yield
would be observed. However this was not the case and in fact a slightly lower yield
was obtained.
Scheme 2.27: Acylation via the silyl enol ether
Acylation was also attempted using cyclohexane-1,3-dione 84 in order to install the
hydroxyl group present in the A ring at C-1 of the natural product. However, this
resulted in predominantly O-acylation when the LDA method was used. The
reaction was repeated using pyridine and before isolating the product, DMAP was
added to isomerise any O-acylated 145 to C-acylated 146 (Scheme 2.28). This was
based on work by Zaitsev et al 124 where they achieved yields in excess of 90%
using this approach. Disappointingly in our hands, this method failed to produce a
significant yield of C-acylated 146.
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O-acylation is usually favoured when hard electrophiles such as acid chlorides are
used.125 However, the hard alkoxy anion of the enolate is bound tightly with the
hard lithium counterion which leads to shielding of the anion.126 This allows
reaction through the carbon despite its ‘softer’ nature. However, in the case of the
diketone 84, the anion is further delocalised not only making the carbanion even
softer in nature greatly reducing its ability to react with the hard acid chloride but
also weakening the interaction between the alkoxy anion and lithium counterion
creating more free enolate, thereby increasing reactivity through oxygen.127
Scheme 2.28: Attempted acylation/isomerisation sequence
The conditions were then repeated but on this occasion the reaction was halted after
the initial acylation step. No C-acylated product 146 was isolated but the O-acylated
product 145 was isolated in 69% yield. In 1996, Burger et al128 reported that after
the initial O-acylation of cyclohexanedione, subsequent isomerisation could be
realised using potassium cyanide and triethylamine in acetonitrile. No yield was
quoted for this isomerisation but we decided to repeat the conditions on our
substrate. Indeed the isomerisation did proceed but in only 40% yield. The O-
acylated (145) and C-acylated (146) products were differentiated by 1H and 13C
NMR spectroscopy. The spectrum of 145 showed a peak at δ 6.06 ppm for the 
enone proton which was not present in the spectrum of 146. The 13C NMR of 145
showed three peaks at δ 199.4, 169.9 and 162.6 ppm for the three quaternary 
carbons adjacent to oxygens whereas in 146, they were much more similar (δ 198.1, 
O
O
O
BrO
O
O
O
BrOH142, pyridine,
CHCl3, rt
DMAP, benzene
rt, 18 h
145 14684
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197.1 and 193.7) which would be expected for those in 146 considering the almost
identical chemical environment of these quaternary carbons. It was therefore
decided that the remaining substrates be synthesised according the first method
described, using LDA in THF.
Scheme 2.29: O-Acylation followed by isomerisation124
2.3.3 Formation of heterocycles using metal catalysis
There is no literature precedent for the metal catalysed cyclisation for the formation
of THXs. However, the syntheses of other heterocycles namely benzopyrans and
benzofurans using metal catalysis, most commonly using copper or palladium are
known.
Li et al 129 demonstrated that depending on the structure of the substrate and on the
reaction conditions, they could perform both C-arylation and O-arylation of β-keto
esters to provide both 3,4-dihydronaphthalen-2(1H)-one derivatives (150) and
benzopyrans (148) (Scheme 2.30). Initial studies involved the optimisation of the
formation of benzopyrans via cyclisation utilising copper catalysis. Various copper
sources were screened (Cu, CuI, CuCl) as well as different bases (Cs2CO3, K3PO4,
DABCO, NatOBu) and different ligands (DMEDA, 1,10-phenanthroline, L-proline,
PPh3) were explored. The optimal conditions were found to be CuI (10 mol %),
DMEDA (20 mol %) and Cs2CO3 (2 equiv.) in refluxing THF (Scheme 2.30).
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In order to widen the scope of this reaction the authors reacted β-keto esters such as
149 under the same conditions to form benzopyran derivatives incorporating an
exocyclic double bond. However, under these conditions, the reaction was very
slow, so the solvent was changed to dioxane so higher temperatures could be
employed. Under these conditions, only the C-arylated product 150 was observed
(Scheme 2.30).
Scheme 2.30: O-arylation and C-arylation of β-keto esters129
SanMartin et al130 isolated an unexpected product in the reaction between
deoxybenzoin 151 and benzylamine in the presence of a copper catalyst. Instead of
the N-arylation product 152, they had anticipated, benzofuran 153 was produced in
66% yield.
Scheme 2.31: Unexpected O-arylation
This prompted them to investigate the synthesis of benzofurans in this manner.
Optimal conditions proved to be CuI (8.5 mol %) and TMEDA (3.5 equiv) in H2O
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at 120 °C (Scheme 2.32). The use of H2O gave the advantage of reduced cost and
toxicity. The reaction was found to have wide scope with the exception that it is
intolerant to electron donating substituents para to the bromine in 154.
Scheme 2.32: Benzofuran synthesis
Palladium catalysis for benzofuran synthesis has also been reported. In 2004, Willis
et al 131 described the use of Pd2(dba)3 for this transformation. Initially, poor yields
(<5%) were observed using xantphos as a ligand and Cs2CO3 as a base. Use of a
stronger base (NaOtBu) didn’t improve the reaction and in this case no product was
isolated. However, it was discovered that with DPEphos, the yield was markedly
improved. The optimal conditions were: Pd2(dba)3 (2.5 mol %), DPEphos (6 mol
%) and Cs2CO3 (2.2 equiv.) in toluene.
When examining the scope of this reaction it became apparent that although the
catalyst, ligand and solvent were general to most substrates, the base required was
substrate dependent. This chemistry has been extended to the synthesis of
benzothiophenes.132
Scheme 2.33: Palladium catalysed benzofuran synthesis
R1
O
Br
R2
O
R1 R2CuI, TMEDA, H2O
154 155
91%
R1
O
X
R3
O
R1 R3
R2 R2
Pd2(dba)3, DPEphos
Cs2CO3, toluene
68 95%–
157156
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2.4 Tetrahydroxanthone Formation using Copper Catalysis
From the above work, we imagined that the synthesis of THXs could potentially be
realised using copper catalysis.
Compound 141 was chosen as a suitable substrate for model studies and once
synthesised, was treated with copper iodide, DMEDA and Cs2CO3 in THF and
heated to reflux for 18 h (Scheme 2.34). Encouragingly, at the first attempt, THX
83 was isolated in 54% yield.
Scheme 2.34: Copper catalysed cyclisation
2.4.1 Optimisation Studies
Optimisation was undertaken as shown in Table 2.2. The reaction time, base,
equivalents of base, ligand and solvent were all changed. Only marginal
improvement was realised when water was used as the solvent in place of THF
(entry 8). However, no further improvements were realised.
CuI (10 mol%)
DMEDA (20 mol%)
Cs2CO3 (2eq), THF
O
OOOH
Br
54%
83141
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Table 2.2: Optimisation of Copper Iodide Catalysed Cyclisation
2.4.2 Scope of Copper Catalysed Cyclisation
Despite moderate yields for this cyclisation, it was decided to synthesise a small
number of other substrates (Figure 2.35). The purpose was not only to ascertain
whether the reaction would tolerate different substrates but also if any of these
substrates cyclised in higher yields.
These were all synthesised using the chemistry described in Section 2.3.2. Despite
moderate to low yields, sufficient material was obtained to test the cyclisation step.
Entry Base Eq.
base
Ligand Solvent Reaction
time (h)
Yield
(%)
1 Cs2CO3 2 DMEDA THF 18 54
2 Cs2CO3 2 DMEDA THF 48 27
3 none none DMEDA THF 18 0
4 Cs2CO3 2 TMEDA THF 18 49
5 K3PO4 2 DMEDA THF 18 54
6 Cs2CO3 2 N,N-
dimethylglycine
THF 18 44
7 Cs2CO3 2 DMEDA CF3CH2OH 18 34
8 Cs2CO3 2 DMEDA H2O 18 56
9 Cs2CO3 2 DMEDA DMF 18 46
10 Cs2CO3 2 DMEDA Dioxane 18 51
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Scheme 2.35: Synthesis of substrates
All substrates were subjected to the optimal copper catalysed cyclisation conditions.
Similar yields were achieved when 83 was formed from the iodide (48%) and 164
synthesised from cycloheptanone (52%). However, 161 and 163 were formed in
poor yields (<10% yield in both cases).
.
Scheme 2.36: Copper catalysed cyclisation
O O
X
LDA, THF
78°C, 1 h–
O
O
O
BrO
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O
BrOH142, pyridine
CHCl3, rt
69% 40%
KCN, NEt3, rt
145 146
HO
O
Cl
X
– 78 °C  rt, 18 h
n
OLi
n n158 n= 2 X= I 43%
159 n= 1 X= Br 39%
160 n= 3 X= Br 59%
84
O
X
HO
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CuI (10 mol%)
DMEDA (20 mol%)
Cs2CO3 (2eq), THF
n83 n= 2 X= I 48%
163 n= 1 X= Br <10%
164 n= 3 X= Br 52%
O
O
BrOH
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2.5 Tetrahydroxanthone Formation using Palladium Catalysis
These results and the work described in Section 2.3.3, prompted us to study the
THX formation using palladium catalysis in order to establish if the reaction could
be improved.
We also reasoned that if palladium could be used, this would provide the
opportunity to greatly extend the scope of the reaction. By manipulating the
reaction conditions, it could be possible to incorporate the 7-aryl component
concurrently via a Suzuki-Miyaura reaction. This would allow the synthesis of 7-
arylated THX analogues via tandem catalysis133-140 by sequential C–O and C–C
bond construction.
Scheme 2.37: Proposed tandem catalysis route to 7-arylated THXs
Initially it was important to determine if palladium could catalyse the cyclisation
reaction. As previously described, Pd2(dba)3 had been reported to effect the
cyclisation to oxygen heterocycles. Since xantphos was to hand, initial experiments
were conducted with this ligand. Reaction of enol 141 with Pd2(dba)3, xantphos and
caesium carbonate in toluene, gave 83 in an improved and very encouraging 76%
yield (Scheme 2.38).
OOH
Br
Br
R1
B(OH)2
R2
O
O
R1
R2
Pd-catalysed C C
bond formation
Pd-catalysed C O
bond formation
7
–
–
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O
O
Pd2(dba)3, xantphos
Cs2CO3, toluene
reflux, 18 h
OOH
Br 76%
141 83
Scheme 2.38: Palladium catalysed cyclisation
2.5.1 Optimisation Studies
Encouraged by these results, we attempted to further improve the yield by variation
of the solvent and ligand. The results are shown in Table 2.3.
An exploration of solvents resulted in an 11% improvement in yield when toluene
was substituted by dioxane. The yield was improved once more through the
consideration of different ligands (Figure 2.7). The use of Xphos in place of
xantphos provided an excellent 93% yield (Table 2.3, entry 10). At this juncture, no
further optimisation was conducted.
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Table 2.3: Optimisation of palladium catalysed cyclisation
Figure 2.7: Ligands used for optimisation study
2.5.2 Catalysed versus uncatalysed reaction
For completion, we sought to establish the role of palladium in this reaction. To our
initial surprise, the cyclisation still occurred in the absence of palladium and in high
yield (86%). This prompted us to conduct studies surrounding the uncatalysed
Entry Ligand Solvent Yield (%)
1 Xantphos Toluene 76
2 Xantphos THF 76
3 Xantphos H2O <25
4 Xantphos DMF 62
5 Xantphos Dioxane 87
6 DPEphos Toluene 79
7 DPEphos Dioxane 86
8 DPPB Dioxane 83
9 Johnphos Dioxane 82
10 Xphos Dioxane 93
O
PPh2 PPh2
O
PPh2 PPh2
iPr iPr
iPr
PCy2 P
Ph2P PPh2
Xantphos
DPEphos
DPPB Xphos
Johnphos
O
O
Pd2(dba)3, ligand
Cs2CO3, solvent
reflux, 18 h
OOH
Br
141 83
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reaction in order to ascertain whether the metal was playing a role in the reaction.
Since the reaction was sensitive to the ligand used, we suspected that it did indeed
play an important role.
Considering the ability of the carbonyl group to stabilise negative charge through
intermediates such as 165 and 166, it is possible that the reaction proceeds via an
SNAr type mechanism.141-143
Scheme 2.39: Proposed catalysed vs. uncatalysed reaction mechanisms
If the uncatalysed reaction is operating, then the reaction might be expected to be
base dependent, specifically with respect to the nature of the counterion. We
reasoned that if the enolate was highly covalent, then the reaction would be more
likely to proceed via the catalysed route, due to the enolate being inherently less
nucleophilic. If the enolate has more ionic character, then the uncatalysed reaction
O
O
Br
O
O Pd
O
O
Br
Pd
O
O
Pd(0) -Br
-Pd
OOH
Br
Cs2CO3
Br
O
O
-Br
-PdCs2CO3
O
O
BrBr
O
O
Palladium catalysed mechanism
Uncatalysed mechanism
– –
–
– –
–
166165
141 83
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would be faster. This has been illustrated by the work of Lee et al144 who calculated
the activation energies of a fluoridation SNAr reaction in the presence of sodium or
caesium counterions (Scheme 2.40). They reported that the strong interaction
between the nucleophile and the sodium counterion greatly increased the activation
energy (to ~39.1 kcal/mol) in comparison to that of the reaction with caesium as the
counterion (~31.4 kcal/mol).
Scheme 2.40: Fluorination reaction with NaF or CsF
In order to test this hypothesis, we undertook a base screen to establish the effect of
the counterion on the yields of the catalysed and uncatalysed reactions. Using 141, a
pair of reactions were conducted in parallel (heated in the same oil bath next to one
another). In each reaction, the starting material was dissolved in dioxane and the
base was added. To one of the reactions, Pd2(dba)3 and Xphos were then added. The
reactions were heated to reflux for 18 h and then purified on silica gel to obtain the
isolated yields for each reaction. The results are shown below in Table 2.4.
NO2
MF
M = Na or Cs F
MNO2
167 168
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Base Yield (%)
catalysed[a]
Yield (%)
uncatalysed
Cs2CO3 85 92
CsF 85 82
K2CO3 96 83
K3PO4 49 65
NaOtBu 51 0
Na2CO3 85 0
[a] 2.5 mol% Pd2(dba)3 and 6 mol% Xphos
Table 2.4: Base screen
It is evident from the results of the base screen shown in Table 2.4, that with
caesium as the counterion, the uncatalysed reaction proceeds equally well as the
catalysed one. A potassium counterion also appears to enable the uncatalysed
reaction to occur. However, using sodium tert-butoxide or carbonate, the
uncatalysed reactions failed with complete recovery of starting material.
Interestingly, the catalysed reactions still proceed under these conditions.
To provide further evidence, we examined the use of crown ethers which have been
shown to coordinate to cations and in particular, 15-crown-5 which has been shown
to coordinate specifically to sodium.145 We postulated that if 15-crown-5 was added
to the uncatalysed reaction involving a sodium counterion, it would bind to the
sodium thus partially separating the counterion from the enolate anion. This in turn
O
OOOH
Br
base, dioxane
reflux, 18 h
141 83
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would make the enolate more ionic in nature, and allow the uncatalysed reaction to
proceed.
The reaction was performed as before with Na2CO3 as the base with 15–crown–5
added. The reaction was heated to reflux in dioxane overnight and was subjected to
the same work up and purification. Instead of no conversion as seen in the absence
of the crown ether, a 27% yield of 83 was obtained. Despite the low yield, this
provides further evidence that increased ionic character of the enolate encourages
the SNAr process.
Next we investigated the reaction using caesium carbonate to establish whether the
reaction with the palladium proceeds at a faster rate than in the absence of the
transition metal. We had previously observed when undertaking the optimisation of
the reaction, that using different ligands influenced the yield of the reaction which
suggested that the palladium and ligand are taking an active role in the reaction
mechanism.
To do this, we elected to study the extent of conversion to product, catalysed and
uncatalysed at various time points in order to observe whether the palladium was
increasing the rate of reaction. A third set of reactions were also carried out using
twice the equivalents of palladium and ligand.
Initially, time course experiments were attempted, whereby an internal standard
(1,3,5-trimethoxybenzene) was added. Aliquots of the reaction mixtures were taken
every 10 min for the first hour, every 20 min for the second hour and every 30 min
thereafter. Each sample was analysed by 1H NMR spectroscopy. Despite changing
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the equivalents of internal standard, there appeared to be loss of the internal
standard towards the end of the reaction with minor or no peaks corresponding to
this product remaining in the spectra. Overlapping starting material and product
peaks meant comparison of the integration of these peaks to monitor the extent of
conversion was also not possible. It was therefore decided that the reaction be
followed by the more labour intensive manner of isolating the product at various
time points.
As before, the reactions were performed in pairs so that identical reaction
conditions were achieved. The reactions were allowed to heat to reflux for 30 min,
1 h, 2, h and 3 h. Isolated yields were then determined for each reaction so that
accurate comparisons could be made.
Time
(min)
Yield (%)
uncatalysed
Yield (%)
2.5 mol % Pd[a]
Yield (%)
5 mol% Pd[b]
0 0 0 0
30 10 23 27
60 23 39 52
120 49 65 80
180 62 75 83
[a] 2.5 mol% Pd2(dba)3 and 6 mol% Xphos, [b] 5 mol% Pd2(dba)3, 12 mol% Xphos
Table 2.5: Time course experiment
O
OOOH
Br
Cs2CO3, dioxane
141 83
Chapter 2: Synthesis of Tetrahydroxanthones
___________________________________________________________________________________________________________________
___________________________________________________________________
83
From Table 2.5, it is clear to see that cyclisation proceeds faster via a catalysed
reaction mechanism with higher catalyst loading, leading to faster conversion to
product. These results are also shown in the graph below (Graph 2.1).
Graph 2.1: Graph to show intramolecular cyclisation: catalysed vs. uncatalysed
It is clear to see that whilst the reaction does work in the absence of catalyst, higher
yields and faster conversions are achieved under palladium catalysis.
2.5.3 Scope of Palladium Catalysed Cyclisation
The scope of the reaction was then investigated. Various substrates were
synthesised and isolated using the method described in Section 2.3.2 (Scheme 2.26).
The size and substituents of the saturated ring were modified as well as substituents
on the aromatic ring (Table 2.6). Despite moderate yields, sufficient material was
isolated to test the subsequent cyclisations.
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Scheme 2.41: Synthesis of substrates for cyclisation
The majority of substrates shown in Table 2.6 exist in enol form exclusively.
However, two substrates exist as a mixture of the keto and enol forms. These are
cyclopentanone derivative 159 (entry 5, 1:13 diketo:enol) and thiophene 177 (entry
10, 1:1 diketo:enol). Mechanistically, it should make no difference to the progress
of the reaction as the substrate is deprotonated (and indeed in the case of entry 10,
the cyclisation progressed in good yield (60%)). With the substrates in hand, they
were subjected to our optimal cyclisation conditions and the results are shown in
Table 2.6.
Scheme 2.42: Cyclisation
The results show a variety of functional groups are tolerated by this reaction. The
reaction with chloride 169 proceeded in high yield (entry 3, 88%) although iodide
158 did not proceed as efficiently (entry 2, 54%). The substrate derived from
cyclopentanone cyclised in a poor yield (entry 5, 23%) but all other substrates
cyclised in good to excellent yields.
O O
X
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78°C, 1 h–
HO
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[a]Yield of substrate formation by C-acylation. [b] Yield of product formation by Pd catalysed cyclisation
Table 2.6: Investigation of the scope of palladium catalysed cyclisation
Entry Substrate Yield[a] (%) Product Yield[b] (%)
1
58 93
2
43 54
3
42 88
4
59 76
5
38 23
6
45 91
7
42
O
O
Br
102
69
8
36 60
9 OOH
O O
Br 175
21 72
10
34 60
12 OOH
Cl
CF3
179
48 82
13
51 78
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As is evident from Table 2.6, the reaction tolerates a wide range of substrates
including electron withdrawing (entry 12) and electron donating substituents (entry
8). It also tolerates acid sensitive groups such as the acetal functional group (entry
9) and additional heteroatoms in the aryl component (entry 10). Expansion of the
saturated ring is tolerated, however, ring contraction resulted in a somewhat lower
yield. This is perhaps due to increased ring strain in 163.
Most encouragingly, entry 7 showed that the reaction tolerates substrates bearing
two C–Br bonds with the palladium regioselectively inserting into the C–Br bond
ortho to the carbonyl group. Some precedent for this kind of regioselectivity can be
found in the literature.146,147 This gave us confidence to attempt the tandem catalysis
described earlier (Scheme 2.37).
2.6 Tandem Catalysis
In order to test whether the Suzuki-Miyaura reaction would occur sequentially with
cyclisation, dibromide 172 was treated under the same conditions as previously,
with phenyl boronic acid (3 equiv.) added. The reaction mixture was heated to
reflux and after 2.5 h, the reaction was complete as determined by TLC.
Gratifyingly after work-up and purification by column chromatography, the 7-
arylated THX 103 was isolated in 78% yield.
Scheme 2.43: One-pot synthesis of 7-aryl THX
OOH
Br
Br
O
O
PhB(OH)2
Pd2(dba)3, xphos
Cs2CO3, dioxane
ref lux, 2.5 h
78%
172 103
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2.6.1 Investigations into the Reaction Mechanism
Time-course experiments were carried out by Ellanna Griffin (an undergraduate
summer student) using GC-MS to monitor the reaction and the intermediates that
were formed. Rapid consumption of starting material was observed with formation
of the cyclised product 102, i.e. where intramolecular C–O bond formation had
occurred. Over time, this product was consumed and the Suzuki-Miyaura product
102 was observed. No trace of 183 resulting from initial C–C bond construction
was observed (Scheme 2.44).
Scheme 2.44: Tandem catalysis pathway
2.6.2 Scope of tandem catalysis using Miyaura –Suzuki couplings
The scope of this reaction was probed and a small library of kigamicin analogues
produced (Scheme 2.45 and Table 2.7). The reaction tolerates changes in the size of
the saturated ring and different substituents on the aryl boronic acid.
OH O
Br
OH O
Br
Br
O
O
Br
O
O
172 102 103
183
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Scheme 2.45: Synthesis of 7-aryl THXs by tandem catalysis
n compound R Yield (%)
1 103 78
2 186 71
1 187 85
2 188 83
1 105
OMeO
68
1 189 60
Table 2.7: Library of compounds by tandem catalysis
It should be noted that compounds 186 and 188 were synthesised from
cycloheptanone by Ellanna Griffin, but the results are presented here for
completeness.
Other substitution patterns were also tolerated, being made from dichloride
substrates 194 and 195 (Scheme 2.46). This observation is important as there are
O OLi
O
O
Cl
Br
172 n=1 42%
185 n=2 38%
OH
Br
LDA, THF
78°C, 1 h– – 78 °C  rt, 18 h
184
Br
Br
O
R
O
R-B(OH)2
Pd2(dba)3, xphos
Cs2CO3, dioxane
reflux, 2.5 h
n n
n n
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biologically active natural products with aryl groups in these positions such as
isokibdelone C (190) and albofungin (191) (Figure 2.8).89,148 The Suzuki-Miyaura
reaction does not appear to proceed any less favourably using these aryl chlorides
(Scheme 2.46).
Figure 2.8: Isokibelone C (190) and albofungin (191)
Scheme 2.46: 5 and 6-arylated THXs from dichloride substrates
2.6.3 Tandem catalysis using Sonogashira and Heck cross couplings
Subsequently we decided to investigate whether other palladium cross coupling
reactions could be combined with THX formation. Due to time constraints, only a
small number of examples were examined. Both Sonagashira couplings 149 and
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Heck couplings 150 were achieved under the one-pot conditions, providing
additional examples of the versatility of this reaction (Scheme 2.47).
The cyclisation with Sonagashira and Heck reactions were performed in an
analogous way to the Suzuki-Miyaura couplings. The appropriate precursor was
treated with Cs2CO3, Pd2(dba)3 and Xphos in dioxane followed by addition of
alkyne or alkene. The Heck product 201 has tentatively been assigned as trans. This
stereochemical outcome is normally preferred.151-153 The 1H NMR spectrum shows
a singlet for the double bond hydrogens, clearly they are in very similar chemical
environments. Despite re-running the 1H NMR in various deuterated solvents
(CDCl3, MeOD, (CD3)2CO, DMSO-d), the peak did not resolve into a pair of
doublets that would have been used to assign stereochemistry more rigorously.
Scheme 2.47: Tandem catalysis utilising Sonagashira and Heck couplings
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O
O
199
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67%
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The Sonogashira coupling at both 5 and 6 positions of the THX were successful
although it was noted that the yield was greatly increased when electron rich alkyne
202 was used, as is typical for this reaction.154,155 Electron rich substrates facilitate
the nucleophilic addition of the alkyne to the palladium catalyst.
2.7 Conclusions and Future Work
In summary, existing literature methods have been used for the formation of simple
THXs that lie at the core of many natural products including the kigamicins.
Subsequent optimisation of the Suzuki-Miyaura reaction of the brominated
substrate allowed the synthesis of a total of twelve 7-arylated THXs whose
biological activity is assessed in Chapter Four.
Scheme 2.48: Suzuki-Miyaura couplings and functional group interconversions
An improved approach using metal catalysis was investigated and it was found that
both copper and palladium could be utilised for this cyclisation. After optimisation,
it was observed that higher yields were obtained using palladium. The scope of both
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reactions was also investigated providing access to a further eleven analogues of the
natural product.
Scheme 2.49: Optimised analogues via copper and palladium catalysis
We discovered that the reaction also proceeds uncatalysed. After conducting a base
screen, it was found that the uncatalysed reaction was base dependent and in
particular on the nature of the enolate anion-counterion interaction. The catalysed
reaction was found to proceed faster than the uncatalysed process, which was
emphasised by a further increase in reaction rate with higher loading of palladium.
Copper catalysed processes have been reported to give very low yields or no
product when there is an electron withdrawing group present promoting the
competing SNAr process.156,157 This was observed by us when investigating copper
to form THXs. However, the uncatalysed reactions gave better yields than those
containing copper. This is also illustrated in the work of Bowman et al.141 They
observed that addition of copper to their SNAr reaction hindered it completely by
coordination to the anion. Lee et al144 suggest that in the presence of a strong
counterion, the addition of H2O decreases the activation energy of the reaction by
coordinating to the counterion and thus partially neutralising the interaction
CuI, DMEDA
Cs2CO3, THF
reflux 18 h
4 examples, 10 54%–
O
X
HO
n
R2R1
O
O
n
R2R1Pd2(dba)3, xphos
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10 examples, 23 93%–
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between the anion and counterion. This was evidenced in our work where the
highest yield of 56% was observed in the copper reaction using H2O as a solvent.
A one-pot reaction was undertaken whereby the C–C and C–O bonds were formed
in the same reaction vessel. Good yields were obtained for this reaction and a
further nine analogues were synthesised. Time-course GCMS analysis showed that
the intramolecular C–O bond formation occurred first, followed by the
intermolecular C–C bond formation. The scope of the tandem catalysis has been
extended to include Sonagashira and Heck coupling reactions. Some of these results
have been published.158
Scheme 2.50: Scope of tandem catalysis
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Cs2CO3, dioxane
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Future work should involve a more detailed investigated of the tandem catalysis
using Sonogashira and Heck couplings, to fully test the scope of these one pot
reactions.
Work should also be carried out to incorporate the hydroxyl and saccharide
moieties surrounding the A ring of the natural product on the 7-arylated THX. As
will be discussed in Chapter Four, another member of the group, Samiullah,
synthesised a number of analogues containing functionalised A rings. However,
they were not coupled to the 7-aryl group which overlays with the natural product.
With these compounds in hand, direct comparisons could be made between the
biological activity of the simple 7-arylated THX (103) and those containing
functionalised A rings. Conclusions could then be drawn as to the importance of
these groups in the bioactivity exhibited by the natural product.
Chapter 3:
Towards the Fused Rings of
the Kigamicins
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3.1 Introduction
Alongside analogues based on the ABCF rings of the kigamicins, we also wanted to
make compounds containing the central CDEF rings of the natural product (Figure
3.1). Moreover by combining the knowledge gained here with that acquired in
Chapter 2, we would then be in a strong position to make the A-F rings of the
natural product and could then target synthesis of the natural product itself.
Figure 3.1: Kigamicin
3.2 Proposed Synthesis of the CDEF Rings of the Kigamicins
At the outset, we realised that the primary challenge to this piece of work was the
hexa-substituted C ring of the natural product (Figure 3.1).
In Chapter Two, attempts were made to synthesise the E ring via Suzuki-Miyaura
couplings of ortho-substituted boronic acids or their pinacol esters followed by
Friedel Crafts cyclisation (Section 2.2). Given the limited success, we decided to
explore alternative routes.
Literature suggested it would be possible to synthesise the aryl-aryl bond at C-7 of
the THX (206-207) via an oxidative coupling directed by the two hydroxyl groups
present ortho to the bond we wished to form (Scheme 3.1).159-161 This is an
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attractive strategy as it would allow for functionalisation at C-7 by C-H activation
thus simplifying the substrate required.
We anticipated that formation of substrate 206 required for the oxidative addition
step might require some investigation, but that we could add to the carbonyl moiety
of substrate 204 with a relevant nucleophile seemed plausible. Subsequent to
oxidative coupling to form 207, we expected that the enantioselective reduction to
form alcohol 208 with the correct stereochemistry would be simple and the acetal
formation to form 209 would also be facile. This would provide the CDEF rings of
the natural product and efforts could then be directed towards the incorporation of
the THX to this motif. To this end, it would be advantageous to incorporate a
carbonyl functional group to the fused CDEF rings as shown in Scheme 3.1.
Scheme 3.1: Strategy to the central ring system
We chose to begin with simple symmetrical substrate 211 which had both the
carbonyl groups and the hydroxyl groups we would require in the synthesis. This
compound had been made previously by oxidation of dicarbonyl cyclohexanedione
210 which was commercially available.162 Dione 210 was dissolved in acetic acid
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and heated to 80 °C before adding the N-bromosuccinimide (NBS). It was necessary
to add the NBS in portions very carefully due to the evolution of HBr. This
provided dimethyl dihydroxyteraphthalate 211 in an excellent 86% yield (Scheme
3.2).
Scheme 3.2: Oxidation of 210
Next, we protected the hydroxyl groups of 211 as methyl ethers. This was easily
accomplished using potassium carbonate and methyl iodide in acetone to give 204
in 84% yield (Scheme 3.3).
Scheme 3.3: Synthesis of the dimethoxy dimethylteraphthalate
The synthesis was scaled up and gram quantities of 204 were produced so that
various options could be explored.
Initial efforts focused on direct mono-addition to the ester. A variety of methods
were considered. Debenham et al163 successfully added the dianion of benzyl
carboxylic acid 212 to ester 213 and after decarboxylation, isolated 214 in 79%
yield (Scheme 3.4).
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Scheme 3.4: Addition and decarboxylation163
We attempted to use these conditions to add the dianion of 3-methoxyphenylacetic
acid 215 to ester 204 (Scheme 3.4). The 3-methoxy substituent on 215 was
necessary for directing oxidative addition later in the synthesis. Only a trace of
product was observed under these conditions as determined by 1H NMR
spectroscopy of the crude material showing a marginal underintegration of the
methyl ester peak and a small additional peak at 4.20 ppm which could correspond
to the methylene of product 205. However, only diester 204 was cleanly isolated.
The conditions of the reaction were modified (Table 1); KHMDS and LiHMDS
were used in place of NaHMDS, the equivalents of base were increased and the
reaction temperature was gradually increased to reflux. In all of these reactions,
only trace product could be detected and therefore it was decided that another
method needed to be found.
Scheme 3.5: Attempted dianion addition
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entry base equiv. base temp time result
1 NaHMDS 2 rt 18 h trace product
2 LiHMDS 2 rt 18 h trace product
3 LiHMDS 2 50 °C 18 h trace product
4 LiHMDS 3 rt 18 h trace product
5 LiHMDS 3 rt 60 h trace product
6 KHMDS 2 rt → 50 °C 18 h trace product 
7 KHMDS 2 reflux 60 h trace product
Table 1: Conditions used for attempted dianion addition
Next, a Claisen condensation of ester 216 with ester 204 was attempted. The
resultant β-keto ester 217, could then be hydrolysed to form the acid which would
then decarboxylate to give 219 (Scheme 3.6). This is very similar to the above
reaction but without the formation of the dianion which could potentially be a
source of problems. Initially the ester 216 was synthesised from the carboxylic acid
215 in 67% yield.
The Claisen condensation was then attempted using NaH in THF.164 Aqueous work
up and purification on silica gel afforded very little product (<18%) which was not
cleanly isolated. Both 1H NMR spectroscopy and mass spectrometry confirmed that
the correct product had formed but further optimisation was not undertaken due to
the complex mixture of products formed and difficulty in isolation of 217.
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Scheme 3.6: Proposed route via Claisen condensation
As an alternative strategy, we explored monoaddition of a Grignard reagent to the
diester. 2-Methoxybenzylchloride 220 was added to magnesium turnings in THF
and the mixture was allowed to stir at room temperature until the magnesium had
dissolved, indicating formation of Grignard 221. This was then added dropwise to a
solution of the starting material in THF at 0 °C. The reaction returned starting
material with no indication of any product having formed. It was postulated that the
failure of these reactions was due to the unreactive nature of ester 204. The ortho
substituted electron donating methoxy group could be making the ester less
electrophilic towards nucleophiles. To test this theory, commercially available
MeMgBr was reacted with diester 204 in THF and again no product was formed.
This provides further evidence that the diester is unreactive and that failure of this
reaction was not due to unsuccessful formation of the Grignard reagent.
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Scheme 3.7: Addition to the ester by a Grignard reagent
These results prompted us to re-evaluate our strategy. Next, attention turned to the
conversion of one of the ester groups into the corresponding acid chloride or
aldehyde, which would remove the symmetry in the molecule and make one of the
carbonyl groups more electrophilic at the same time.
Treatment of diester 204 with aqueous sodium hydroxide in THF provided a
mixture of products which was observed in the 1H NMR spectrum of the crude
material to be predominantly diester 204 and the corresponding diacid. The
competing diacid formation could be encouraged in this biphasic mixture.
Monohydrolysed product formed would be deprotonated and therefore more soluble
in the aqueous phase. It could then be hydrolysed faster than the diester which is
likely to be predominantly in the organic phase.
There have been examples in the literature such as the work by Valoti et al165 where
high yields of mono-acids are achieved by addition of MeOH to the reaction
mixture. Following Valoti’s work, diester 204 was therefore treated with aqueous
potassium hydroxide in THF with an equal volume of MeOH added to aid the
miscibility of the aqueous and organic phases. This gave product 222 in 50% yield.
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The low yield presumably reflects that diacid formation still competitively occurs
but is much improved compared with the biphasic reaction.
Scheme 3.8: Mono-hydrolysis
Acid 222 was then converted to the corresponding acid chloride using thionyl
chloride. We wished to add Grignard reagent 221 to this acid chloride but first
attempted the reaction using MeMgBr in THF to test the reactivity of the substrate.
Disappointingly, no product was apparent in the 1H NMR of the crude material,
only acid 222 and a complex mixture of other products in much smaller quantities.
Due to the complex mixture, it was not attempted to isolate these products.
Our efforts then turned to the synthesis of mono-aldehyde 223. To this end, direct
reduction of ester 211 using DIBAL was attempted (Scheme 3.9). Instead of
observing the aldehyde 223, a complex mixture of products was observed; benzyl
alcohol (resulting from over-reduction of one or both esters) and the dialdehyde as
well as starting material.
Scheme 3.9: Attempted reduction to aldehyde
Reduction of 211 to benzyl alcohol 224 without reduction of the second ester
moiety has been reported by Suzuki et al.162 This approach was investigated and the
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diester was treated with NaBH4 in THF/H2O at 0 °C. The reaction was complete in
1 h and product 224 isolated in 69% yield.
Scheme 3.10: Reduction of diester
Next, oxidation of alcohol 224 was explored. A range of oxidising agents (MnO2,
PCC, IBX, DMP) were examined but no successful oxidation was realised, perhaps
due to competitive oxidation of the hydroquinone. Selective protection of the
hydroxyl groups was attempted. Alcohol 224 was treated with methyl iodide and
potassium carbonate in acetone. However, the reaction did not go to completion and
only mono-protected product 225 was observed in low yield.
Scheme 3.11: Mono-protection
The hydroxyl group remaining unprotected was shown by NOE experiments to be
as depicted in Scheme 3.11. Irradiation of the methylene group of the primary
alcohol at 4.68 ppm (CH2) enhanced an aromatic singlet at 6.99 ppm (Ha). When
this signal was subsequently irradiated, both the phenolic hydroxyl group at 10.43
ppm (phenol) and the CH2OH (4.68 ppm) were enhanced. Conversely, irradiation of
the other aromatic hydrogen (7.23 ppm, Hb) enhanced the methyl ester (3.97 ppm)
and ether (3.84 ppm). On this basis, we were able to confidently assign the site of
the alkylation.
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Oxidation of alcohol 225 with MnO2 in CH2Cl2 at room temperature provided
aldehyde 226 in 91% yield. The conversion was not therefore attempted using other
oxidising agents. The high yield of oxidation of 225 is further evidence that
oxidation to the hydroquinone is a problem of substrate 224 and protection of the
phenolic hydroxyl group eliminates this side reaction.
Scheme 3.12: Oxidation using MnO2
Next we attempted to selectively add a Grignard reagent to aldehyde 226. The
Grignard reagent derived from 2-methoxybenzylchloride 220 was made (Scheme
3.13) and was added to the aldehyde in THF. Unfortunately no reaction occurred
and only starting material was isolated. This could have been due to the Grignard
reagent not forming properly but reactions with commercial Grignard reagents were
not investigated due to time constraints.
Scheme 3.13: Attempted addition of Grignard reagent to aldehyde
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3.2.1 Synthesis of a model substrate for oxidative addition studies
In parallel to the studies described above, we also targeted 229, which could be
used to study the oxidative cyclisation step for formation of the E ring of the natural
product.
Scheme 3.14: Oxidative cyclisation to form the E ring
Desai et al166 have developed a mild method using palladium catalysis for the α-
arylation of ketones. The method was shown to be general and applicable to a wide
array of substrates. This appeared an attractive method to assemble oxidative
cyclisation precursor 228.
2,5-Dimethoxyacetophenone 230 and 3-bromoanisole 231 were added to dioxane
followed by Pd(OAc)2, xantphos, K3PO4, THF and toluene according to Desai’s
conditions.166 This reaction afforded 232 in a modest 40% yield. In 2000, Buchwald
et al167 reported the use of various conditions for the α-arylation of ketones. They
established that the selection of base and ligand were very important with optimal
conditions substrate specific.167 They found higher yields when NaOtBu was used,
however, more sensitive substrates required weaker bases. Encouraged by their
findings, we examined the use of NaOtBu as base. When the reaction in Scheme
3.15 was repeated using NaOtBu, 232 was isolated in a much improved 88% yield.
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Scheme 3.15: Reaction using 2,5 dimethoxyacetophenone
Next, we attempted oxidative cyclisation of ketone 232. Wang et al 168 has reported
similar oxidative couplings of aromatic compounds catalysed by FeCl3 and
mCPBA. This method offers advantages over historic methods169 which use
thallium, lead or vanadium salts 170-174; its less expensive, less toxic and the
reactions can occur under much milder conditions. They showed that the reaction
provides excellent yields for intramolecular reactions and the scope can be extended
to intermolecular reactions albeit in reduced yields (Scheme 3.16).
Scheme 3.16: Intermolecular and intramolecular coupling using iron
Treatment of 232 with FeCl3 and mCPBA in CH2Cl2 at room temperature for 18 h
returned predominantly starting material. The reaction was repeated increasing the
reaction time to 48 h. In this case, there was much less starting material remaining
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and one main product formed (2:1 starting material to product) but the product and
starting material proved difficult to separate by chromatography. The major product
was assigned as 238 (Scheme 3.17).
Scheme 3.17: Possible regioisomers from oxidative coupling
The 1H NMR spectrum showed two doublets at 7.20 ppm and 6.80 ppm (J = 7.8
Hz) which coupled with one another assigned as Ha and Hb. There was also a
doublet at 7.25 ppm with a small coupling (3.4 Hz) assigned as He, a doublet at 6.85
ppm with a larger coupling (9.0 Hz) assigned as Hc and a doublet doublet at 6.97
ppm with a small and large coupling (3.4 Hz and 9.0 Hz) assigned as Hd. The
splitting pattern is fully consistent with the formation of 238. If isomer 237 had
been formed then with the methoxy group ortho to the bond formed, hydrogens
would be expected to have one large J coupling. Isomer 238 could be formed
preferentially due to less steric hindrance in comparison to 237. The formation of
this isomer is consistent with observations made by Wang et al.168 The product
could not be completely separated from the other fractions and could not therefore
be fully characterised.
There is an abundance of literature examples for oxidative coupling reactions on
substrates containing two hydroxyl moieties ortho to the bond forming.159 We
therefore set out to remove the methyl groups on our substrate and explore this
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chemistry. This was performed using 3.5 equivalents of BBr3 in CH2Cl2 at –78 °C
which gave 239 in an excellent 89% yield (Scheme 3.18).
Scheme 3.18: Deprotection
Amongst the reported oxidative couplings of phenolic compounds is the total
synthesis of TMC-66 by Hosokawa et al161 (Scheme 3.19). The structure of this
compound is quite similar to the kigamicin natural products despite the lack of THX
nucleus.
Scheme 3.19: Total synthesis of TMC-66161
The authors chose to construct the natural product using oxidative coupling (242-
243) as the final step (excluding deprotection steps). They investigated a range of
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oxidants and discovered that the only reagent that effected this transformation was
CuCl(OH).(TMEDA) which is a reagent developed by Koga et al175 for the
synthesis of binaphthol derivatives. The use of this reagent enabled Hosokawa to
obtain 243 in 20% yield. Further modification to the reagent by replacement of
TMEDA with N-methylimidazole (NMI) improved the yield to 89%.
We set out to explore the use of CuCl(OH).(TMEDA) and CuCl(OH).(NMI)2 in the
oxidative cyclisation of 239. TMEDA was added to CuCl in MeOH and stirred in
the presence of air at room temperature for 5 h. This provided a dark purple solid,
whose appearance and melting point (m.p = 137-138 °C, lit. 137-138 °C) matched
those described in the literature. This method was repeated with the substitution of
NMI for TMEDA, however neither the appearance nor the melting point matched
those described in the literature. Therefore, we proceeded with only
CuCl(OH).(TMEDA).
Substrate 239 was treated with CuCl(OH).(TMEDA) under Hosokawa’s
conditions.161 1H NMR spectroscopy of the crude material showed no consumption
of starting material. Triol 239 displayed poor solubility in CH2Cl2 and we were
concerned that this might be the reason for the failure of the reaction. The reaction
was therefore repeated with added MeOH to aid solubility of reagents, however this
led to no improvement.
Scheme 3.20: Attempted oxidative coupling
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To improve the solubility of the substrate, we sought to convert it into the
corresponding acetal 247 (Scheme 3.21).
Scheme 3.21: Planned synthesis of acetal 247
The reduction of ketone 239 was realised using NaBH4 which gave 246 in 53%
yield.
Scheme 3.22: Reduction using NaBH4
The main challenge with the purification and subsequent use of this compound was
again its solubility.
The synthesis was therefore re-evaluated. It was decided to attempt the mono-
deprotection of trimethoxy 232 prior to reduction of the ketone. It was hoped this
would provide a more soluble compound for acetal formation (Scheme 3.23).
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Scheme 3.23: Proposed synthesis
Ketone 232 was treated with 1.2 equivalents of BBr3 in CH2Cl2 at –78 °C. The
solution was stirred at this temperature for 1 h before pouring over a mixture of ice
and H2O to quench, providing 248 in 90% yield. It was predicted that the boron of
the BBr3 would coordinate to the carbonyl leading to removal of the adjacent
methyl group.176
Scheme 3.24: Directed deprotection
Detailed NMR analysis using COSY, HMQC and HMBC techniques, confirmed the
methyl group closest to the carbonyl oxygen was indeed removed. The doublet at
6.93 ppm (J = 9.2 Hz) is assigned as Ha as it is the only doublet with only a large
coupling and no additional smaller coupling. Ha is shown to be attached to C-3 by
HMQC and the hydroxyl group shows an interaction with C-3 by HMBC. Also, the
hydroxyl hydrogen appeared at 11.82 ppm suggesting hydrogen bonding to the
adjacent carbonyl oxygen atom.
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Asymmetric reduction of ketone 248 to the R-enantiomer as shown in Scheme 3.25
was next examined.
Scheme 3.25: Enantioselective reduction
Initially, a ruthenium (II) based catalyst developed by Noyori177,178 (Figure 3.2) was
utilised. This catalyst was made in situ by stirring (p-cymene) ruthenium(II)chloride
dimer and (R,R)-TsDPEN in a 5:2 mixture of NEt3: formic acid at 28 °C for 30 min
before adding ketone 248. Successful asymmetric reduction was achieved with this
catalyst providing 251 in 79% yield and 91% ee. Concurrently, the reduction was
attempted using a tethered catalyst developed by Wills et al 179-181 (Figure 3.2). A
small sample of catalyst was kindly provided by this group and the reduction was
realised in 76% yield and 93% ee.
Figure 3.2: Ruthenium catalysts used for asymmetric reduction
The ee of 251 was determined using HPLC with a chiral AD column and eluting
with 10% iPrOH in n-hexane at 1.0 mL/min. Under these conditions, two separate
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peaks of equal area were observed from the racemic substrate (the synthesis of
which is described below). When chiral compound 251, obtained using either
Noyori or Wills’ catalyst, was eluted under identical conditions, both peaks were
again observed but one was major and one minor. The major peak was the same for
251 obtained using both catalysts which provides evidence that both catalysts
provide the same enantiomer.
Product 251 has been tentatively assigned as the R-enantiomer. Wills’ et al180
describe the use of their tethered catalyst on a number of substrates and the (R,R)
catalyst has been shown to provide the (R) product in most cases. In cases of
acetophenone derivatives, excellent ee’s are reported. It is believed that the
reduction occurs via a 6-membered transition state (254) as depicted in Figure 3.3,
where there is an edge-face CH/π stabilising interaction. This directs the sense of 
reduction to give the preferred R product.
Figure 3.3: Transition state showing favourable CH/π interaction 
Alcohol 249 was also produced in racemic form using NaBH4. (±) 249 was isolated
in near quantitative yield.
Scheme 3.26: Reduction using NaBH4
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The cyclic acetal was then formed from the two hydroxyl groups. This step proved
more challenging than we had anticipated. We attempted this reaction using
paraformaldehyde with BF3.OEt182 or H2SO4183,184, using pTsOH with
dimethoxymethane in the presence of lithium bromide,185,186 and finally using
sodium hydride with diiodomethane or bromochloromethane.187 Most success was
achieved with the latter conditions, which gave 250 in 31% yield (Scheme 3.27).
Sufficient material was produced to examine further deprotection of the methyl
ethers.
Scheme 3.27: Acetal formation
We had concerns using BBr3 to protodemethylate 250. However, Taylor et al 188
had achieved chemoselective protodemethylations in the presence of acetals in the
total synthesis of preussomerins. On this basis, we elected to examine the use of
BBr3 for this transformation. Disappointingly upon treatment with BBr3,
degradation of 250 was observed and no product could be isolated from the reaction
mixture.
Seidel et al189 had encountered difficulties with the deprotection of methyl ethers
with BBr3 and they reported 9-I-BBN as a much milder reagent for this
transformation. However, when our substrate was treated with 9-I-BBN in CH2Cl2
at room temperature, no product was isolated. No success was encountered using
LiCl in DMF at 85 °C.190 No reaction occurred and only starting material was
isolated. Use of AlCl3 in CH2Cl2 was also ineffective.188
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Our final attempt at the deprotection of the methoxy groups was utilising NaSEt.
The use of this reagent was developed by Mirrington et al in the 1970s.191,192 NaSEt
was formed in situ from NaH and ethanethiol in DMF before adding 250. The crude
1H NMR spectrum showed the presence of the acetal group with the peaks for the
methyl groups underintegrating. This suggested that the reaction was proceeding,
albeit slowly but importantly without degradation of the acetal. Encouraged by
these results, the reaction was repeated and heated to reflux for 68 h. Despite the
much greater reaction time, there was still a large proportion of starting material
visible by crude 1H NMR spectroscopy, although even at reflux for this length of
time, the acetal was still intact. Due to time constraints, this work wasn’t pursued
further.
3.3 Attempted Synthesis of Hexa-Substituted THX Precursor
Based on the work carried out in Chapter Two, we wished to investigate the THX
formation of a hexa-substituted system to evaluate whether this would be a valid
route to more complex analogues (Scheme 3.28).
Scheme 3.28: Planned route to hexa-substituted THX 259
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Initially we oxidised the cyclohexanedione as in Section 3.2 (Scheme 3.2) but
instead, an additional 3.4 equivalents of NBS were added in order to brominate 211
before reducing it to 261 with Na2S2O4 (Scheme 3.29). This was carried out
following the conditions of Hintermann et al193, using NBS instead of NCS that
they used to synthesise the chlorinated analogue. This material was methylated
directly to give 255 in 17% yield over 3 steps.
Scheme 3.29: Synthesis of dibrominated, hexa-substituted substrate
Initial attempts to monohydrolyse 255 under the conditions established earlier using
KOH in methanol and THF returned clean starting material. The conditions were
modified to those used by Hart et al194 for monohydrolysis of a different diester.
255 was treated with NaOH in dioxane but at room temperature, again only starting
material was returned. After heating to reflux for 3 h, 256 was isolated in 40%
yield. Subsequent reaction with thionyl chloride at reflux gave the acid chloride in
high yield (Scheme 3.30).
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Scheme 3.30: Synthesis of acid chloride
With the acid chloride in hand we sought to make THX precursor 262 through
union with cyclohexanone 96. Initial attempts by direct deprotonation of
cyclohexanone with LDA were unsuccessful (Scheme 3.31).
Scheme 3.31: Attempted synthesis of THX precursor
However, when the lithium enolate was formed from the isolated silyl enol ether,
the addition of the cyclohexanone component was accomplished in low yield
(Scheme 3.32). Closer examination of the 1H and 13C NMR data, revealed that the
O-acylated product 263 had been isolated instead of the C-acylated product (262).
The alkene proton (Hb) appears at 5.61 ppm which is consistent with earlier O-
acylated product 145 (6.06 ppm). If C-acylation had occurred, resulting in the enol
tautomer, this proton would not be present. If C-acylation had resulted in diketone
262, Ha would be expected in the same region as for diketone 159 and 177 (4.15
and 4.63 ppm ) formed in Section 2.5.3. The 13C NMR spectrum showed the carbon
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signal for C-2 in 263 was at 115 ppm which is consistent with O-acylated product
145 formed earlier (118 ppm) (Scheme 2.29). The carbon signal at C-2 for diketone
159 and 177 was seen between 60 and 61 ppm. This result is perhaps not surprising
due the steric hindrance in acid chloride 257. Isomerisation of 263 was not
attempted due to limited material.
Scheme 3.32: Attempted synthesis from silyl enol ether
3.4 Conclusions
In summary, the E ring of the natural product has been formed by α-arylation of 
ketone 232 in high yield followed by aryl-aryl coupling of the C and F ring. The
unwanted regioisomer was formed in this reaction with iron, but attempts to realise
this transformation using copper catalysis were unsuccessful. Further investigation
is required to establish if both isomers are formed in this reaction and if the correct
isomer could be isolated.
Reduction of ketone 248 was achieved in high yield and ee and the resulting alcohol
was converted to the cyclic acetal. This bodes well for the synthesis of the natural
product.
Deprotection of the methyl ethers in the presence of the acetal, was met with limited
success although partial deprotection was observed when using NaSEt. Future work
should include the optimisation of this process and subsequent oxidative couplings
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of this substrate could then be investigated. It is anticipated that with free hydroxyl
groups, ortho oxidative coupling could be achieved.
Synthesis of a hexa-substituted THX precursor was attempted but only O-acylated
product was isolated and in low yield. Isomerisation to the C-acylated product could
be attempted, although there may be limited success with this route due to inherent
steric hindrance of this substrate.
3.5 Future Work
Future work should involve optimisation and completion of the synthesis of the C-F
rings of the natural product in the ways discussed above. Elaboration of this
synthesis to include rings G and H of the natural product should then be explored.
Analogous F-H rings have been made before by Hosokawa et al161 in the total
synthesis of TMC-66 (Scheme 3.33).
Scheme 3.33: Synthetic steps as part of TMC-66 total synthesis
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Combining this synthetic route with what has been learned throughout this chapter,
it is hoped that the synthesis of rings C-H could be completed. Initial coupling of
269 with ketone 230 under the conditions developed in Section 3.2.1 should provide
270 in good yield. Following the synthetic steps described in Hosokawa’s work,161
it is hoped that 271 could be made in a similar fashion. With 271 in hand,
protodemethylation, enantioselective reduction and acetal formation would provide
272 for oxidative coupling to 273.
Scheme 3.34: Possible route to F-H rings of the kigamicins
To achieve this synthesis, there are two main challenges to overcome. The chiral
centre in 271; this is controlled by Hosokawa using the enantiomerically pure
reagent 267, however, a much simpler substrate, not encorporating a chiral centre,
would be required in our synthesis. Achieving high enantioselectivity in this
reaction will need to be investigated. Selective protodemethylation of 271 could
also be problematic as there are two methyl ethers adjacent to carbonyl moieties.
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Complete protodemethylation could be carried out on this substrate as an
alternative.
This would provide complex analogues for biological screening but would also
pave the way for total synthesis of the natural product.
In this Chapter, one of the key steps is the high yielding palladium catalysed
arylation of ketone 232. In order to combine the work here with the tandem
catalysis developed in Chapter Two, a one-pot reaction involving both palladium
catalysed THX formation and arylation should be attempted (Scheme 3.35). If
successful, it could be possible to combine the THX A-C rings with the F-H rings
of the natural product (Figure 3.35).
Scheme 3.35: Tandem catalysis involving THX formation and arylation
Further elaboration of the C ring followed by the steps described in Scheme 3.34
would allow for total synthesis of the A-H rings of the natural product.
Figure 3.4: Kigamicin A-H rings
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4.1 Introduction
As described in Chapter 1, the kigamicins have shown cytotoxicity against the
pancreatic cancer cell line PANC-1.51 Importantly, the natural product also shows
selectivity, exhibiting a higher potency under nutrient deprived conditions in
comparison to nutrient rich conditions. This is key, as this mimics the austere
environment in which cancer cells survive in comparison to the nutrient rich
conditions of the environment of healthy cells. Significantly, this selectivity is
reversed in known chemotherapeutics with a reduced cytotoxic effect shown under
austere conditions, as described in more detail in Chapter One. In this chapter, we
report our own work to verify these findings for the natural product and the fuller
testing of all the analogues produced in Chapter Two, in these assays.
4.2 Attempted Isolation of Kigamicin D
For the biological assays it was essential to have an authentic sample of kigamicin
D for use as a positive control. This compound is not commercially available so we
initially attempted to re-isolate the natural product from one of the producing
bacterial strains.
The Amycolatopsis ML630-mF1 bacteria used by Kunimoto et al51 to isolate the
kigamicins are not commercially available but there is a more recent report by Tan
et al, suggesting that a different strain of bacteria, namely Amycolatopsis
regifaucium sp. nov. also produces the kigamicins.195 This bacteria is commercially
available and was purchased from Leibniz Institute DSMZ111 to establish if
appreciable quantities of kigamicin D could be isolated using it.
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Initial studies focused on the growth of the bacteria on two different types of agar to
observe on which it grew more rapidly. It was inoculated onto GYM (glucose,
yeast, malt) Streptomyces medium and GPHF medium. Successful growth was
observed on both growth media but the bacteria grew faster on the GYM
Streptomyces medium so this agar was selected for further studies.
The bacteria were inoculated from the agar into a liquid seed culture medium as
described in the experimental section. After three days, this culture was used to
inoculate the production medium. This was cultured for a further five days and
subjected to centrifugation followed by an aqueous work up of the resulting
supernatant.
Samples before and after inoculation and during the culture period were compared
by TLC and LCMS analysis. No product was detected. The crude material from the
broth extraction was analysed by HPLC and preparative TLC. No product was
detected or isolated by either method but this could have been due to limited
material.
This prompted us to scale up the bacteria culture ten fold in order to obtain further
material for analysis. The UV absorbance showed a broad absorbance at 390 nm.
For kigamicin D, the absorbance is reported to be 384 nm with the other kigamicin
compounds absorbing at similar wavelengths. 1H NMR spectroscopy showed many
peaks, some of which could have corresponded to the natural product but nothing
was conclusive. There were twelve components isolated by preparative TLC and
despite obtaining a considerable quantity of mass spectrometry data using LCMS
and MALDI-TOF methods, no mass ion corresponding to the natural product or
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aglycone were observed. We concluded that the bacteria did not produce the
kigamicins under our conditions. To make progress, we elected to purchase
kigamicin C from Enzo Life Sciences. (£192 / 0.5 mg, Nov 2012) due to the almost
identical biological activity reported compared with kigamicin D.51
4.3 Biological Assays
4.3.1 Introduction and assay development
In order for biological data to be obtained, we worked in collaboration with Dr
Jackie Whatmore at the Peninsula Medical School in Exeter. With their experience
and facilities for tissue culturing, I spent time here setting up our own anti-austerity
assays to screen our compounds.
In 2000, Esumi et al46 reported the high level of tolerance of PANC-1 cells to
austere conditions. In this work, they incubated PANC-1 cells in Dulbecco’s
modified Eagles medium (DMEM) and nutrient deprived media (NDM) and used
the trypan blue exclusion method to determine cell viability. In 2003, Kunimoto et
al51 reported the isolation, physico-chemical properties and biological activity of the
kigamicins and in 2004, Lu et al47 described this biological activity in more detail.
In both reports, the anti-austerity effect of the kigamicins was determined following
the procedures and NDM composition described by Esumi,46 but cell viability was
measured using WST (water soluble tetrazolium) colourimetric assays. We tried to
follow both methods as closely as possible in this work.
Commercially sourced PANC-1 cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with foetal bovine serum, glutamine and
gentamicin according to the experimental procedure in Chapter 5. These cells were
Chapter 4: Biological Assays and Development of Analogue SAR
___________________________________________________________________________________________________________________
___________________________________________________________________
127
adherent, growing attached to the bottom of the plastic flask used to culture them.
To feed the cells, the media was simply removed every 2-3 days and replaced with
fresh media. When approximately 80% confluence was reached (when
approximately 80% of the surface area on the base of the flask was covered with
cells), the cells were passaged by trypsinisation. In order to passage the cells (divide
them into new flasks to provide them more space to grow), the media was removed
and the cells washed using PBS (phosphate buffered saline) warmed to 37 °C. The
PBS was removed and the cells were treated with 1 mL trypsin solution (0.2
mg/mL) which is an enzyme used to detach the cells from the flask. After 5 min
incubation at 37 °C under 5% CO2/ 95% air atmosphere, the bottom of the flask was
gently tapped to encourage detachment. DMEM (10 mL) was then added to
neutralise the trypsin and the cell suspension was centrifuged at 200 g for 5 min.
The media/trypsin mixture was removed and the cell pellet was resuspended in 10
mL fresh media before dividing between new flasks.
Each flask of cells was checked on a daily basis for levels of confluency and also
for signs of infection or contamination.
4.3.2 Trypan blue assay
At the outset, it was important to test kigamicin C against the PANC-1 cell line and
to obtain results comparable to those published in the literature.47,51 This would
validate the published biological activity of kigamicin C in both DMEM and NDM
and confirm the variability of the assay in our laboratory. Kigamicin C could then
be used as a positive control and direct comparisons could be made between its
potency/selectivity and those of the analogues synthesised.
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It was decided that the first experiments would utilise the trypan blue exclusion
method following the original work by Esumi.46 Trypan blue is a diazo dye (Figure
4.1)196 which the cells can be treated with. Live cells with viable cell membranes
will not allow the dye to pass through the membrane. However, the cell membranes
of dead cells are no longer viable and intact and therefore the dye can easily pass
into the cells and stain them blue. Under the microscope, it is then obvious as to
which cells are alive and which are dead. This can be quantitatively measured by
counting the cells using a haemocytometer.
Figure 4.1: Trypan Blue Dye196
We wished to measure the levels of PANC-1 cell death at various concentrations of
kigamicin C, in both DMEM and NDM with control experiments using just DMSO
in NDM at the same concentrations. DMSO was used to dissolve kigamicin C and
all the other analogues tested hence it was important to establish that at the
concentrations tested, it was having no detrimental effect to the cells and any effects
observed were directly due to kigamicin C. Interestingly, this control experiment
was seemingly not carried out by Lu47 or Kunimoto.51
Initially cells were seeded into a 6 well plate and incubated at 37 °C under a 5%
CO2 / 95% air atmosphere. Once confluency was reached, the cells were treated
with kigamicin C at 0 µg/mL, 0.01 µg/mL, 0.1 µg/mL, 1.0 µg/mL and 10.0 µg/mL
in DMEM and separately NDM with a control experiment of DMSO in NDM also
at the same concentrations. The cells were then incubated for 24 h before
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trypsinising and staining with trypan blue dye. Counting both live and dead cells
under the microscope allowed percentage cell death to be calculated for each
different condition.
Although the trypan blue exclusion method is a very simple method and our results
clearly revealed cell death induced by kigamicin C, it is very labour intensive and
time consuming due to the manual cell counting of every well in each plate. The
experiment was therefore only carried out in duplicate and no statistical analysis
could be carried out. The results obtained were plotted and the IC50 values
measured from this (Table 4.1). There is considerable opportunity for human error
as is reflected by the anomalous result at 0.01 µg/mL in DMEM (Graph 4.1).
Having said this, the overall results clearly showed the expected trend both
qualitatively and quantitatively which matched the literature data (Graph 4.1 and
Table 4.1).
Table 4.1: Comparison with literature values 51,57
The plates containing DMEM with various concentrations of kigamicin C showed
that at very low concentrations, the cells survived but at higher concentrations, the
cells died with only 1% cell survival at 10 µg/mL. In the NDM, the same trend was
observed but lower concentrations of the kigamicin C killed the cells and with no
cell survival at only 1 µg/mL. At 0.1 µg/mL there was only 25% cell survival. This
assay shows that the cells are more susceptible to kigamicin C under nutrient
deprived conditions. The control experiment carried out with increasing
Media IC50 Measured
(µM)
Literature IC50
(µM)
DMEM 1.31 1.24
NDM 0.07 0.012
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concentrations of DMSO alone, showed that even at the highest concentration used
in the experiment, the cells survived, showing that at these concentrations DMSO
was not toxic.
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Graph 4.1: Cytotoxicity of kigamicin C on PANC-1 cells
4.3.3 WST-1 colourimetric assay
The trypan blue exclusion method is not suitable for high throughput work because
it is too labour intensive. We required a method that would allow for analogues to
be rapidly tested and all experiments to be carried out at least in triplicate.
It was decided to repeat the experiment using a WST-1 cell death assay as described
by Kunimoto.51 WST-1 is a tetrazolium salt which can be converted to formazan by
living cells. Metabolically active cells can oxidise NADH to NAD+ which in turn
reduces WST-1 to formazan (Scheme 4.1).197 Increase in the production of
formazan dye is therefore directly linked to the number of viable cells present in
each well of the plate. WST-1 reagent is pale red and formazan a dark red so the
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absorbance can be measured to determine how much formazan has been produced
using an ELISA microplate reader at 490 nm.
Scheme 4.1: Conversion of WST-1 reagent to formazan by living cells197
Despite there being an abundance of other available and widely used assays, the
WST-1 assay has the advantage that the formazan compound produced is water
soluble and therefore dissolves in the culture media. In contrast, other assays such
as MTT 198 involve additional steps in the assay where the crystals formed must be
redissolved in DMSO for analysis. The WST-1 assay avoids these additional steps
which reduces the time required for the assay and also avoids additional sources of
error.
In this assay, the cells were seeded in a 96 well plate at 1 x 104 cells and 100 µL
medium per well and incubated at 37 °C under a 5% CO2 / 95% air atmosphere for
24 h. In order to establish number of cells per well, the cells were trypsinised from
the flask they were grown in, centrifuged and resuspended in 10 mL of medium. A
small aliquot of cell suspension was further diluted (100 µL of cell suspension
added to 100 µL of medium) before counting cells using a haemocytometer. Once
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the concentration of cells per mL was known, the dilution factor could be calculated
based on total number of cells and total volume of medium required.
After 24 h incubation, the DMEM was removed and each well was washed with
100 µL PBS and this was then also removed. As with the trypan blue exclusion
method, serial dilutions of kigamicin C were prepared at 0 µg/mL, 0.001 µg/mL,
0.01 µg/mL, 0.1 µg/mL, 1.0 µg/mL and 10.0 µg/mL in both DMEM and NDM. The
cells were treated with these concentrations and each condition run in
quadruplicate. After 24 h incubation at 37 °C under a 5% CO2 / 95% air
atmosphere, the WST-1 reagent was added. After 1 h incubation, the absorbance of
the wells was read using the ELISA microplate reader and the results recorded.
Initial results showed the expected trend from the wells with DMEM and kigamicin
but results from all the wells containing NDM showed no difference in absorbance
between the control (with no kigamicin C) and the wells containing the kigamicin
C. This implies that none of the cells in any of the wells were metabolising WST-1
to formazan which implies 100% cell death in all wells including the controls.
There is literature suggesting that the cells should survive up to 72 h in NDM 46
with no cell death at all after just 24 h and this is what we had observed and
measured using the trypan blue exclusion method. Under the microscope it
appeared that the cells with no kigamicin were alive even though the assay
suggested they were not metabolising the WST-1 reagent. Although this is a
qualitative observation, it was obvious that there wasn’t 100% cell death as the
results indicated.
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After 24 h starvation it was possible that the cells were just metabolising very
slowly. The experiment was repeated but the same results were obtained. Cells were
then seeded at 2 x 104 cells per well and 3 x 104 cells per well, in case there weren’t
enough cells per well to metabolise the reagent to a significant level to be observed.
Fresh NDM medium was prepared and sterile filtered, different volumes (10 µL, 20
µL, 50 µL and 100 µL) of WST-1 reagent were added and different incubation
periods were allowed both with the kigamicin (16 h and 24 h) and also with the
WST-1 reagent (1 h, 2 h, 3 h and 4 h) but there was no change in the results.
Another explanation for the results could be that the reagent wasn’t compatible with
the NDM. There is literature to suggest that in some cases, the inhibition of the
WST-1 reagent has been observed despite metabolically active cells present.199
After many attempts to modify the procedure, it was decided to purchase a different
cytotoxicity detection kit.
4.3.4 Lactate dehydrogenase assay
Due to the problems encountered using the WST-1 cell assay, we sought a cell
death assay that would not be reliant upon metabolism of a reagent by the cells or
on such sensitive assay reagents. It was therefore decided that the lactate
dehydrogenase cell death assay200 would be appropriate for our requirements. This
assay has been reported for the determination of cell viability previously in an anti-
austerity assay for PANC-1 cells,48 however, it has not been used previously to
determine the biological activity of the kigamicins.
Lactate dehydrogenase is a soluble enzyme present in the cytoplasm of normal
cells. As previously explained, when a cell dies, the cell membrane loses its
integrity. In this case, the lactate dehydrogenase present in the cell can leak out of
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the cell cytoplasm and into the media surrounding the cell.201 By adding lactate to
the media, any lactate dehydrogenase present will oxidise the lactate to pyruvate.
This will initiate the reduction of NAD+ to NADH and H+. In the presence of added
diaphorase catalyst, the H+ generated and hydride from the NADH is transferred to
the tetrazolium salt thus reducing it to the formazan salt (Scheme 4.2).202
Scheme 4.2: Mechanism of reaction induced using LDH reagent202
The tetrazolium is a very pale yellow and the formazan salt is a dark red and so it is
very easy to observe in which wells of the plate there is the most lactate
dehydrogenase present. Not only is the change observed qualitatively but it can also
be measured quantitatively using an ELISA microplate reader. Given that there is a
direct link between concentration of lactate dehydrogenase in the media and cell
death, the absorbance measured can be used to determine the percentage
cytotoxicity of each well of a given plate.
Initial studies again focused on use of kigamicin C in both DMEM and NDM at
various concentrations alongside a control containing DMSO in NDM at the same
concentrations. Cells were seeded at 3 x 104 cells per well in a 96 well plate in
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DMEM, which was then incubated at 37 °C under a 5% CO2 / 95% air atmosphere
for 24 h. The DMEM was then removed and the cells were washed with PBS
(warmed to 37 °C). The cells were then treated with serial dilutions of kigamicin C
or DMSO. Kigamicin C was tested up to 10 µg/mL for a direct comparison to be
made with the literature. However, we wished to test the analogues synthesised up
to a concentration of 100 µg/mL and therefore the DMSO control experiment was
also carried out at this concentration.
Blank controls (containing only media), low controls (containing untreated cells)
and high controls (containing lysed cells to determine maximum cellular LDH
levels) were all included in the plate. Each concentration was carried out in
quadruplicate for this first study and each experiment was carried out on at least
three separate occasions.
The plate was allowed to incubate for 24 h at 37 °C under a 5% CO2 / 95% air
atmosphere. At this point, the plate was centrifuged in order for any dead cells to be
driven to the bottom of the plate and then 80 µL of supernatant was transferred to a
new plate. This was to keep the assay cell free as there is potential for the cells to
interfere with the absorbance measurements. The assay reagents as described in the
experimental section were mixed immediately prior to use and 80 µL of the mixture
was added per well of the plate. The plate was immediately covered to protect it
from the light and allowed to stand at room temperature for 30 min. Meanwhile, the
wells containing the untreated cells were lysed using a 2% (v/v) Triton X solution
in DMEM or NDM as appropriate. After 5 min at room temperature, the plate was
centrifuged and the supernatant mixed with the reagents as described above. This
was used as the high control to ascertain the maximum cellular LDH levels. After
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30 min incubation with the reagent, the absorbances of the wells were immediately
read with the ELISA microplate reader and the results recorded. Percentage
cytotoxicity could then be calculated for each compound according to the formula
in Figure 4.2.
Figure 4.2: Formula used to calculate percentage cytotoxicity
Once calculated, this data was plotted in a graph with error bars (Graph 4.2) and the
IC50 of kigamicin C was measured. This was compared with the potency values
published for kigamicin C (Table 4.2). 51,57
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Graph 4.2: Cytotoxicity of kigamicin C on PANC-1 cells
Table 4.2: Comparison with literature values 51,57
Media IC50 Measured
(µM)
Literature IC50
(µM)
DMEM 0.80 1.24
NDM 0.089 0.012
Absorbance measured - Low control
High control - Low control
x 100 = Percentage Cytotoxicity
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This shows that the results obtained in our assay are comparable to that of literature
values which validates our assay and it could therefore be conducted in the same
way for the analogues synthesised.
4.4 Assay Results for Kigamicin Analogues
4.4.1 Introduction
With the assay running successfully, the analogues could then be tested for
cytotoxicity against the PANC-1 cell line.
Each plate was set out similarly to the initial kigamicin screen but with a row for a
higher concentration (100 µg/mL) of compound to be added. Each plate could
contain two different analogues to be tested, one in each half of the plate. The plates
contained the same blank, low and high controls and the assay was carried out as
described previously. Each condition was assayed in triplicate and each experiment
was carried out on at least three separate occasions.
4.4.2 Results for the first generation analogues
The percentage cytotoxicity for each condition was calculated and the results
compiled for each analogue in DMEM and NDM. The results of any active
compounds can be seen in graphs in Appendix II. The trends observed from the
graphs are described herein.
Compounds 118, 120, 110 and 108 showed no cytotoxicity at any concentration up
to 100 µg/mL in either DMEM or NDM (Figure 4.3).
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Figure 4.3: Inactive compounds
Compounds 123 and 105 showed no activity in DMEM at all and very weak
potency (<50%) in NDM but only at the highest concentration of 100 µg/mL.
Compound 107 showed very similar activity to that of 123 and 105 but with
reversed selectivity showing weak potency in DMEM at 100 µg/mL.
Figure 4.4: Compounds with very little activity
Compound 111 showed approximately 90% cytotoxicity at 100 µg/mL in both
NDM and DMEM indicating no selectivity between the two media despite the high
cytotoxicity at the highest concentration. Compound 112 and 121 showed very
similar activity, showing almost 100% cytotoxicity in NDM at 100 µg/mL. The
selectivity of 121 was superior however with 27% cell death in DMEM whereas
112 showed 56% cell death in DMEM.
O
O
O
O
O
O
108
120
110
118
O
O
NH2O O NH
Me
O HO
O
O
O OMe
O
O
O N
O
HO O
O
HO
105 123 107
Chapter 4: Biological Assays and Development of Analogue SAR
___________________________________________________________________________________________________________________
___________________________________________________________________
139
Figure 4.5: Compounds with high potency in NDM
Compound 119 showed 35% cytotoxicity at 10 µg/mL in NDM with no toxic
effects to cells in DMEM at the same concentration. However, curiously there
appears to be no activity at 100 µg/mL in either media. In some plates, crystals
were observed under the microscope at 100 µg/mL which could suggest that the
compound precipitated at high concentrations when added to the aqueous media.
This could explain the apparent loss of activity at 100 µg/mL.
Figure 4.6: Compound 119
Despite being the simplest analogue, 103 showed more potency and selectivity than
any of the other analogues screened and was the only compound other than the
natural product to show significant activity at concentrations below 100 µg/mL.
Figure 4.7: Most active analogue
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There was 72% cell death at 10 µg/mL in NDM with no significant cell death
observed in DMEM at this concentration. Cytotoxic effects were only observed in
DMEM at 100 µg/mL and only 40% cell death was observed (see Appendix II for
graph).
We decided to re-evaluate this compound at more concentrations, as there was a
large increase in cell death between 1 µg/mL and 10 µg/mL in NDM and between
10 µg/mL and 100 µg/mL in DMEM. It was decided to screen this compound at 5
µg/mL and 50 µg/mL as well as the concentrations normally dosed. Pleasingly the
results showed that there was 17% cytotoxicity at 5 µg/mL and almost complete
cell death at just 50 µg/mL in NDM whereas in DMEM no cell death was observed
until 100 µg/mL (Graph 4.3).
Graph 4.3: Cytotoxicity of 103 on PANC-1 cells
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From the graph, the IC50 values in the different media could be calculated. For this
compound, the IC50 against PANC-1 cells in DMEM was >362 µM and 24 µM in
NDM.
To our disappointment, there was no immediately obvious trend between the
analogues to show which functional groups were needed for biological activity. The
more bulky tertiary amide groups were more active than the primary or secondary
amides. When an ester moiety was incorporated, activity improved when a hydroxyl
group was added to the saturated ring, however when the hydroxyl group was added
in the same position on the analogues with the amide moiety, the potency was
reduced.
The IC50 values of the most potent analogue (103) and three other analogues
showing activity against the PANC-1 cells were compared to the natural product
(Table 4.3).
Compound Selectivity bIC50 in DMEM
(µM) a
IC50 in NDM
(µM) a
Kigamicin C
(RMM = 809)
0.8 0.089 9.0
103
(RMM = 276)
>362 24 >15.1
121
(RMM = 350)
>286 155 >1.8
112
(RMM = 389)
229 121 1.9
111
(RMM = 347)
174 157 1.1
a estimated from concentration plots. b IC50 in DMEM / IC50 in NDM
Table 4.3: PANC-1 cell cytotoxicity data for the most active compounds
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As is clear from Table 4.3, the analogues synthesised show somewhat reduced
potency compared to the natural product. Even the most potent analogue identified
is 300 fold less potent. However, encouragingly 103 shows greater selectivity than
that of kigamicin C between cells grown in DMEM and those subjected to more
austere growing conditions.
4.4.3 Results for the second generation analogues
A selection of quite simple analogues were tested in the second screen as 103 was
shown from the first screen to be the most active. The analogues included those
with a ring expanded and contracted saturated ring of the THX, a 7-aryl xanthone
and also analogues with a naphthalene, acetal or methyl substituents resulting from
the one-pot methodology developed as described in Chapter Two (Figure 4.8).
Analogues 278, 186, 279 and 188 were synthesised by Ellanna Griffin.
Figure 4.8: Analogues for screening
Analogues synthesised by another group member, Samiullah, were also screened.
These all contained modifications to the saturated ring of the THX (Figure 4.9). It
was hoped they would provide an insight into the role of the hydroxyl and sugar
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moieties surrounding the saturated ring and whether they formed part of the
pharmacophore of the natural product.
Figure 4.9: Samiullah’s analogues
As with the screening of the first generation of analogues, the assay was validated
using a positive control. On this occasion, due to limited material, kigamicin C was
rechecked against 103, then 103 was used as the positive control in the remaining
assays.
For this screen, the analogues were tested at four concentrations instead of the
seven concentrations used in the first screen. This was to enable a higher throughput
of samples. Any compounds showing good activity and/or selectivity could be
retested but inactive compounds could be immediately eliminated from further
testing. The compounds were therefore tested at 0 µg/mL, 0.01 µg/mL, 1.0 µg/mL,
100.0 µg/mL. The assay itself was carried out as previously described.
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From the analogues shown in Figure 4.8, 189 and 176 showed no activity in either
DMEM or NDM at all. Compound 279, however, showed quite high potency at the
highest concentration. Despite this, there was very little selectivity shown between
the types of media used. In contrast, 186 and 278 both showed good selectivity but
the potency was poor with less than 40% cell death observed in both cases in
DMEM at 100 µg/mL. 188 showed less than 20% cytotoxicity and no selectivity.
Disappointingly, the majority of the analogues synthesised by Samiullah were also
inactive. Compounds 282 and 284 were both selective and showed no activity at all
in DMEM (Figure 4.10). In NDM, both displayed weak potency at the highest
concentration dosed (100.0 µg/mL) but not exceeding 40% cytotoxicity.
Figure 4.10: Compounds with activity
The only other analogue that showed any activity was 288 (Figure 4.10). Despite
this compound showing only weak activity at 100 µg/mL, due to excess material
available, it was possible to screen it at a very high concentration (1 mg/mL) in
addition to the standard concentrations screened. At 1 mg/mL, it caused 85% cell
death in NDM and only 22% cell death in DMEM. Clearly this compound is not
very potent but exhibits some selectivity.
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Compound tested % Cytotoxicity at 100 µg/mL
In DMEM In NDM
49 65
0 35
0 14
16 16
0 10
1 29
2 36
Table 4.4: Most active second generation analogues
4.5 Kibdelone C and Analogues
The kibdelone natural products as described in Chapter One, are very similar in
structure to the kigamicins.90 In 2011, Porco and coworkers93 reported their work on
the synthesis and biological evaluation of the ABCD ring fragments of the
kibdelones. This was later followed by the realisation of the total synthesis of
kibdelone C by the same group.91 The ABCD ring fragments 60 and 61 (Figure
4.11) were screened in the NCI 60 human tumour cell line screen203 and were found
to have GI50 values of 4.5 µM compared to kibdelone C which they found to be 100
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fold more potent at 2.4 nM. They concluded that the anti-cancer potency must lie in
part in the THX portion of the natural product not found in their analogues. We
were intrigued to find out what potency the kibdelones and ABCD fragments would
exhibit in our assay using the PANC-1 cell line as they have not been previously
screened in an anti-austerity assay.
We sought to establish a collaboration with the Porco group in order that we might
be able to obtain a sample of these compounds to screen in our assay. We were
successful and were kindly provided with a small sample of 41, 289, 60 and 61
(Figure 4.11).
Figure 4.11: Kibdelone C related compounds
We tested these compounds in parallel with the analogues in the second compound
screen against the PANC-1 cell line. These compounds were anticipated to have
high potency and they were screened at all seven concentrations at the first pass.
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The results are summarised in graph form (Appendix II) and in Table 4.5 showing
the comparison with kigamicin C and our most potent synthetic analogue of the
kigamicins.
The ABCD quinone and hydroquinone (60 and 61) both showed very similar
results with no activity at 1 µg/mL in either media. At 10 µg/mL there was greater
than 50% cell death in NDM for both compounds with very little if any activity in
the DMEM. At 100 µg/mL there was complete cell death in NDM.
Kibdelone C and methyl ether analogue 289 of this natural product both exhibited
much higher potency than that of the smaller analogues lacking the THX moiety.
Cell death could be observed from 0.1 µg/mL in NDM when cells were dosed with
289 and from as low as 0.01 µg/mL in NDM when treated with kibdelone C (41)
itself. Compound 289 exhibited greater selectivity than the natural product only
achieving 51% cell death in DMEM at the maximum concentration whereas 100%
cell death was reached at 10 µg/mL in DMEM with kibdelone C.
Compound
IC50 (µM) a
Selectivity bDMEM NDM
Kigamicin C
(RMM = 809)
0.8 0.089 9.0
103
(RMM = 276)
>362 24 >15.1
Kibdelone C
(RMM = 585.5)
6.7 0.69 9.7
289
(RMM = 600.5)
160 1.45 110.3
60
(RMM = 429.5)
142 16 8.9
61
(RMM = 431.5)
218 20 10.9
a estimated from concentration plots b IC50 in DMEM / IC50 in NDM
Table 4.5: Comparing Kigamicin and Kibdelone analogues
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The results show that the most potent compound against the PANC-1 cell line is
kigamicin C although 289 exhibits excellent selectivity and good potency.
4.6 Conclusions and Future Work
In this chapter, we have discussed the attempted isolation of kigamicin C from
Amycolatopsis regifaucium strain of bacteria. This involved the culture of this
bacteria and extraction from the culture broth. Despite using different analytical
techniques, no evidence for the production of the kigamicins could be obtained.
The PANC-1 cell line was utilised to test the potency of the analogues and the
natural product itself. The trypan blue exclusion method was used to show the
effect of kigamicin C on pancreatic cancer cells under normal conditions and also
those of nutrient deprivation. It was found that these results were very similar to
those already published for the natural product.51 However, this assay was not
suitable for high throughput screening and therefore was not further investigated.
The WST-1 cell death assay was undertaken in accordance with earlier work by
Kunimoto51 in this field. Despite obtaining results analogous to those found with the
trypan blue exclusion method in DMEM, the assay failed to provide any reliable
results when tested in NDM and this assay method was thus abandoned.
The LDH assay was successfully implemented for the screening of kigamicin C.
The results showed that the data matched that of the trypan blue exclusion method
and also correlated with potencies previously reported.51 This assay was then
utilised to screen a further twelve analogues made in Chapter 2, or provided by
coworkers.
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There were mixed results from the assay with THX analogues exhibiting varying
potencies and selectivities between the two media. The most potent analogue
identified was 103. This compound exhibited high cytotoxicity at 100µg/mL and in
our hands, greater selectivity than the kigamicin C itself.
The second compound screen (fifteen compounds) was composed of some similar
compounds but also those with substituents on the saturated ring of the THX.
Disappointingly, none of the compounds showed better potency or selectivity than
that of 103.
Kibdelone C, 41, the methyl ether analogue 289, the ABCD quinone 60 and
hydroquinone 61 were obtained from Porco and coworkers at Boston University.
The cancer cells were also treated with these compounds and screened in our assay.
The results showed for the first time that structurally related kibdelones are also
active in anti-austerity assays.
From our work, we can conclude that some structures bearing the THX nucleus can
display anti-austerity activity. However, the fact that small structural changes (eg.
103 to 120) lead to a complete loss of activity, perhaps suggests that the situation is
complex and that the THX nucleus per se is not responsible for activity. The fact
that the ABCD fragments of kibdelone C (devoid of the THX) are active at similar
levels of potency/selectivity supports this suggestion. Work to more fully address
the origins of bioselectivity of the natural products is needed.
Other 7-arylated natural products (as described in Chapter One) should be procured
if possible and screened in our assay to ascertain if these also exhibit anti-austerity
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activity. Synthetic analogues of these compounds could be made in order to obtain
more information about the pharmacophore of this family of compounds.
Kigamicin is known to inhibit the phosphorylation of Akt suggesting inhibition of
the PI3K-Akt pathway as discussed in Chapter One. However the molecular target
is not known. To further understand the activity of the analogues and indeed the
kibdelones, it is vital to discover if they target the same pathway as the kigamicins.
In order to do this Western-Blot analysis should be undertaken to observe if they
also inhibit the phophorylation of Akt. Flow cytometry should also be carried out to
determine whether the analogues induce necrosis (as kigamicin) or apoptosis to
cancer cells. This would give some indication that they have a similar mode of
action. Although target pathway cannot by inferred from this information, if the
analogues induce apoptotic cell death or if they do not inhibit phosphorylation of
Akt, this would strongly suggest they are acting in a different way to the natural
product.
Chapter 5:
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General Information
Anhydrous solvents were purchased in Sure/SealTM bottles from Sigma-Aldrich Co.
All other solvents and reagents were used as received or purified by standard
protocols. Petroleum ether refers to the fraction of petroleum ether having a boiling
point between 40-60°C. All experiments were performed under an inert atmosphere
in oven-dried or flame-dried glassware as required. Column chromatography was
carried out using Matrex silica 60. Thin layer chromatography was performed on
pre-coated aluminium-backed plates (Merck Kieselgel 60 F254) and were visualised
using UV light and staining with potassium permanganate or ceric ammonium
molybdate followed by heating. Melting points were recorded on a Gallenkamp
MPD350 apparatus and are reported as observed. Single crystal X-ray diffraction
data were obtained using a Siemens SMART XRD system or an Oxford Diffraction
Gemini XRD system. Optical rotations were measured with an AA1000 polarimeter
and are quoted in 10-1 deg cm2 g-1. Chiral HPLC was conducted using a Hewlett
Packard 1050 Series machine using a chiral AD column (10% iPrOH/n-hexane: 1.0
mL/min). Infrared spectra were recorded on a Perkin Elmer Paragon 1000 FT-IR
Spectrometer with internal calibration and are given in cm-1. 1H and 13C NMR
spectra were recorded at 300 MHz and 75 MHz respectively on a Bruker
Spectrospin DPX300; at 400 MHz and 100 MHz respectively on a Bruker
Spectrospin DPX400; at 500 MHz and 125 MHz respectively on a Bruker
Spectrospin DPX500 and at 600 MHz and 150 MHz respectively on a Bruker
Spectrospin DPX600. Chemical shifts are reported in ppm using TMS as the
internal standard. Signals are reported as singlets (s), doublets (d), triplets (t) etc
which refer to the spin-spin coupling patterns. Coupling constants are reported in
Hertz. High resolution mass spectra were obtained using a Bruker ESI-Micro TOF
instrument. Warwick Analytical Service carried out all elemental analysis.
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1,2,3,4-Tetrahydro-xanthen-9-one (by acid catalysed dehydration) (83)
iPr2NH (0.45 mL, 5.0 mmol) and n-BuLi (1.6 M in hexane) (3.1
mL, 5.0 mmol) were added to THF (10 mL) at -78 ºC under
nitrogen. The solution was allowed to stir for 5 min before
addition of cyclohexanone (0.53 mL, 5.0 mmol). The solution was stirred at -78 ºC
for 2 h. Acetylsalicyloyl chloride (1.02 g, 5.0 mmol) was dissolved in THF (10 mL)
and added to the reaction mixture which continued to stir at -78 ºC for 5 h before
allowing to warm to room temperature overnight. The solvent was removed in
vacuo and the residue treated with a saturated aqueous solution of NH4Cl (20 mL).
The aqueous phase was extracted with toluene (3 x 30 mL), washed with brine (2 x
20 mL), dried (MgSO4), filtered and the solvent removed in vacuo. The brown oily
residue was then treated with HCl: AcOH 1:20 (3 mL mmol-1) and heated to 60 ºC
for 1 h. The mixture was allowed to cool to room temperature and poured over ice
(15 g). The aqueous phase was extracted with toluene (3 x 30 mL), washed with a
saturated aqueous solution of NaHCO3 (30 mL), dried (MgSO4), filtered and the
solvent removed in vacuo to give an orange oil which solidified on standing at room
temperature. The crude material was purified by column chromatography eluting
with 10% EtOAc in petroleum ether to give a white solid. Trituration with Et2O
provided the title compound as a white solid (226 mg, 22%). m.p. 104-105 °C (lit.
m.p. 100-101 °C); Rf = 0.35 (10% EtOAc in petroleum ether); IR (film) 2946, 1619,
1607, 1462, 1408, 765 cm-1; δH (400 MHz, CDCl3) 8.20 (1H, d, J = 7.8, ArH), 7.60
(1H, t, J = 7.8, ArH), 7.41-7.31 (2H, m, ArH), 2.72-2.64 (2H, m, CH2), 2.63-2.55
(2H, m, CH2), 1.93-1.83 (2H, m, CH2), 1.83-1.73 (2H, m, CH2). δC (100 MHz,
CDCl3) 177.7 (C=O), 163.8 (=CCO), 155.9 (C, Ar), 132.9 (CH, Ar), 125.7 (CH,
Ar), 124.4 (CH, Ar), 123.2 (C, Ar), 118.4 (=CO), 117.6 (CH, Ar), 28.2 (CH2), 21.6
(CH2), 21.5 (CH2), 21.0 (CH2); MS (ES+) m/z 223 [MNa+]; HRMS (ES+) calcd. for
O
O
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C13H12NaO2 [MNa+]: 223.0730; found: 223.0728. Anal. calcd. for C13H12O2: C
77.98; H 6.04 %. Found C 77.68; H 6.03 %. Data is in accordance with literature
values. 109,204
2-Acetoxy-5-bromobenzoic acid (99)
Acetic anhydride (1.6 mL, 16.6 mmol) and pyridine (80 µl, 1.0
mmol) were added to a suspension of 5-bromosalicylic acid (2.0
g, 9.2 mmol) in acetic acid (18 mL). The mixture was stirred at
room temperature for 18 h before filtering the resultant white
precipitate (985 mg, 49%). m.p. 153-155 °C; IR (film) 2878, 1760, 1660, 1595,
1296, 866 cm-1; δH (400 MHz, CDCl3) 10.91 (1H, s, OH), 7.76 (1H, dd, J = 2.4, 8.6,
ArH), 8.27 (1H, d, J = 2.4, ArH), 7.06 (1H, d, J = 8.6, ArH), 2.37 (3H, s, CH3); δC
(100 MHz, CDCl3) 169.4 (C=O), 168.5 (C=O), 150.3 (C, Ar), 137.8 (CH, Ar),
135.2 (CH, Ar), 125.8 (CH, Ar), 123.8 (C, Ar), 119.2 (C, Ar), 20.9 (CH3); MS
(ES+) m/z 280 [MNa+, 79Br], 282 [MNa+, 81Br] ; HRMS (ES+) calcd. for
C9H7BrNaO4 [MNa+, 79Br]: 280.9420; found: 280.9417. Data is in accordance with
literature values.205
Acetic acid 4-bromo-2-chlorocarbonyl-phenyl ester (100)
Carboxylic acid 99 (10 g, 39 mmol) was treated with thionyl
chloride (26.3 mL, 360 mmol) and heated to 70°C for 1 h. The
mixture was allowed to cool to room temperature before
removing excess thionyl chloride in vacuo. The resultant bright
yellow solid was recrystallised from hexane to give the title compound as a pale
yellow solid (9.49 g, 89%). m.p. 60-61 °C; IR (film) 1751, 1464, 1370, 1176, 882,
841, 747 cm-1; δH (400 MHz, CDCl3) 8.32 (1H, d, J = 2.3, ArH), 7.78 (1H, dd, J =
Br
HO
O
O
O
Br
Cl
O
O
O
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O
O
Br
2.3, 8.6, ArH), 7.06 (1H, d, J = 8.6, ArH), 2.35 (3H, s, CH3); δC (100 MHz, CDCl3)
169.5 (C=O), 168.7 (C=O), 150.4 (C, Ar), 135.3 (CH, Ar), 126.1 (CH, Ar), 126.0
(CH, Ar), 123.9 (C, Ar), 119.3 (C, Ar), 21.1 (CH3).
7-Bromo-1,2,3,4-tetrahydro-xanthen-9-one (102)
iPr2NH (4.5 mL, 32 mmol) and n-BuLi (1.6 M in hexane)
(20.3 mL, 32 mmol) were added to THF (90 mL) at -78 ºC
under nitrogen. The solution was stirred at -78 ºC for 5 min
before addition of cyclohexanone (3.3 mL, 32 mmol). The solution was stirred at -
78 ºC for 1 h. Acid chloride 100 (9.0 g, 32 mmol) was dissolved in THF (90 mL)
and added to the reaction mixture which continued to stir at -78 ºC for 5 h before
allowing to warm to room temperature overnight. The solvent was removed in
vacuo and the residue treated with a saturated aqueous solution of NH4Cl (200 mL).
The product was extracted with toluene (2 x 200mL), washed with brine (2 x 200
mL), dried (MgSO4), filtered and the solvent removed in vacuo. The orange oily
residue was then treated with HCl:AcOH 1:20 (3 mL/mmol) and heated to 60º C for
3 h. The mixture was allowed to cool to room temperature and poured over ice (150
g). The aqueous phase was extracted with toluene (2 x 200 mL), washed with a
saturated aqueous solution of NaHCO3 (200 mL), dried (MgSO4) and filtered. The
solvent was removed in vacuo to give an orange oil which solidified on standing at
room temperature overnight. The crude material was recrystallised from MeOH to
give the title compound as a pale orange solid (4.02 g, 44%). m.p. 150-151 °C; IR
(film) 2940, 1627, 1602, 1435, 1304, 826, 648 cm-1; δH (400 MHz, CDCl3) 8.30
(1H, d, J = 2.2, ArH), 7.67 (1H, dd, J = 2.2, 8.8, ArH), 7.28 (1H, d, J = 8.8, ArH),
2.71-2.62 (2H, m, CH2), 2.61-2.51 (2H, m, CH2), 1.93-1.83 (2H, m, CH2), 1.81-1.72
(2H, m, CH2); δC (100 MHz, CDCl3) 176.4 (C=O), 164.2 (=CCO), 154.7 (C, Ar),
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135.9 (CH, Ar), 128.3 (CH, Ar), 124.5 (C, Ar), 119.6 (CH, Ar), 118.7 (C, Ar),
117.7 (=CO), 28.2 (CH2), 21.8 (CH2), 21.5 (CH2), 21.0 (CH2); MS (ES+) m/z 301
[MNa+, 79Br], 303 [MNa+, 81Br]; HRMS (ES+) calcd. for C13H11BrNaO2 [MNa+,
79Br]: 300.9835; found: 300.9835. Anal. calcd. for C13H11O2Br: C 55.94; H 3.97; Br
28.63 %. Found C 55.74; H 3.96; Br 28.79 %.
7-Phenyl-1,2,3,4-tetrahydro-xanthen-9-one (103)
Pd(PPh3)4 (8 mg, 0.007 mmol) was added to a biphasic
mixture of 102 (100 mg, 0.36 mmol) and phenylboronic
acid (88 mg, 0.72 mmol) in ethanol (1.5 mL), toluene (1.5
mL) and 2M Na2CO3 (0.36 mL). Mixture subjected to microwave irradiation
(300W) for 10 min at 110 °C. The solvent was removed in vacuo before adding
H2O (10 mL). The aqueous phase was extracted with EtOAc (10 mL) and washed
with H2O (10 mL) and brine (10 mL). The organic phase was dried (MgSO4),
filtered and solvent removed in vacuo to give a dark yellow oil. The crude material
was purified using column chromatography eluting with 10% EtOAc in petroleum
ether to give the title compound as a white solid (70 mg, 71%). m.p. 120-121 °C; Rf
= 0.19 (10% EtOAc in petroleum ether); IR (film) 2934, 1640, 1608, 1471, 1149,
824, 764, 700, 610 cm-1; δH (400 MHz, CDCl3) 8.42 (1H, d, J = 2.3, ArH), 7.88
(1H, dd, J = 2.3, 8.7, ArH), 7.66 (2H, d, J = 7.5, ArH), 7.46 (3H, m, ArH), 7.37
(1H, t, J = 7.5, ArH), 2.74-2.66 (2H, m, CH2), 2.65-2.56 (2H, m, CH2), 1.94-1.84
(2H, m, CH2), 1.83-1.74 (2H, m, CH2); δC (100 MHz, CDCl3) 177.8 (C=O), 163.9
(=C), 155.3 (C, Ar), 139.6 (C, Ar), 137.5 (C, Ar), 131.8 (CH, Ar), 128.9 (CH, Ar),
127.6 (CH, Ar), 127.2 (CH, Ar), 123.6 (CH, Ar), 123.3 (C, Ar), 118.5 (=C), 118.1
(CH, Ar), 28.2 (CH2), 21.9 (CH2), 21.7 (CH2), 21.1 (CH2); MS (ES+) m/z 299
O
O
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[MNa+]; HRMS (ES+) calcd. for C19H16O2 [MNa+]: 299.1043; found: 299.1053.
Anal. calcd. for C19H16NaO2: C 82.58; H 5.84 %. Found: C 82.29; H 5.85 %.
3-(9-Oxo-5,7,8,9-tetrahydro-6H-xanthen-2-yl)benzoic acid methyl ester (105)
Pd(PPh3)4 (8 mg, 0.007 mmol) was added to a
biphasic mixture of 102 (100 mg, 0.36 mmol) and 3-
methoxycarbonylphenylboronic acid (196 mg, 1.07
mmol) in ethanol (1.5 mL), toluene (1.5 mL) and
2M Na2CO3 (0.36 mL). Mixture subjected to microwave irradiation (300W) for 10
min at 110 °C. The solvent was removed in vacuo before adding H2O (5 mL). The
aqueous phase was extracted with EtOAc (3 x 5 mL), washed with H2O (5 mL) and
brine (2 x 5 mL), dried (MgSO4), filtered and solvent removed in vacuo. The crude
material was purified using column chromatography eluting with 25% EtOAc in
petroleum ether to give the title compound as a pale yellow solid (72 mg, 61%).
m.p. 138-140 °C; Rf = 0.10 (20% EtOAc in petroleum ether); IR (film) 2941, 1711,
1636, 1610, 1299, 1239, 819, 764 cm-1; δH (400 MHz, CDCl3) 8.44 (1H, d, J = 2.0,
ArH), 8.32 (1H, s, ArH), 8.04 (1H, d, J = 7.9, ArH), 7.86 (2H, dt, J = 2.0, 7.9,
ArH), 7.53 (1H, t, J = 7.9, ArH), 7.47 (1H, d, J = 8.5, ArH), 3.95 (3H, s, OCH3),
2.75-2.66 (2H, m, CH2), 2.66-2.55 (2H, m, CH2), 1.96-1.84 (2H, m, CH2), 1.84-1.71
(2H, m, CH2); δC (100 MHz, CDCl3) 177.7 (C=O), 166.9 (C=O), 164.0 (=C), 155.6
(C, Ar), 139.9 (C, Ar), 136.4 (C, Ar), 131.8 (CH, Ar), 131.5 (CH, Ar), 130.9 (C,
Ar), 129.1 (CH, Ar), 128.7 (CH, Ar), 128.2 (CH, Ar), 123.8 (CH, Ar), 123.4 (C,
Ar), 118.6 (=C), 118.3 (CH, Ar), 52.2 (OCH3), 28.2 (CH2), 21.9 (CH2), 21.7 (CH2),
21.1 (CH2); MS (ES+) m/z 357 [MNa+]; HRMS (ES+) calcd. for C21H18NaO4
[MNa+]: 357.1097; found: 357.1089. Anal. calcd. for C21H18O4: C 75.06; H 5.43 %.
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Found: C 75.43; H 5.43 %. Slow evaporation of chloroform provided crystals
suitable for X-ray analysis (see Appendix I)
Crystal Data. C21H18O4, M =334.35, monoclinic, a = 12.2467(2) Ǻ, b = 
7.47592(13) Ǻ, c = 17.7579(3) Ǻ, U = 1614.63(5) Ǻ3, T = 100(2) K, space group
P21/c, Z = 4, µ(MoKα) = 0.095, 21519 reflections measured, 5502 unique (Rint =
0.0309) which were used in all calculations. The final wR2 was 0.1072 and R1 was
0.0429 (>2 sigma (I)).
7-(2-Hydroxy-phenyl)-1,2,3,4-tetrahydro-xanthen-9-one (107)
Pd(PPh3)4 (16 mg, 0.014 mmol) was added to a biphasic
mixture of 102 (200 mg, 0.72 mmol) and 2-
hydroxybenzene boronic acid (296 mg, 2.14 mmol) in
ethanol (3 mL), toluene (3 mL) and 2M Na2CO3 (0.72 mL). Half of this mixture at a
time was subjected to microwave irradiation (300 W) for 10 min at 110°C. The
mixtures were recombined and the solvent was removed in vacuo before adding
H2O (20 mL). The aqueous phase was extracted with EtOAc (20 mL), washed with
H2O (20 mL), brine (20 mL), dried (MgSO4), filtered and solvent removed in
vacuo. The crude material was purified using column chromatography eluting with
25% EtOAc in petroleum ether. Trituration of the resultant solid with MeOH
provided the title compound as a brown solid (22 mg, 11%). Rf = 0.20 (25% EtOAc
in petroleum ether); δH (400 MHz, CDCl3) 8.20 (1H, d, J = 2.3, ArH), 7.96 (1H, dd,
J = 2.3, 8.8, ArH), 7.60 (1H, d, J = 8.8, ArH), 7.33 (1H, dd, J = 1.7, 7.6, ArH), 7.20
(1H, dt, J = 1.7, 7.6, ArH), 6.98 (1H, d, J = 7.6, ArH), 6.90 (1H, t, J = 7.6, ArH),
2.73 (2H, t, J = 6.3, CH2), 2.46 (2H, t, J = 6.3, CH2), 1.88-1.80 (2H, m, CH2), 1.76-
1.68 (2H, m, CH2); δC (100 MHz, CDCl3): δ 176.8 (C=O), 164.4 (=C), 155.8 (C, 
Ar), 154.6 (C, Ar), 135.8 (C, Ar), 135.0 (CH, Ar), 130.6 (CH, Ar), 129.4 (CH, Ar),
O
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126.5 (C, Ar), 125.0 (CH, Ar), 122.5 (C, Ar), 119.5 (CH, Ar), 117.9 (=C), 117.8
(CH, Ar), 117.0 (CH, Ar), 27.9 (CH2), 21.8 (CH2), 21.6 (CH2), 21.3 (CH2); MS
(ES+) m/z 293 [MH+]; HRMS (ES+) calcd. for C19H17O3 (M+H)+: 293.1172; found:
293.1160.
3-(9-Oxo-5,7,8,9-tetrahydro-6H-xanthen-2-yl)benzamide (108)
Carboxylic acid 109 (100 mg, 0.30 mmol) was
dissolved in DMF (10 mL) and NEt3 (92 µl, 0.66
mmol), HOBt (53 mg, 0.39 mL), PyBOP (187 mg,
0.36 mmol) and NH3 (35% in H2O) (41 µl, 0.75 mmol)
were added. The reaction mixture was stirred at room temperature for 18 h. H2O (25
mL) and EtOAc (25 mL) were added and the organic phase was separated and
washed with 1.5M HCl (5 mL), H2O (25 mL) and a saturated aqueous solution of
NaHCO3 (25 mL). The organic phase was dried (MgSO4), filtered and the solvent
removed in vacuo. The resultant yellow solid was triturated with DCM and filtered
to give the title compound as a pale yellow solid (45 mg, 31% over 2 steps). m.p.
233-235 °C; IR (film) 3344, 3152, 2358, 1682, 1624, 1597, 1454, 802 cm-1; δH (500
MHz, CDCl3) 8.32 (1H, d, J = 1.9, ArH), 8.25 (1H, s, ArH), 8.20 (1H, br s, NH),
8.13 (1H, dd, J = 1.9, 7.0, ArH), 7.93-7.89 (2H, m, ArH), 7.70 (1H, d, J = 7.0,
ArH), 7.59 (1H, t, J = 6.2, ArH), 7.47 (1H, br s, NH), 2.76-2.70 (2H, m, CH2), 2.49-
2.44 (2H, m, CH2), 1.87-1.80 (2H, m, CH2), 1.75-1.68 (2H, m, CH2); δC (125 MHz,
CDCl3) 176.7 (C=O), 168.1 (H2NC=O), 164.7 (=C), 155.4 (C, Ar), 139.1 (C, Ar),
136.5 (C, Ar), 135.6 (C, Ar), 132.6 (CH, Ar), 130.0 (CH, Ar), 129.6 (CH, Ar),
127.5 (CH, Ar), 126.2 (CH, Ar), 123.2 (CH, Ar), 123.0 (C, Ar), 119.3 (CH, Ar),
118.1 (=C), 28.0 (CH2), 21.8 (CH2), 21.5 (CH2), 21.3 (CH2); MS (ES+) m/z 320
[MH+]; HRMS (ES+) calcd. for C20H18NO3 [MH+]: 320.1281; found: 320.1280
O
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3-(9-Oxo-5,7,8,9-tetrahydro-6H-xanthen-2-yl)benzoic acid (109)
Ester 105 (350 mg, 1.05 mmol) was dissolved in THF
(17.5 mL) and H2O (17.5 mL) and LiOH.H2O (220 mg,
5.25 mmol) was added. The mixture was stirred for 18
h at room temperature. The solvent was partially removed in vacuo before adding
H2O (5 mL) and adjusting to pH 1 using 1.5 M HCl. The aqueous phase was
extracted with EtOAc (5 x 10 mL), dried (MgSO4), filtered and the solvent removed
in vacuo to give the title compound as a yellow solid (226 mg, 67%). The crude
material was used without further purification. δH (400 MHz, DMSO-d6) 13.10 (1H,
brs, CO2H), 8.25-8.22 (2H, m, ArH), 8.11 (1H, dd, J = 2.4, 8.8, ArH), 8.04-7.95
(2H, m, ArH), 7.69 (1H, d, J = 8.8, ArH), 7.64 (1H, t, J = 7.7, ArH), 2.75-2.70 (2H,
m, CH2), 2.48-2.43 (2H, m, CH2), 1.87-1.79 (2H, m, CH2), 1.75-1.67 (2H, m, CH2);
MS (ES+) m/z 321 [MH+].
N-Methyl-3-(9-oxo-5,7,8,9-tetrahydro-6H-xanthen-2-yl)benzamide (110)
Carboxylic acid 109 (180 mg, 0.56 mmol) was
dissolved in DMF (30 mL) and NEt3 (172 µl, 1.24
mmol), HOBt (99 mg, 0.73 mmol), PyBOP (354 mg,
0.68 mmol) and methylamine (2M in THF) (0.72
mL, 1.41 mmol) were added. The reaction mixture was stirred for 18 h at room
temperature. H2O (40 mL) and EtOAc (40 mL) were added and the organic phase
separated and washed with 1.5M HCl (10 mL), H2O (40 mL) and a saturated
aqueous solution of NaHCO3 (2 x 40 mL). The organic phase was dried (MgSO4),
filtered and the solvent removed in vacuo. The resultant off-white solid was
triturated with DCM and filtered to give the title compound as a white solid (16 mg,
6% over 2 steps). m.p. 248-249 °C; IR (film) 3379, 2940, 2358, 1660, 1630, 1606,
O
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1444, 1149, 752 cm-1; δH (400 MHz, CDCl3) 8.43 (1H, d, J = 2.3, ArH), 8.05 (1H,
s, ArH), 7.89 (1H, dd, J = 2.3, 8.7, ArH), 7.79 (2H, d, J = 7.8, ArH), 7.54 (1H, d, J
= 7.8, ArH), 7.49 (1H, d, J = 8.7, ArH), 6.40 (1H, br s, NH), 3.09 (3H, d, J = 4.8,
NCH3), 2.77-2.70 (2H, m, CH2), 2.66-2.60 (2H, m, CH2), 1.97-1.89 (2H, m, CH2),
1.85-1.77 (2H, m, CH2); δC (150 MHz, CDCl3): δ 177.7 (C=O), 168.0 (RNC=O), 
164.1 (=C), 155.5 (C, Ar), 140.0 (C, Ar), 136.5 (C, Ar), 135.5 (C, Ar), 131.8 (CH,
Ar), 129.9 (CH, Ar), 129.2 (CH, Ar), 126.1 (CH, Ar), 125.5 (CH, Ar), 123.7 (CH,
Ar), 123.3 (C, Ar), 118.6 (=C), 118.4 (CH, Ar), 28.2 (CH2), 26.9 (CH3), 21.9 (CH2),
21.6 (CH2), 21.0 (CH2); MS (ES+) m/z 334 [MH+]; HRMS (ES+) calcd. for
C21H20NO3 (M+H)+: 334.1438; found: 334.1438.
N,N-Dimethyl-3-(9-oxo-5,7,8,9-tetrahydro-6H-xanthen-2-yl)benzamide (111)
Carboxylic acid 109 (60 mg, 0.19 mmol) was
dissolved in DMF (10 mL) and NEt3 (52 µl, 0.41
mmol), HOBt (34 mg, 0.24 mmol), PyBOP (117 mg,
0.23 mmol) and dimethylamine (2M in MeOH) (0.24
mL, 0.47 mmol) were added. The reaction mixture was stirred for 18 h at room
temperature. H2O (50 mL) and EtOAc (30 mL) were added and the organic phase
separated and washed with 1.5M HCl (5 mL), H2O (50 mL) and a saturated aqueous
solution of NaHCO3 (2 x 30 mL) and brine (30 mL). The organic phase was dried
(MgSO4), filtered and the solvent removed in vacuo. The resultant off-white solid
was purified using column chromatography eluting with 75% EtOAc in petroleum
ether to give the title compound as a white solid (27 mg, 18% over 2 steps). IR
(film) 2920, 1631, 1607, 1444, 807, 614 cm-1; δH (400 MHz, CDCl3) 8.41 (1H, d, J
= 2.3, ArH), 7.85 (1H, dd, J = 2.3, 8.7, ArH), 7.70 (2H, m, ArH), 7.53-7.43 (2H, m,
ArH), 7.40 (1H, d, J = 7.7, ArH), 3.15 (3H, br s, NCH3), 3.03 (3H, br s, NCH3),
O
O
O N
Me
Me
Chapter 5: Experimental
___________________________________________________________________________________________________________________
___________________________________________________________________
162
2.74-2.66 (2H, m, CH2), 2.64-2.57 (2H, m, CH2), 1.94-1.85 (2H, m, CH2), 1.83-1.73
(2H, m, CH2); δC (100 MHz, CDCl3) 177.6 (C=O), 171.4 (RNC=O), 164.0 (=C),
155.5 (C, Ar), 139.9 (C, Ar), 137.2 (C, Ar), 136.7 (C, Ar), 131.8 (CH, Ar), 129.0
(CH, Ar), 128.2 (CH, Ar), 126.2 (CH, Ar), 125.8 (CH, Ar), 123.8 (CH, Ar), 123.3
(C, Ar), 118.6 (=C), 118.3 (CH, Ar), 39.7 (CH3), 35.4 (CH3), 28.2 (CH2), 21.9
(CH2), 21.7 (CH2), 21.1 (CH2); MS (ES+) m/z 370 [MNa+]; HRMS (ES+) calcd. for
C22H21NNaO3 (M+Na)+: 370.1414; found: 370.1423.
7-[3-(Morpholine-4-carbonyl)-phenyl]-1,2,3,4-tetrahydro-xanthen-9-one (112)
Carboxylic acid 109 (60 mg, 0.19 mmol) was
dissolved in DMF (10 mL) and NEt3 (57 µl, 0.41
mmol), HOBt (34 mg, 0.24 mmol), PyBOP (117
mg, 0.23 mmol) and morpholine (41 µl, 0.47 mmol)
were added. The reaction mixture was stirred for 18 h at room temperature. H2O (50
mL) and EtOAc (30 mL) were added and the organic phase separated and washed
with 1.5M HCl (5 mL), H2O (50 mL), a saturated aqueous solution of NaHCO3 (2 x
30 mL) and brine (30 mL). The organic phase was dried (MgSO4), filtered and the
solvent removed in vacuo to give a yellow oil which solidified on standing at room
temperature. The solid was purified using column chromatography eluting with
75% EtOAc in petroleum ether to give the title compound as a white solid (39 mg,
36% over 2 steps). m.p. 174-175 °C; IR (film) 2933, 1632, 1611, 1447, 1106, 613
cm-1; δH (400 MHz, CDCl3) 8.40 (1H, d, J = 2.3, ArH), 7.82 (1H, dd, J = 2.3, 8.8,
ArH), 7.74-7.67 (2H, m, ArH), 7.51 (1H, t, J = 7.7, ArH), 7.47 (1H, d, J = 8.8,
ArH), 7.39 (1H, d, J = 7.7, ArH), 3.94-3.41 (8H, br m, CH2), 2.74-2.66 (2H, m,
CH2), 2.64-2.58 (2H, m, CH2), 1.94-1.86 (2H, m, CH2), 1.83-1.74 (2H, m, CH2); δC
(400 MHz, CDCl3) 177.6 (C=O), 170.2 (RNC=O), 164.0 (=C), 155.6 (C, Ar), 140.2
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(C, Ar), 136.4 (C, Ar), 136.2 (C, Ar), 131.7 (CH, Ar), 129.2 (CH, Ar), 128.6 (CH,
Ar), 126.1 (CH, Ar), 125.8 (CH, Ar), 123.8 (CH, Ar), 123.3 (C, Ar), 118.6 (=C),
118.4 (CH, Ar), 66.9 (4 x CH2), 28.2 (CH2), 21.9 (CH2), 21.7 (CH2), 21.1 (CH2);
MS (ES+) m/z 412 [MNa+]; HRMS (ES+) calcd. for C24H23NNaO4 [MNa+]:
412.1519; found: 412.1512.
[2-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]acetonitrile (128)
Triethylamine (0.98 mL, 7.06 mmol), Pd(OAc)2 (20 mg, 0.09
mmol) and SPhos (145 mg, 0.35 mmol) added to a stirred
solution of 2-bromophenylacetonitrile (0.23 mL, 1.77 mmol) in
dioxane (4 mL). Pinacolborane (0.76 mL, 5.30 mmol) then added
dropwise. Reaction mixture heated to 90 ºC for 1 h. After allowing the mixture to
cool to room temperature, a saturated aqueous solution of NH4Cl (10 mL) was
added to quench. The product was extracted with Et2O (2 x 20 mL), dried (MgSO4),
filtered and the solvent removed in vacuo. The resultant black oil was purified using
column chromatography eluting with 3% EtOAc in petroleum ether to give the title
compound as an off-white solid (100 mg, 23%). Rf = 0.30 (5% EtOAc in petroleum
ether); δH (400 MHz, CDCl3) δ 7.90 (1H, d, J = 7.3, ArH), 7.51-7.44 (2H, m, ArH),
7.38 (1H, dt, J = 1.7, 7.3, ArH), 4.11 (2H, s, CH2), 1.37 (12H, s, CH3); δC (100
MHz, CDCl3) 136.9 (CH, Ar), 136.7 (C, Ar), 131.9 (CH, Ar), 128.6 (CH, Ar),
127.3 (CH, Ar), 119.0 (CN), 84.1 (OC(CH3)2), 24.9 (4 x CH3), 23.6 (CH2) ; MS
(ES+) m/z 338 [MNa+]. Data is in accordance with literature values.206
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[2-(9-Oxo-5,7,8,9-tetrahydro-6H-xanthen-2-yl)-phenyl]acetonitrile (129)
Boronic ester 128 (115 mg, 0.41 mmol) added to a
stirring mixture of compound Y (100 mg, 0.41 mmol),
Pd(OAc)2 (4.5 mg, 0.02 mmol) and Ba(OH)2.8H2O
(390 mg, 1.23 mmol) in dioxane (1 mL). The reaction mixture was heated to 100 ºC
for 1 h. After allowing the mixture to cool to room temperature, the mixture was
filtered through Celite® washing with CH2Cl2 (2 x 20 mL). The combined organic
phases were washed with brine (20 mL), dried (MgSO4), filtered and the solvent
removed in vacuo to give a yellow oil which solidified on standing at room
temperature. The resulting solid was purified using column chromatography eluting
with 20% EtOAc in petroleum ether to give an off-white residue which was
triturated with Et2O and filtered off to give the title compound as a white solid (38
mg, 29%). δH (300 MHz, CDCl3) δ 8.10 (1H, d, J = 2.2, ArH), 7.60-7.53 (2H, m,
ArH), 7.49 (1H, d, J = 8.6, ArH), 7.45-7.40 (2H, m, ArH), 7.33-7.29 (1H, m, ArH),
3.65 (2H, s, CH2CN), 2.76-2.68 (2H, m, CH2), 2.64-2.56 (2H, m, CH2), 1.96-1.85
(2H, m, CH2), 1.84-1.74 (2H, m, CH2); δC (125 MHz, CDCl3) 177.6 (C=O), 164.3
(=C), 155.5 (C), 140.5 (C), 136.3 (C), 133.8 (CH, Ar), 130.8 (CH, Ar), 129.3 (CH,
Ar), 128.8 (CH, Ar), 128.6 (CH, Ar), 127.9 (C), 125.9 (CH, Ar), 123.3 (C), 118.9
(CN), 118.4 (CH, Ar), 118.0 (=C), 28.3 (CH2), 22.3 (CH2CN), 22.0 (CH2), 21.8
(CH2), 21.2 (CH2); MS (ES+) m/z 338 [MNa+]; HRMS (ES+) calcd. for
C21H17NNaO2 [MNa+]: 338.1151; found: 338.1150.
(2-Bromo-phenyl)acetic acid methyl ester (131)
2-Bromo-phenylacetic acid (3.0 g, 14.0 mmol) dissolved in
MeOH (20 mL) and treated with concentrated HCl (0.1 mL).
The solution was heated to reflux for 2 h. After allowing the
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reaction mixture to cool to room temperature the organic solvent was removed in
vacuo. The product was extracted with Et2O (100 mL) and washed with a saturated
aqueous solution of NaHCO3 (100 mL) and brine (100 mL). The organic phase was
dried (MgSO4), filtered and the solvent removed in vacuo to give the title
compound as a colourless oil (3.02 g, 94%). δH (300 MHz, CDCl3) δ 7.58 (1H, d, J
= 7.8, ArH), 7.31-7.27 (2H, m, ArH), 7.20-7.10 (1H, m, ArH), 3.81 (2H, s, CH2),
3.73 (3H, s, CH3); δC (100 MHz, CDCl3) 171.1 (C=O), 134.3 (C, Ar), 133.0 (CH,
Ar), 131.6 (CH, Ar), 129.0 (CH, Ar), 127.7 (CH, Ar), 125.2 (C, Ar), 52.3 (CH3),
41.6 (CH2); MS (ES+) m/z 251 [MNa+, 79Br], 253 [MNa+, 81Br]; HRMS (ES+) calcd.
for C9H9BrNaO2 [MNa+, 81Br]: 252.9658; found: 252.9668. Data is in accordance
with literature values.207
[2-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]acetic acid methyl
ester (132)
Triethylamine (4.9 mL, 34.9 mmol), Pd(OAc)2 and cyclohexyl
JohnPhos (612 mg, 1.75 mmol) added to a stirring solution of
131 in dioxane (20 mL). Pinacolborane (3.8 mL, 26.2 mmol)
then added dropwise. The reaction mixture was heated to 90
ºC for 2 h. After allowing the reaction mixture to cool to room temperature, the
solvent was removed in vacuo. An aqueous saturated solution of NH4Cl (5 mL) was
added to quench the reaction and the product was extracted with Et2O (50 mL). The
organic phase was washed with H2O (2 x 50 mL), dried (MgSO4), filtered and the
solvent was removed in vacuo to give an orange oil. Purified using column
chromatography eluting with 5% EtOAc in petroleum ether to give the title
compound as an orange solid (1.5 g, 63%). m.p. 67-68 °C; IR (film) 2975, 2924,
1739, 1342, 1143, 658 cm-1;  δH (400 MHz, CDCl3) 7.84 (1H, d, J = 7.6, ArH), 7.39
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(1H, t, J = 7.6, ArH), 7.28 (1H, t, J = 7.6, ArH), 7.20 (1H, d, J = 7.6, ArH), 3.99
(2H, s, CH2), 3.67 (3H, s, CH3), 1.33 (12H, s, CH3); δC (75 MHz, CDCl3) 173.0
(C=O), 140.5 (C, Ar), 136.2 (CH, Ar), 131.1 (CH, Ar), 130.2 (CH, Ar), 127.2 (C,
Ar), 126.5 (CH, Ar), 83.7 (OC(CH3)2), 51.8 (CO2CH3), 41.1 (CH2), 25.0 (CH3); MS
(ES+) m/z 277 [MH+]. Data is in accordance with literature values.208
[2-(9-Oxo-5,7,8,9-tetrahydro-6-H-xanthen-2-yl)phenyl]acetic acid methyl ester
(133)
Boronic ester 132 (200 mg, 0.71 mmol), compound Y
(394 mg, 1.42 mmol), Pd(OAc)2 (8 mg, 0.04 mmol)
and 2M Na2CO3 (1.07 mL, 2.14 mmol) dissolved in
H2O (0.3 mL) and dioxane (1.7 mL) and the reaction mixture heated to 100 ºC for 1
h. After allowing the reaction mixture to cool to room temperature, the mixture was
filtered through Celite® washing with CH2Cl2 (2 x 20 mL). The combined organic
phases were washed with brine (20 mL), dried (MgSO4), filtered and the solvent
removed in vacuo to give a black oil. Purified using column chromatography
eluting with 10% EtOAc in petroleum ether to give the title compound as a
colourless oil (115 mg, 46%). δH (400 MHz, CDCl3) δ 8.14 (1H, d, J = 2.1, ArH),
7.60 (1H, dd, J = 2.1, 8.6, ArH), 7.44 (1H, d, J = 8.6, ArH), 7.41-7.33 (3H, m,
ArH), 7.31-7.28 (1H, m, ArH), 2.74-2.68 (2H, m, CH2), 2.64-2.58 (2H, m, CH2),
1.94-1.86 (2H, m, CH2), 1.83-1.75 (2H, m, CH2), 3.64 (3H, s, CH3), 3.60 (2H, s,
CH2CO2Me); δC (100 MHz, CDCl3) 177.6 (C=O), 172.1 (CO2Me), 164.0 (=C),
155.1 (C, Ar), 141.1 (C, Ar), 137.5 (C, Ar), 134.1 (CH, Ar), 131.9 (C, Ar), 130.5
(CH, Ar), 130.4 (CH, Ar), 128.0 (CH, Ar), 127.4 (CH, Ar), 126.0 (CH, Ar), 122.9
(C, Ar), 118.6 (=C), 117.6 (CH, Ar), 52.1 (CO2CH3), 38.9 (CH2CO2Me), 28.2
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O O O
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Cl
BrnBuLi, iPr2NH
Li
THF, -78°C
O
Br
(CH2), 21.9 (CH2), 21.7 (CH2), 21.1 (CH2); MS (ES+) m/z 371 [MNa+]; HRMS
(ES+) calcd. for C22H20NaO4 [MNa+]: 371.1254; found: 371.1252.
Acylation using lithium diisopropylamide
General Method 1a:
Lithium diisopropylamide (2M in THF/heptane/ethylbenzene) (1.0 molar equiv) in
THF (2-10 mL) was cooled to -78 °C whereupon the relevant ketone (1.0 molar
equiv) was added. The solution was stirred at -78 °C for 1 h before addition of the
acid chloride (1.0 molar equiv). The solution was then allowed to warm to room
temperature and stirred at room temperature for 5 h. 2M HCl (10 mL) was added
and the product was extracted with DCM (2 x 10 mL) and dried (MgSO4). Removal
of the solvent and purification gave the title compounds predominantly in the enol
form with the exception of compound 177 (50:50 enol:diketone forms) and
compound 159 (13:1 enol:diketone forms).
General Method 1b:
Diisopropylamine (2.0 molar equiv) in THF (10 mL) was cooled to -78 °C and n-
BuLi (2.5M in hexane) (2.0 molar equiv) was added. The solution was stirred for 5
min before adding cyclohexanone (2.0 molar equiv). The solution was stirred at -78
°C for 1 h before addition of the acid chloride (1.0 molar equiv). The solution was
then allowed to warm to room temperature and stirred at room temperature for 18 h.
2M HCl (15 mL) was added and the product was extracted with EtOAc (3 x 50 mL)
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and dried (MgSO4). Removal of the solvent and purification gave the title
compounds predominantly in the enol form.
Copper catalysed synthesis of tetrahydroxanthones
General Method 2:
The appropriate ketone (1.0 molar equiv) was dissolved in THF (0.10 moldm-3) and
CuI (0.1 molar equiv), DMEDA (0.2 molar equiv) and Cs2CO3 (2.0 molar equiv)
were added. The mixture was heated to reflux for 18 h. After all the mixture to cool
to room temperature it was filtered over Celite® washing with EtOAc (5 x 10 mL).
The combined organic phases were dried (MgSO4) and filtered. Removal of the
solvent in vacuo and purification provided the title compounds.
Palladium catalysed synthesis of tetrahydroxanthones
General Method 3:
The appropriate ketone (1.0 molar equiv) was dissolved in dioxane (0.29-0.37
moldm-3) and Pd2(dba)3 (2.5 mol%), Cs2CO3 (2.2 molar equiv), and Xphos (6.0
mol%) were added. The mixture was heated to reflux for 18 h. After allowing the
mixture to cool to room temperature it was filtered over Celite® washing with
CH2Cl2 (5 x 10 mL). The combined organic phases were dried (MgSO4) and
filtered. Removal of the solvent in vacuo and purification provided the title
compounds.
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(2-Bromophenyl)(2-hydroxycyclohex-1-enyl)methanone (141)
To lithium diisopropylamide (2M in THF/heptane/ethylbenzene,
4.55 mL, 9.10 mmol) and cyclohexanone (0.94 mL, 9.10 mmol)
in THF (10 mL) was added 2-bromo-benzoyl chloride (1.19 mL,
9.10 mmol) according to General Method 1a. Workup followed by column
chromatography eluting with 3% EtOAc in petroleum ether gave the title compound
as a white solid (1.48 g, 58%). m.p. 62-63 °C (lit. m.p 63-64 °C); Rf = 0.29 (5%
EtOAc in petroleum ether); IR (film) 2933, 1575, 1406, 1315, 936, 742 cm-1; δH
(400 MHz, CDCl3) 15.82 (1H, s, OH), 7.58 (1H, d, J = 7.8 Hz, ArH), 7.40-7.33
(1H, m, ArH), 7.29-7.22 (1H, m, ArH), 7.22-7.17 (1H, m, ArH), 2.50-2.43 (2H, m,
CH2), 2.10-2.01 (2H, m, CH2), 1.78-1.69 (2H, m, CH2), 1.65-1.56 (2H, m, CH2); δC
(100 MHz, CDCl3) 192.9 (C=O), 187.4 (COH), 139.3 (C, Ar), 132.8 (CH, Ar),
130.4 (CH, Ar), 127.6 (CH, Ar), 127.5 (CH, Ar), 118.9 (C, Ar), 107.6 (=C), 32.1
(CH2), 24.6 (CH2), 22.9 (CH2), 21.6 (CH2); MS (ES+) m/z 303 [MNa+, 79Br], 305
[MNa+, 81Br]; HRMS (ES+) calcd. for C13H13BrNaO2 [MNa+, 81Br]: 304.9971;
found: 304.9971. Anal. Calcd. for C13H13O2Br: C 55.54; H 4.66 %. Found: C 55.38;
H 4.60 %. Data is in accordance with literature values.209
1,2,3,4-Tetrahydro-xanthen-9-one (83)
141 (100 mg, 0.36 mmol) was dissolved in dioxane (1 mL) and
Pd2(dba)3 (8 mg, 0.009 mmol), Xphos (10 mg, 0.021 mmol) and
Cs2CO3 (255 mg, 0.75 mmol) added according to General
Method 2. Workup followed by column chromatography eluting with 5% EtOAc in
petroleum ether gave the title compound as a white solid (66 mg, 93%). Data as
previously reported.
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2-Bromo-benzoic acid 3-oxo-cyclohex-1-enyl ester (145)
Pyridine (0.17 mL, 2.09 mmol) and 2-bromobenzoyl chloride
(0.30 mL, 2.28 mmol) added to a stirring solution of 1,3-
cyclohexanedione (213 mg, 1.90 mmol) in chloroform (4 mL).
The reaction mixture was stirred at room temperature for 2 h. The solution was
washed with H2O (20 mL) and further extracted with DCM (10 mL). The combined
organic phases were dried (MgSO4) and filtered and the solvent was removed in
vacuo to give the title compound as a white solid (465 mg, 69%). Rf = 0.21 (10%
EtOAc in petroleum ether); δH (400 MHz, CDCl3) 7.93-7.88 (1H, m, ArH), 7.75-
7.70 (1H, m, ArH), 7.46-7.39 (2H, m, ArH), 6.06 (1H, s, =CH), 2.74-2.69 (2H, m,
CH2), 2.50-2.44 (2H, m, CH2), 2.18-2.10 (2H, m, CH2); δC (100 MHz, CDCl3)
199.4 (C=O), 169.9 (OC=), 162.6 (CO2R), 134.9 (CH, Ar), 133.8(CH, Ar), 132.1
(CH, Ar), 130.4 (C, Ar), 127.6 (CH, Ar), 122.6 (C, Ar), 118.2 (=CH), 36.9 (CH2),
28.4 (CH2), 21.4 (CH2).
2-(2-Bromo-benzoyl)cyclohexane-1,3-dione (146)
Triethylamine (0.09 mL, 0.0007 mmol) and KCN (0.33 mg,
0.005 mmol) added to a stirring solution of compound 145 in
MeCN (1 mL). The reaction mixture was stirred at room
temperature for 18 h. The solvent was then removed in vacuo. The resulting residue
was dissolved in EtOAc (3 mL) and 2M HCl (3 mL) added. The mixture was stirred
at room temperature for 5 min. The organic layer was separated and washed with a
saturated aqueous solution of NaHCO3 (2 x 5 mL). The aqueous layer was then
neutralised using 2M HCl and re-extracted with EtOAc (10 mL). The organic layer
was dried (MgSO4), filtered and the solvent removed in vacuo to give a colourless
oil which solidified on standing at room temperature. The solid was recrystallised
O
O
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from MeOH and filtered to give the title compound as a white solid (40 mg, 40%).
δH (300 MHz, CDCl3) enol proton not observed, 7.56 (1H, d, J = 7.7, ArH), 7.38
(1H, t, J = 7.7, ArH), 7.29 (1H, t, J = 7.7, ArH), 7.18 (1H, dd, J = 1.6, 7.7, ArH),
2.84-2.73 (2H, m, CH2), 2.52-2.40 (2H, m, CH2), 2.05 (2H, p, J = 6.5, CH2); δC
(100 MHz, CDCl3) 198.1 (ArC=O), 197.1 (H2CC=O), 193.7 (COH), 141.0 (C, Ar),
132.5 (CH, Ar), 130.7 (CH, Ar), 127.4 (CH, Ar), 127.2 (CH, Ar), 118.4 (C, Ar),
114.0 (=C), 37.9 (CH2), 32.6 (CH2), 19.2 (CH2); MS (ES+) m/z 317 [MNa+, 79Br],
319 [MNa+, 81Br].
(2-Iodophenyl)(2-hydroxycyclohex-1-enyl)methanone (158)
To lithium diisopropylamide (2M in THF/heptane/ethylbenzene,
0.90 mL, 1.88 mmol) and cyclohexanone (0.19 mL, 1.88 mmol)
in THF (2 mL) was added 2-iodo-benzoyl chloride (500 mg, 1.88
mmol) according to General Method 1a. Workup followed by column
chromatography eluting with 3% EtOAc in petroleum ether gave the title compound
as a white solid (262 mg, 43%). Rf = 0.46 (5% EtOAc in petroleum ether); δH (300
MHz, CDCl3) 15.84 (1H, s, OH), 7.85 (1H, dd, J = 1.4, 7.9 Hz, ArH), 7.40 (1H, dt,
J = 1.4, 7.9, ArH), 7.16 (1H, dd, J = 1.4, 7.9, ArH), 7.08 (1H, dt, J = 1.4, 7.9, ArH),
2.47 (2H, m, CH2), 2.03 (2H, m, CH2), 1.80-1.70 (2H, m, CH2), 1.68-1.57 (2H, m,
CH2).
(2-Bromophenyl)(2-hydroxycyclopent-1-enyl)methanone (159)
To lithium diisopropylamide (2M in THF/heptane/ethylbenzene,
2.28 mL, 4.56 mmol) and cyclopentanone (0.40 mL, 4.56 mmol)
in THF (5.0 mL) was added 2-bromo-benzoyl chloride (0.60 mL,
4.56 mmol) according to General Method 1a. Workup followed by column
OOH
I
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chromatography eluting with 2 % EtOAc in petroleum ether gave the title
compound as a yellow oil (467 mg, 38%). Mixture of enol to diketone (13:1). Rf =
0.27 (5% EtOAc in petroleum ether); IR (film) 2933, 1582, 1241, 743 cm-1; δH (400
MHz, CDCl3) enol: 13.48 (1H, s, OH), 7.62 (1H, d, J = 7.9 Hz, ArH), 7.41-7.32
(2H, m, ArH), 7.31-7.24 (1H, m, ArH), 2.50 (2H, t, J = 7.9, CH2), 2.45 (2H, t, J =
7.9, CH2), 1.93 (2H, p, J = 7.9, CH2), diketone: δ 7.65-7.58 (1H, m, ArH), 7.47 (1H, 
dd, J = 1.8, 7.7, ArH), 7.42-7.39 (1H, m, ArH), 7.32-7.30 (1H, m, ArH), 4.15 (1H, t,
J = 8.8, CH), 2.37-2.31 (4H, m, CH2), 2.2-2.15 (2H, m, CH2); δC (100 MHz,
CDCl3) enol: 209.4 (C=O), 169.4 (COH), 135.0 (C, Ar), 133.2 (CH, Ar), 131.1
(CH, Ar), 129.6 (CH, Ar), 127.4 (CH, Ar), 120.7 (C, Ar), 111.7 (=C), 38.0 (CH2),
26.5 (CH2), 20.9 (CH2), diketone (no quaternary carbons observed): 133.5 (CH,
Ar), 131.9 (CH, Ar), 129.4 (CH, Ar), 127.6 (CH, Ar), 61.4 (CHCO), 38.9 (CH2),
27.4 (CH2), 22.6 (CH2); MS (ES+) m/z 267 [MH+, 79Br], 269 [MH+, 81Br]; HRMS
(ES+) calcd. for C12H12O2Br [MH+, 81Br]: 268.9995; found: 268.9990.
(2-Bromophenyl)((Z)-2-hydroxycyclohept-1-enyl)methanone (160)
To lithium diisopropylamide (2M in THF/heptane/ethylbenzene,
1.4 mL, 2.86 mmol) and cycloheptanone (0.54 mL, 4.56 mmol)
in THF (5.0 mL) was added 2-bromo-benzoyl chloride (0.60
mL, 4.56 mmol) according to General Method 1a. Workup followed by column
chromatography eluting with 5% EtOAc in petroleum ether gave the title compound
as a pale pink oil (788 mg, 59%). Rf = 0.44 (10% EtOAc in petroleum ether); IR
(film) 2932, 1592, 1245, 943, 742 cm-1; δH (300 MHz, CDCl3) 16.26 (1H, s, OH),
7.61 (1H, d, J = 8.0, ArH), 7.41-7.32 (1H, m, ArH), 7.31-7.20 (2H, m, ArH), 2.66
(2H, br s, CH2), 2.15 (2H, br s, CH2), 1.74 (4H, br s, CH2), 1.61 (1H, br s, CH2),
1.47 (1H, br s, CH2); δC (100 MHz, CDCl3) 179.6 (C=O), 178.3 (COH), 137.4 (C),
O
Br
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132.9 (CH, Ar), 130.5 (CH, Ar), 128.9 (CH, Ar), 127.4 (CH, Ar), 120.6 (C), 112.6
(C), 42.0 (CH2), 31.1 (CH2), 29.1 (CH2), 27.7 (CH2), 24.8 (CH2); MS (ES+) m/z 295
[MH+, 79Br], 297 [MH+, 81Br]; HRMS (ES+) calcd. for C14H16BrO2 [MH+, 79Br]:
295.0328; found: 295.0327.
2,3-Dihydro-1H-cyclopenta[b]chromen-9-one (163)
159 (100 mg, 0.37 mmol) was dissolved in dioxane (1 mL) and
Pd2(dba)3 (9 mg, 0.009 mmol), Xphos (11 mg, 0.021 mmol) and
Cs2CO3 (268 mg, 0.82 mmol) added according to General Method
2. Workup followed by column chromatography eluting with 10% EtOAc in
petroleum ether gave the title compound as a white solid (16 mg, 23%). m.p. 118-
121 °C; IR (film) 2954, 2354, 1639, 1607, 1461, 1429, 762 cm-1; δH (400 MHz,
CDCl3) 8.24 (1H, d, J = 7.7, ArH), 7.61 (1H, t, J = 7.7, ArH), 7.43 (1H, d, J = 7.7,
ArH), 7.38 (1H, t, J = 7.7, ArH), 3.02-2.94 (2H, m, CH2), 2.91-2.83 (2H, m, CH2),
2.13 (2H, p, J = 7.4, CH2); δC (75 MHz, CDCl3) 175.7 (C=O), 169.0 (=C), 156.4 (C,
Ar), 132.1 (CH, Ar), 125.2 (CH, Ar), 124.2 (CH, Ar), 123.6 (C, Ar), 120.4 (=C),
117.3 (CH, Ar), 31.7 (CH2), 25.5 (CH2), 18.9 (CH2); MS (ES+) m/z 187 [MH+];
HRMS (ES+) calcd. for C12H11O2 [MH+]: 187.0754; found 187.0754.
7,8,9,10-Tetrahydro-6H-5-oxa-cyclohepta[b]naphthalen-11-one (164)
160 (100 mg, 0.34 mmol) was dissolved in dioxane (1 mL) and
Pd2(dba)3 (8 mg, 0.008 mmol), Xphos (12 mg, 0.02 mmol) and
Cs2CO3 (243 mg, 0.75 mmol) added according to General
Method 2. Workup followed by column chromatography eluting with 10% EtOAc
in petroleum ether gave the title compound as a yellow solid (55 mg, 75%). m.p.
84-85 °C (lit. m.p 82-83 °C) ; Rf = 0.44 (10% EtOAc in petroleum ether); IR (film)
O
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2922, 2840, 2360, 1624, 1464, 1400, 1606, 757 cm-1. δH (400 MHz, CDCl3) 8.21
(1H, dd, J = 1.2, 7.9, ArH), 7.60 (1H, dt, J = 1.2, 7.9, ArH), 7.41-7.31 (2H, m,
ArH), 2.90-2.83 (2H, m, CH2), 2.83-2.76 (2H, m, CH2), 1.91-2.80 (2H, m, CH2),
1.80-1.71 (2H, m, CH2), 1.66-1.57 (2H, m, CH2); δC (100 MHz, CDCl3) 177.1
(C=O), 169.0 (=C), 155.7 (C, Ar), 132.8 (CH, Ar), 126.1 (CH, Ar), 124.6 (CH, Ar),
123.0 (C, Ar), 122.8 (=C), 117.8 (CH, Ar), 34.8 (CH2), 32.0 (CH2), 26.4 (CH2),
25.0 (CH2), 22.3 (CH2); MS (ES+) m/z 215 [MH+]; HRMS (ES+) calcd. for
C14H15O2 [MH+]: 215.1067; found: 215.1069. Data is in accordance with literature
values.109
(2-Chlorophenyl)(2-hydroxycyclohex-1-enyl)methanone (169)
To lithium diisopropylamide (2M in THF/heptane/ethylbenzene,
1.4 mL, 2.86 mmol) and cyclohexanone (0.30 mL, 2.86 mmol) in
THF (2.50 mL) was added 2-chloro-benzoyl chloride (0.36 mL,
2.86 mmol) according to General Method 1a. Workup followed by column
chromatography eluting with 5% EtOAc in petroleum ether gave an off-white solid
which was triturated with hexane and filtered off to give the title compound as a
white solid (286 mg, 42%). m.p. 69-70 °C; Rf = 0.35 (5% EtOAc in petroleum
ether); IR (film) 2937, 1575, 1406, 1317, 1279, 1243, 745 cm-1; δH (300 MHz,
CDCl3) 15.88 (1H, s, OH), 7.44-7.28 (3H, m, ArH), 7.27-7.19 (1H, m, ArH), 2.52-
2.42 (2H, m, CH2), 2.12-2.02 (2H, m, CH2), 1.80-1.66 (2H, m, CH2), 1.67-1.53 (2H,
m, CH2); δC (100 MHz, CDCl3) 191.9 (C=O), 187.5 (C-OH), 137.2 (C, Ar), 130.3
(CH, Ar), 130.2 (C, Ar), 129.7 (CH, Ar), 127.7 (CH, Ar), 127.1 (CH, Ar), 108.0 (C,
Ar), 32.1 (CH2), 24.4 (CH2), 22.8 (CH2), 21.6 (CH2). MS (ES+) m/z 237 [MH+,
35Cl], 239 [MH+, 37Cl]; HRMS (ES+) calcd. for C13H14ClO2 [MH+, 35Cl]: 237.0677;
OOH
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found: 237.0674. Anal. calcd. for C13H13O2Cl: C 65.97; H 5.54; Cl 14.98 %. Found:
C 65.83; H 5.55; Cl 14.90 %. Data is in accordance with literature values.210
(2-Bromophenyl)(1,2-dihydro-4-hydroxynaphthalen-3-yl)methanone (170)
To lithium diisopropylamide (2M in
THF/heptane/ethylbenzene, 2.28 mL, 4.56 mmol) and α-
tetralone (0.61 mL, 4.56 mmol) in THF (5 mL) was added
2-bromo-benzoyl chloride (0.60 mL, 4.56 mmol) according to General Method 1a.
Workup followed by column chromatography eluting with 2% EtOAc in petroleum
ether gave the title compound as a white solid (672 mg, 45%). m.p. 53-56 °C; Rf =
0.22 (5% EtOAc in petroleum ether); IR (film) 2933, 2843, 1595, 1246, 762 cm-1;
δH (400 MHz, CDCl3) 16.23 (1H, s, OH), 8.05 (1H, d, J = 7.8 Hz, ArH), 7.64 (1H,
d, J = 7.8, ArH), 7.49-7.26 (5H, m, ArH), 7.21 (1H, d, J = 7.8, ArH), 2.88-2.80 (2H,
m, CH2), 2.42 (2H, br s, CH2); δC (100 MHz, CDCl3) 185.8 (C=O), 182.4 (C-OH),
141.8 (C, Ar), 138.1 (C, Ar), 132.9 (CH, Ar), 132.8 (CH, Ar), 131.6 (C, Ar), 130.7
(CH, Ar), 128.6 (CH, Ar), 127.9 (CH, Ar), 127.6 (CH, Ar), 127.0 (CH, Ar), 126.5
(CH, Ar), 120.0 (C, Ar), 107.0 (CCO), 28.5 (CH2), 23.4 (CH2); MS (ES+) m/z 329
[MH+, 79Br], 331 [MH+, 81Br]; HRMS (ES+) calcd. for C17H14BrO2 [MH+, 79Br]:
329.0172; found 329.0165.
5,6-Dihydro-benzo[c]xanthen-7-one (171)
170 (100 mg, 0.30 mmol) was dissolved in dioxane (1 mL) and
Pd2(dba)3 (7 mg, 0.008 mmol), Xphos (9 mg, 0.018 mmol) and
Cs2CO3 (218 mg, 0.67 mmol) added according to General
Method 2. Workup followed by column chromatography eluting with 5% EtOAc in
petroleum ether gave the title compound as a white solid (68 mg, 91%). m.p. 143-
OOH
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144 °C; Rf = 0.12 (5% EtOAc in petroleum ether); IR (film) 3064, 2926, 1624,
1606, 1559, 1463, 753 cm-1; δH (300 MHz, CDCl3) 8.27 (1H, dd, J = 1.5, 8.0, ArH),
8.02, 7.93 (1H, m, ArH), 7.68 (1H, dt, J = 1.6, 7.8, ArH), 7.55 (1H, d, J = 8.0,
ArH), 7.45-7.34 (3H m, ArH), 7.32-7.25 (1H, m, ArH), 2.96 (4H, s, CH2); δC (100
MHz, CDCl3) 176.6 (C=O), 157.1 (=C), 155.0 (C, Ar), 138.8 (C, Ar), 132.6 (CH,
Ar), 130.5 (CH, Ar), 127.8 (C, Ar), 127.6 (CH, Ar), 126.3 (CH, Ar), 125.2 (CH,
Ar), 124.2 (CH, Ar), 123.2 (CH, Ar), 123.0 (C, Ar), 117.3 (CH, Ar), 116.0 (=C),
26.5 (CH2), 18.3 (CH2). MS (ES+) m/z 249 [MH+]; HRMS (ES+) calcd. for
C17H13O2 [MH+]: 249.0901; found: 249.0909.
(2,5-Dibromophenyl)(2-hydroxycyclohex-1-enyl)methanone (172)
To lithium diisopropylamide (2M in
THF/heptane/ethylbenzene, 0.97 mL, 1.95 mmol) and
cyclohexanone (0.2 mL, 1.95 mmol) in THF (5.8 mL) was
added 2,5-dibromobenzoyl chloride (582 mg, 1.95 mmol) according to General
Method 1a. Workup followed by column chromatography eluting with 2% EtOAc
in petroleum ether gave the title compound as a white solid (298 mg, 42%). m.p.
75-77 °C Rf = 0.5 (10% EtOAc in petroleum ether); IR (film) 29938, 2852, 1566,
813 cm-1; δH (400 MHz, CDCl3) 15.66 (1H, s, OH), 7.45 (1H, d, J = 8.8 Hz, ArH),
7.40-7.32 (2H, m, ArH), 2.47 (2H t, J = 6.5, CH2,), 2.11-2.02 (2H, m, CH2), 1.79-
1.70 (2H, m, CH2), 1.67-1.57 (2H, m, CH2); δC (100 MHz, CDCl3) 191.3 (C=O),
187.7 (COH), 141.0 (C, Ar), 134.3 (CH, Ar), 133.4 (CH, Ar), 130.4 (CH, Ar),
121.09 (C, Ar), 117.7 (C, Ar), 107.4 (CCO), 32.0 (CH2), 24.5 (CH2), 22.8 (CH2),
21.5 (CH2). MS (ES+) m/z 381 [MNa+, 79Br,79Br], 383 [MNa+, 79Br,81Br], 385
[MNa+, 81Br,81Br]; HRMS (ES+) calcd. for C13H12Br2NaO2 [MNa+, 79Br, 81Br]:
382.9076; found 382.9075.
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7-Bromo-1,2,3,4-tetrahydro-xanthen-9-one (102)
172 (100 mg, 0.28 mmol) was dissolved in dioxane (1 mL)
and Pd2(dba)3 (6 mg, 0.007 mmol), Xphos (8 mg, 0.017
mmol) and Cs2CO3 (199 mg, 0.61 mmol) added according to
General Method 2. Workup followed by column chromatography eluting with 5%
EtOAc in petroleum ether gave the title compound as a white solid (54 mg, 69%).
Data as previously reported.
(2-Bromo-5-methoxyphenyl)(2-hydroxycyclohex-1-enyl)methanone (173)
To lithium diisopropylamide (2M in
THF/heptane/ethylbenzene, 1.00 mL, 2.00 mmol) and
cyclohexanone (0.21 mL, 2.00 mmol) in THF (5 mL) was
added 2-bromo, 5-methoxybenzoyl chloride (500 mg, 2.00 mmol) according to
General Method 1a. Workup followed by column chromatography eluting with 5%
EtOAc in petroleum ether gave the title compound as a colourless oil (223 mg,
36%). Rf = 0.64 (10% EtOAc in petroleum ether); IR (film) 2934, 1703, 1567,
1463, 1412, 1309, 1238, 1016, 730 cm-1;  δH (300 MHz, CDCl3) 15.77 (1H, s, OH),
7.45 (1H, d, J = 9.0 Hz, ArH), 6.81 (1H, dd, J = 3.1, 9.0, ArH), 6.74 (1H, d, J = 3.1,
ArH), 3.79 (3H, s, OCH3), 2.49-2.41 (2H, m, CH2), 2.11-2.02 (2H, m, CH2), 1.78-
1.67 (2H, m, CH2), 1.65-1.55 (2H, m, CH2); δC (75 MHz, CDCl3): δ 199.9 (C=O), 
187.1 (C-OH), 159.0 (C, Ar), 140.0 (C, Ar), 133.7 (CH, Ar), 116.5 (CH, Ar), 112.8
(CH, Ar), 109.0 (C, Ar), 107.5 (CCO), 55.6 (CH3), 32.0 (CH2), 24.5 (CH2), 22.8
(CH2), 21.6 (CH2); MS (ES+) m/z 333 [MNa+, 79Br], 335 [MNa+, 81Br]; HRMS
(ES+) calcd. for C14H15BrNaO3 [MNa+, 79Br]: 333.0097; found: 333.0099.
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7-Methoxy-1,2,3,4-tetrahydro-xanthen-9-one (174)
173 (100 mg, 0.34 mmol) was dissolved in dioxane (1 mL)
and Pd2(dba)3 (8 mg, 0.008 mmol), Xphos (10 mg, 0.02
mmol) and Cs2CO3 (243 mg, 0.75 mmol) added according
to General Method 2. Workup followed by column chromatography eluting with
5% EtOAc in petroleum ether gave the title compound as a white solid (47 mg,
60%). m.p. 102-104 °C (lit. m.p 116 °C); Rf 0.41 (10% EtOAc in petroleum ether);
IR (film) 2940, 1609, 1484, 1438, 1030, 820, 758 cm-1; δH (300 MHz, CDCl3) 7.56
(1H, d, J = 3.0, ArH), 7.30 (1H, d, J = 8.9, ArH), 7.19 (1H, dd, J = 3.0, 8.9, ArH),
3.89 (3H, s, OCH3), 2.70-2.62 (2H, m, CH2), 2.62-2.54 (2H, m, CH2), 1.92-1.82
(2H, m, CH2), 1.82-1.70 (2H, m, CH2); δC (75 MHz, CDCl3) 176.9 (C=O), 163.0
(=C), 155.7 (C, Ar), 150.1 (C, Ar), 123.0 (C, Ar), 122.4 (CH, Ar), 118.4 (CH, Ar),
117.0 (=C), 104.2 (CH, Ar), 55.2 (CH3), 27.5 (CH2), 21.3 (CH2), 21.1 (CH2), 20.5
(CH2); MS (ES+) m/z 231 [MH+]; HRMS (ES+) calcd. for C14H15O3 [MH+]:
231.1016; found: 231.1014. Data is in accordance with literature values.211
7-(2-Bromo-benzoyl)-1,4-dioxa-spiro[4.5]decan-8-one (175)
To lithium diisopropylamide (2M in THF/heptane/ethylbenzene,
1.14 mL, 2.28 mmol) and 1,4-cyclohexadione monoethylene
acetal (355 mg, 2.28 mmol) in THF (2.5 mL) was added 2-
bromo-benzoyl chloride (0.30 mL, 2.28 mmol) according to General Method 1a.
Workup followed by column chromatography eluting with 50% DCM in petroleum
ether gave the title compound as a white solid (159 mg, 21%). m.p. 106-107 °C; Rf
= 0.19 (10% EtOAc in petroleum ether); IR (film) 2896, 1430, 1307, 1242, 1055,
947, 858, 1562, 775 cm-1; δH (300 MHz, CDCl3) 15.80 (1H, s, OH), 7.59 (1H, dd, J
= 1.5, 7.7 Hz, ArH), 7.38 (1H, dt, J = 1.5, 7.7, ArH), 7.27 (1H, dt, J = 1.5, 7.7,
OOH
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ArH), 7.21 (1H, dd, J = 1.5, 7.7, ArH) , 3.96-3.89 (4H, m, 2CH2), 2.69 (2H, t, J =
6.9, CH2), 2.30 (2H, s, CH2), 1.90 (2H, t, J = 6.9, CH2); δC (100 MHz, CDCl3): δ 
192.6 (C=O), 186.3 (COH), 138.9 (C, Ar), 132.9 (CH, Ar), 130.7 (CH, Ar), 127.6
(CH, Ar), 127.6 (CH, Ar), 118.8 (C, Ar), 107.1 (OCO), 105.3 (CCO), 64.57 (2 x
acetal CH2), 34.3 (CH2), 30.7 (CH2), 30.0 (CH2); MS (ES+) m/z 361 [MNa+, 79Br],
363 [MNa+, 81Br]; HRMS (ES+) calcd. for C15H15BrNaO4 [MNa+, 79Br]: 361.0046;
found 361.0047. Anal. calcd. for C15H15O4Br: C 53.12; H 4.46 %. Found: C 52.98;
H 4.46 %.
2-Dioxa-spiro-1,2,3,4-tetrahydro-xanthen-9-one (176)
175 (100 mg, 0.29 mmol) was dissolved in dioxane (1 mL)
and Pd2(dba)3 (7 mg, 0.007 mmol), Xphos (8 mg, 0.018
mmol) and Cs2CO3 (211 mg, 0.65 mmol) added according to General Method 2.
Workup followed by column chromatography eluting with hexane/ DCM/ acetone
(10:3:1) gave the title compound as a white solid (55 mg, 72%). m.p. 182-183 °C;
Rf = 0.16 (hexane/ DCM/ acetone 10:3:1); IR (film) 2890, 1608, 1466, 1148, 1094,
1060, 1003, 764 cm-1; δH (400 MHz, CDCl3) δ 8.18 (1H, dd, J = 1.6, 7.8, ArH),
7.62 (1H, dt, J = 1.6, 7.8, ArH), 7.43-7.31 (2H, m, ArH), 4.11-3.98 (4H, m, CH2),
2.93 (2H, t, J = 6.8, CH2), 2.81 (2H, s, CH2), 2.04 (2H, t, J = 6.8, CH2); δC (100
MHz, CDCl3) 177.5 (C=O), 162.6 (=C), 155.9 (C, Ar), 133.2 (CH, Ar), 125.7 (CH,
Ar), 124.6 (CH, Ar), 122.8 (C, Ar), 117.6 (CH, Ar), 116.0 (OCO), 107.1 (=C), 64.7
(2 x CH2), 31.1 (CH2), 30.7 (CH2), 27.3 (CH2); MS (ES+) m/z 259 [MH+]; HRMS
(ES+) calcd. for C15H15O4 [MH+]: 259.0965; found: 259.0962.
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(3-Bromothiophen-2-yl)(2-hydroxycyclohex-1-enyl)methanone (177)
To lithium diisopropylamide (2M in THF/heptane/ethylbenzene,
2.10 mL, 4.26 mmol) and cyclohexanone (0.44 mL, 4.26 mmol)
in THF (5 mL) was added 3-bromo-thiophene-2-carbonyl
chloride (961 mg, 4.26 mmol) according to General Method 1a. Workup followed
by column chromatography eluting with 5% EtOAc in petroleum ether gave the title
compound as an orange oil (404 mg, 34%) as a mixture of the diketone and enol
forms (1:1). Rf = 0.62 and 0.24 (10% EtOAc in petroleum ether); IR (film) 2939,
1706, 1652, 872 cm-1; δH (400 MHz, CDCl3) 16.11 (1H, s, OH), 7.53 (1H, d, J = 5.3
Hz, diketone ArH), 7.39 (1H, d, J = 5.3, enol ArH), 7.07 (1H, d, J = 5.3, diketone
ArH), 7.00 (1H, d, J = 5.3, enol ArH), 4.63-4.57 (1H, m, diketone CH), 2.60-2.54
(2H, m, CH2), 2.51-2.46 (2H, t, J = 6.5, CH2), 2.41-2.36 (2H, t, J = 6.5, CH2), 2.24-
2.16 (2H, m, CH2), 2.13-2.05 (2H, m, CH2), 2.03-1.95 (2H, m, CH2), 1.81-1.72 (2H,
m, CH2), 1.69-1.61 (2H, m, CH2); δC (100 MHz, CDCl3) 207.9 (diketone C=O),
190.9 (enol C=O), 189.9 (diketone COH), 182.3 (enol COH), 138.7 (C), 133.6 (CH,
Ar), 133.2 (C), 132.8 (CH, Ar), 131.0 (CH, Ar), 127.9 (CH, Ar), 114.0 (C), 111.2
(C), 109.1 (C), 60.8 (enol HCCO), 42.8 (CH2), 33.0 (CH2), 29.8 (CH2), 27.6 (CH2),
25.3 (CH2), 23.8 (CH2), 23.0 (CH2), 21.6 (CH2); MS (ES+) m/z 309 [MNa+, 79Br],
311 [MNa+, 81Br]; HRMS (ES+) calcd. for C11H11O2BrS [MNa+, 79Br]: 310.9535;
found: 310.9537.
5,6,7,8-Tetrahydro-4-oxa-1-thia-cyclopenta[b]naphthalen-9-one (178)
177 (100 mg, 0.35 mmol) was dissolved in dioxane (1 mL) and
Pd2(dba)3 (8 mg, 0.009 mmol), Xphos (10 mg, 0.02 mmol) and
Cs2CO3 (250 mg, 0.77 mmol) added according to General Method
2. Workup followed by column chromatography eluting with 20% EtOAc in
O
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petroleum ether gave the title compound as a white solid (43 mg, 60%). m.p. 148-
149 °C; Rf = 0.56 (20% EtOAc in petroleum ether); IR (film) 3066, 2944, 1598,
1460, 1419, 1139, 1032, 750 cm-1; δH (400 MHz, CDCl3) 7.62 (1H, d, J = 5.4,
ArH), 7.07 (1H, d, J = 5.4, ArH), 2.73-2.64 (2H, m, CH2), 2.63-2.55 (2H, m, CH2),
1.93-1.82 (2H, m, CH2), 1.82-1.72 (2H, m, CH2); δC (100 MHz, CDCl3) 174.1
(C=O), 162.6 (=C), 158.3 (C, Ar), 131.3 (CH, Ar), 123.9 (C, Ar), 118.6 (=C), 117.6
(CH, Ar), 27.8 (CH2), 22.0 (CH2), 21.7 (CH2), 21.1 (CH2); MS (ES+) m/z 207
[MH+]; HRMS (ES+) calcd. for C11H11O2S [MH+]: 207.0474; found: 207.0471.
(2-Chloro-3-(trifluoromethyl)phenyl)(2-hydroxycyclohex-1-enyl)methanone
(179)
To lithium diisopropylamide (2M in THF/heptane/ethylbenzene,
1.03 mL, 2.06 mmol) and cyclohexanone (0.21 mL, 2.06 mmol)
in THF (5 mL) was added 2-chloro-3 (trifluoromethyl)benzoyl chloride (500 mg,
2.06 mmol) according to General Method 1a. Workup followed by column
chromatography eluting with 5% EtOAc in petroleum ether gave the title compound
as a colourless oil which crystallised on standing at room temperature (298 mg,
48%). m.p. 80-81 °C; Rf = 0.52 (10% EtOAc in petroleum ether); IR (film) 2938,
2360, 1559, 1304, 1118, 816, 743 cm-1; δH (400 MHz, CDCl3) 15.70 (1H, s, OH),
7.75 (1H, d, J = 7.6 Hz, ArH), 7.50-7.38 (2H, m, ArH), 2.53-2.45 (2H, m, CH2),
2.03 (2H, br s, CH2), 1.79-1.71 (2H, m, CH2), 1.66-1.58 (2H, m, CH2); δC (100
MHz, CDCl3) 191.1 (C=O), 187.5 (COH), 139.8 (C, Ar), 130.9 (CH, Ar), 129.3 (q,
2JFC = 32, C-CF3), 128.6 (q, 3JFC = 5, CH, Ar), 127.1 (CH, Ar), 122.7 (q, 1JFC = 272,
CF3,), 107.8 (CCO), 32.0 (CH2), 24.3 (CH2), 22.7 (CH2), 21.5 (CH2); MS (ES+) m/z
305 [MH+, 35Cl], 307 [MH+, 37Cl]; HRMS (ES+) calcd. for C14H13ClF3O2 [MH+,
O
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35Cl]: 305.0551; found 305.0549. Anal. calcd. for C14H12O2ClF3: C 55.19; H 3.97
%. Found: C 55.07; H 3.96 %.
5-Trifluoromethyl-1,2,3,4-tetrahydro-xanthen-9-one (180)
179 (100 mg, 0.33 mmol) was dissolved in dioxane (1 mL) and
Pd2(dba)3 (8 mg, 0.008 mmol), Xphos (9 mg, 0.020 mmol) and
Cs2CO3 (235 mg, 0.72 mmol) added according to General
Method 2. Workup followed by column chromatography eluting with 10% EtOAc
in petroleum ether gave the title compound as a white solid (72 mg, 82%). m.p.
138-140 °C. Rf = 0.49 (10% EtOAc in petroleum ether); IR (film) 2936, 2361,
1640, 1607, 1414, 1304, 1111, 759 cm-1; δH (300 MHz, CDCl3) 8.38 (1H, dd, J =
1.2, 7.6, ArH), 7.89 (1H, dd, J = 1.2, 7.6, ArH), 7.40 (1H, t, J = 7.6, ArH), 2.78-
2.68 (2H, m, CH2), 2.64-1.54 (2H, m, CH2), 1.96-1.85 (2H, m, CH2), 1.85-1.72 (2H,
m, CH2); δC (75 MHz, CDCl3) 176.4 (C=O), 164.1 (=C), 152.7 (C, Ar), 130.4 (q,
3JFC = 5, CH), 130.1 (CH, Ar), 122.8 (q, 1JFC = 271, CF3), 124.0 (C, Ar), 123.5 (CH,
Ar), 119.4 (q, 2JFC = 32, CCF3), 119.2 (=C), 28.0 (CH2), 21.7 (CH2), 21.4 (CH2),
20.9 (CH2); MS (ES+) m/z 291 [MNa+]; HRMS (ESI) calcd. for C14H11F3NaO2
[MNa+]: 291.0603; found: 291.0602.
(2-Bromo-4,5-difluorophenyl)(2-hydroxycyclohex-1-enyl)methanone (181)
To lithium diisopropylamide (2M in
THF/heptane/ethylbenzene, 1.76 mL, 3.50 mmol) and
cyclohexanone (0.37 mL, 3.50 mmol) in THF (9 mL) was
added 2-bromo-4,5-difluoro-benzoyl chloride (900 mg, 3.50 mmol) according to
General Method 1a. Workup followed by column chromatography eluting with 1%
EtOAc in petroleum ether gave the title compound as an off-white solid (567 mg,
O
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51%). m.p. 92-94 °C; Rf = 0.42 (5% EtOAc in petroleum ether); IR (film) 3046,
2933, 1592, 1491, 1289, 786 cm-1; δH (400 MHz, CDCl3) 15.65 (1H, s, OH), 7.44
(1H, dd, J = 7.0, 9.0 Hz, ArH), 7.07 (1H, dd, J = 7.0, 9.0, ArH), 2.51-2.46 (2H, m,
CH2), 2.09-2.04 (2H, m, CH2), 1.79-1.72 (2H, m, CH2), 1.67-1.59 (2H, m, CH2); δC
(100 MHz, CDCl3) 190.4 (C=O), 188.2 (COH), 150.3 (dd, 1JFC = 253, 2JFC = 13,
CF), 149.7 (dd, 1JFC = 253, 2JFC = 13, CF), 135.9 (dd, 3JFC = 9, 5JFC = 5, C), 122.1
(d, 2JFC = 20, CH), 116.7 (d, 2JFC = 20, CH), 113.1 (dd, 3JFC = 7, 5JFC = 4, C), 107.4
(CCO), 32.1 (CH2), 24.5 (CH2), 22.8 (CH2), 21.5 (CH2); MS (ES+) m/z 339 [MNa+,
79Br], 341 [MNa+, 81Br]; HRMS (ES+) calcd. for C13H11BrF2NaO2 [MNa+, 81Br]:
340.9782; found: 340.9786.
6,7-Difluoro-1,2,3,4-tetrahydro-xanthen-9-one (182)
181 (100 mg, 0.32 mmol) was dissolved in dioxane (1 mL)
and Pd2(dba)3 (8 mg, 0.008 mmol), Xphos (9 mg, 0.019
mmol) and Cs2CO3 (226 mg, 0.69 mmol) added according to
General Method 2. Workup followed by column chromatography eluting with 10%
EtOAc in petroleum ether gave the title compound as a white solid (58 mg, 78%).
m.p. 151-152 °C; Rf = 0.49 (10% EtOAc in petroleum ether); IR (film) 3044, 2945,
1617, 1588, 1459, 1144, 892, 756 cm-1; δH (300 MHz, CDCl3) 7.93 (1H, dd, J = 8.8,
10.4, ArH), 7.19 (1H, dd, J = 6.2, 10.4, ArH), 2.71-2.61 (2H, m, CH2), 2.61-2.50
(2H, m, CH2), 1.94-1.82 (2H, m, CH2), 1.82-1.70 (2H, m, CH2); δC (75 MHz,
CDCl3) 176.1 (C=O), 164.5 (=C), 153.5 (dd, 1JFC = 271, 2JFC = 16, CF), 152.3 (C,
Ar), 148.1 (dd, 1JFC = 248, 2JFC = 14, CF), 120.0 (C, Ar), 118.2 (=C), 112.9 (d, 2JFC
= 18, CH), 106.6 (d, 2JFC = 21, CH), 28.0 (CH2), 21.8 (CH2), 21.5 (CH2), 20.9
(CH2); MS (ES+) m/z 259 [MNa+]; HRMS (ES+) calcd. for C13H10F2NaO2 [MNa+]:
259.0541; found: 259.0539.
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(2,5-Dibromophenyl)((Z)-2-hydroxycyclohept-1-enyl)methanone (185)
To lithium diisopropylamide (2M in
THF/heptane/ethylbenzene, 7.0 mL, 0.014 mol) and
cycloheptanone (1.67 mL, 0.014 mol) in THF (15 mL) was
added 2,5-dibromo-benzoyl chloride (4.23 g, 0.014 mol) according to General
Method 1. Workup followed by column chromatography (0.5% EtOAc in
petroleum ether) gave the title compound as a white solid (2.00 g, 38%). m.p. 106
°C; IR (film) 2924, 1565, 810 cm-1; δH (300 MHz, CDCl3) 16.10 (1H, s, OH), 7.47
(1H, m, ArH), 7.38 (1H, m, ArH), 7.36 (1H, m, ArH), 2.49 (2H, m, CH2), 1.98 (2H,
m, CH2), 1.57 (4H, m, CH2); δC (300 MHz, CDCl3) 204.3 (C=O), 177.4 (COH),
138.5 (C), 133.7 (CH), 132.9 (CH), 131.0 (CH), 120.7 (C), 118.8 (C), 112.0 (C),
41.2 (CH2), 30.9 (CH2), 28.4 (CH2), 27.0 (CH2), 24.2 (CH2); MS (ES+) m/z 372
[MH+]; HRMS (ES+) calcd. for C14H14O2Br2 [MH+]: 372.9433; found: 372.9433.
(2,3-Dichloro-phenyl)-(2-hydroxy-cyclohex-1-enyl)methanone (194)
To diisopropylamine (2.7 mL, 19.09 mmol), n-BuLi (2.5 M in
hexane, 7.6 mL, 19.09 mmol) and cyclohexanone (2.0 mL, 19.09
mmol) in THF (10 mL) was added 2,3 dichlorobenzoyl chloride
(1.3 mL, 9.55 mmol) according to General Method 1b. Workup followed by column
chromatography eluting with 35% EtOAc in petroleum ether gave the title
compound as a white solid (2.12 g, 82%). m.p. 101-102 °C; IR (film) 2935, 1557,
1410, 1316, 1153, 900, 795 cm-1; δH (400 MHz, CDCl3) 15.71 (1H, s, enol), 7.50
(1H, dd, J = 1.5, 7.8, ArH), 7.27 (1H, t, J = 7.8, ArH), 7.13 (1H, dd, J = 1.5, 7.8,
ArH), 2.48 (2H, t, J = 6.5, CH2), 2.05 (2H, brs, CH2), 1.78-1.70 (2H, m, CH2), 1.64-
1.57 (2H, m, CH2); δC (100 MHz, CDCl3) 191.6 (C=O), 187.4 (COH), 139.4 (C,
Ar), 133.7 (C, Ar), 131.0 (CH, Ar), 128.8 (C, Ar), 127.9 (CH, Ar), 125.7 (CH, Ar),
OOH
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107.8 (=C), 32.0 (CH2), 24.4 (CH2), 22.8 (CH2), 21.6 (CH2); MS (ES+) m/z 271
[MH+, 35Cl, 35Cl], 273 [MH+, 35Cl, 37Cl], 275 [MH+, 37Cl, 37Cl]; HRMS (ES+)
calcd. for C13H12Cl2NaO2 [MNa+, 35Cl, 35Cl]: 293.0107; found 293.0106.
(2,4-Dichloro-phenyl)-(2-hydroxy-cyclohex-1-enyl)methanone (195)
To diisopropylamine (2.7 mL, 19.09 mmol), n-BuLi (2.5 M in
hexane, 7.6 mL, 19.09 mmol) and cyclohexanone (2.0 mL,
19.09 mmol) in THF (10 mL) was added 2,4 dichlorobenzoyl
chloride (1.3 mL, 9.55 mmol) according to General Method 1b. Workup followed
by column chromatography eluting with 35% DCM in petroleum ether gave a pale
pink oil which solidified on standing at room temperature. Trituration with Et2O
and filtration gave the title compound as a white solid (2.02 g, 78%). m.p. 62-63 °C;
IR (film) 2951, 1584, 1409, 1100, 822, 781 cm-1; δH (400 MHz, CDCl3) 15.81 (1H,
s, enol), 7.44 (1H,d, J = 2.0, ArH), 7.31 (1H, dd, J = 2.0, 8.1, ArH), 7.18 (1H, d, J =
8.1, ArH); δC (100 MHz, CDCl3) 190.7 (C=O), 188.1 (COH), 135.8 (C, Ar), 131.4
(C, Ar), 129.8 (CH, Ar), 128.8 (CH, Ar), 127.4 (CH, Ar), 108.1 (=C), 32.3 (CH2),
24.5 (CH2), 22.9 (CH2), 21.7 (CH2), one quaternary carbon not observed; MS (ES+)
m/z 271 [MH+, 35Cl, 35Cl], 273 [MH+, 35Cl, 37Cl], 275 [MH+, 37Cl, 37Cl]; HRMS
(ES+) calcd. for C13H12Cl2NaO2 [MNa+, 35Cl, 35Cl]: 293.0107; found 293.0108.
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Synthesis of 7-arylated tetrahydroxanthones by sequential C–O and C–C bond
construction
General Method 4:
Ketone (1.0 molar equiv) was dissolved in dioxane (1 mL) and Pd2(dba)3 (2.5
mol%), Cs2CO3 (2.2 molar equiv), Xphos (6 mol%) and the appropriate boronic
acid (3.0 molar equiv), alkyne (1.3 equiv.) or alkene (5 equiv.) were added. The
mixture was heated to reflux for 2.5 h. After allowing the mixture to cool to room
temperature, the mixture was filtered through Celite® washing with CH2Cl2 (5 x 10
mL). The combined organic phases were dried (MgSO4), filtered and the solvent
removed in vacuo. Column chromatography provided the title compounds.
7-Phenyl-1,2,3,4-tetrahydro-xanthen-9-one (103)
172 (100 mg, 0.28 mmol) was dissolved in dioxane (1
mL) and Pd2(dba)3 (6 mg, 0.007 mmol), Xphos (8 mg,
0.02 mmol), Cs2CO3 (199 mg, 0.61 mmol) and phenyl
boronic acid (102 mg, 0.83 mmol) added according to General Method 4. Workup
followed by column chromatography (10% EtOAc in petroleum ether) gave the title
compound as a white solid (60 mg, 78%). Data as previously reported.
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3-(9-Oxo-5,7,8,9-tetrahydro-6H-xanthen-2-yl)benzoic acid methyl ester (105)
172 (30 mg, 0.08 mmol) was dissolved in dioxane (1
mL) and Pd2(dba)3 (2 mg, 0.002 mmol), Xphos (2 mg,
0.005 mmol), Cs2CO3 (60 mg, 0.18 mmol) and 3-
methoxycarbonyl phenylboronic acid (45 mg, 0.25
mmol) added according to General Method 4. Workup followed by column
chromatography (10% EtOAc in petroleum ether) gave the title compound as a
white solid (19 mg, 68%). Data as previously reported.
7,8,9,10-Tetrahydro-2-phenylcyclohepta[b]chromen-11(6H)-one (186)
185 (100 mg, 0.27 mmol) was dissolved in dioxane (1
mL) and Pd2(dba)3 (6 mg, 0.007 mmol), Xphos (8 mg,
0.02 mmol) Cs2CO3 (192 mg, 0.59 mmol) and
phenylboronic acid (98 mg, 0.80 mmol) added according to General Method 4.
Workup followed by column chromatography (hexane/ acetone/ ether 8:1:1) gave
the title compound as a white solid (55 mg, 71%). m.p. 148 °C; IR (film) 2918,
1611, 1146, 830, 765, 698 cm-1; δH (400 MHz, CDCl3) 8.43 (1H, d, J = 2.3, ArH),
7.86 (1H, dd, J = 2.3, 6.5, ArH), 7.67 (2H, d, J = 6.5, ArH), 7.48 (3H, t, J = 6.5,
ArH), 7.39 (1H, t, J = 6.5, ArH), 2.92-2.86 (2H, m, CH2), 2.86-2.79 (2H, m, CH2),
1.92-1.83 (2H, m, CH2), 1.82-1.73 (2H, m, CH2), 1.68-1.57 (2H, m, CH2); δC (100
MHz, CDCl3) 177.1 (C=O), 169.0 (=C), 155.2 (C), 139.7 (C, Ar), 137.7 (C, Ar),
131.8 (CH, Ar), 128.9 (CH, Ar), 127.6 (CH, Ar), 127.2 (CH, Ar), 124.0 (CH, Ar),
123.1 (C, Ar), 123.0 (C, Ar), 118.3 (CH, Ar), 34.8 (CH2), 32.0 (CH2), 26.5 (CH2),
25.0 (CH2), 22.4 (CH2); MS (ES+) m/z 291 [MH+]; HRMS (ES+) calcd. for
C20H18O2 [MH+]: 291.1380; found: 291.1391.
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7-p-Tolyl-1,2,3,4-tetrahydro-xanthen-9-one (187)
172 (100 mg, 0.28 mmol) was dissolved in dioxane
(1 mL) and Pd2(dba)3 (6 mg, 0.007 mmol), Xphos (8
mg, 0.02 mmol), Cs2CO3 (199 mg, 0.61 mmol) and
p-tolylboronic acid (113 mg, 0.83 mmol) added according to General Method 4.
Workup followed by column chromatography (5% EtOAc in petroleum ether) gave
the title compound as a white solid (69 mg, 85%). m.p. 154-155 °C; IR (film) 2933,
1625, 1607, 1463, 1407, 1146, 810, 752, 702, 668 cm-1; δH (400 MHz, CDCl3) 8.39
(1H, d, J = 2.2, ArH), 7.83 (1H, dd, J = 2.2, 8.2, ArH), 7.56 (2H, d, J = 8.2, ArH),
7.43 (1H, d, J = 8.2, ArH), 7.27 (2H, d, J = 8.2, ArH), 2.73-2.65 (2H, m, CH2),
2.65-2.58 (2H, m, CH2), 2.40 (2H, m, CH2), 1.94-1.84 (2H, m, CH2), 1.83-1.74 (2H,
m, CH2); δC (100 MHz, CDCl3) 177.8 (C=O), 163.8 (=C), 155.2 (C, Ar), 137.5 (C,
Ar), 137.4 (C, Ar), 137.4 (C, Ar), 136.8 (C, Ar), 131.7 (2 x CH, Ar), 129.7 (2 x CH,
Ar), 127.0 (CH, Ar), 123.3 (CH, Ar), 118.4 (=C), 118.1 (CH, Ar), 28.2 (CH2), 22.0
(CH2), 21.7 (CH3), 21.1 (CH2), 21.1 (CH2); MS (ES+) m/z 313 [MNa+]; HRMS
(ES+) calcd. for C20H18NaO2 [MNa+]: 313.1199; found: 313.1194.
7,8,9,10-Tetrahydro-2-p-tolylcyclohepta[b]chromen-11(6H)-one (188)
185 (100 mg, 0.27 mmol) was dissolved in dioxane
(1 mL) and Pd2(dba)3 (6 mg, 0.007 mmol), Xphos (8
mg, 0.02 mmol), Cs2CO3 (192 mg, 0.59 mmol) and
p-tolylboronic acid (109 mg, 0.80 mmol) added according to General Method 4.
Workup followed by column chromatography (5% EtOAc in petroleum ether) gave
the title compound as a white solid (70 mg, 85%). m.p. 148 °C; IR (film) 2924,
1606, 1444, 1149, 804, 698 cm-1; δH (300 MHz, CDCl3) 8.40 (1H, d, J = 2.2, ArH),
7.83 (1H, dd, J = 2.2, 8.7, ArH), 7.55 (2H, d, J = 7.5, ArH), 7.43 (1H, d, J = 8.7,
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ArH), 7.26 (2H, d, J = 7.5, ArH), 2.91-2.85 (2H, m, CH2), 2.85-2.78 (2H, m, CH2),
2.10 (3H, s, CH3), 1.92-1.82 (2H, m, CH2), 1.82-1.72 (2H, m, CH2) 1.67-1.58 (2H,
m, CH2); δC (75 MHz, CDCl3) 176.5 (C=O), 168.4 (=C), 154.4 (C, Ar), 137.0 (C,
Ar), 136.9 (C, Ar), 136.2 (C, Ar), 131.0 (CH, Ar), 129.0 (2 x CH, Ar), 126.4 (2 x
CH, Ar), 123.0 (CH, Ar), 122.4 (=C), 122.3 (C, Ar), 117.6 (CH, Ar), 34.2 (CH2),
31.4 (CH2), 25.8 (CH2), 24.4 (CH2), 21.8 (CH2), 20.5 (CH3); MS (ES+) m/z 327
[MNa+]; HRMS (ES+) calcd. for C21H20O2 [MNa+]: 327.1356; found: 327.1351.
7-Naphthalen-1-yl-1,2,3,4-tetrahydro-xanthen-9-one (189)
172 (100 mg, 0.28 mmol) was dissolved in dioxane (1
mL) and Pd2(dba)3 (6 mg, 0.007 mmol), Xphos (8 mg,
0.02 mmol), Cs2CO3 (199 mg, 0.61 mmol) and
naphthylene boronic acid (143 mg, 0.83 mmol) added according to General Method
4. Workup followed by column chromatography (5% EtOAc in petroleum ether)
gave the title compound as a white solid (55 mg, 60%). m.p. 171-173 °C; Rf = 0.27
(5% EtOAc in petroleum ether); IR (film) 2935, 1640, 1606, 1151, 768 cm-1; δH
(300 MHz, CDCl3) 8.34 (1H, d, J = 2.1, ArH), 7.91 (2H, t, J = 8.5, ArH), 7.83 (1H,
d, J = 8.5, ArH), 7.75 (1H, dd, J = 2.1, 8.5, ArH), 7.58-7.38 (5H, m, ArH), 2.78-
2.67 (2H, m, CH2), 2.67-2.56 (2H, m, CH2), 1.97-1.85 (2H, m, CH2), 1.85-1.74 (2H,
m, CH2); δC (100 MHz, CDCl3) 177.7 (C=O), 164.0 (=C), 155.3 (C, Ar), 138.7 (C,
Ar), 137.1 (C, Ar), 134.9 (CH, Ar), 133.8 (C, Ar), 131.5 (C, Ar), 128.4 (CH, Ar),
128.1 (CH, Ar), 127.4 (CH, Ar), 126.7 (CH, Ar), 126.3 (CH, Ar), 125.9 (CH, Ar),
125.6 (CH, Ar), 125.4 (CH, Ar), 123.1 (C, Ar), 118.6 (=C), 117.6 (CH, Ar), 28.2
(CH2), 22.0 (CH2), 21.7 (CH2), 21.1 (CH2); MS (ES+) m/z 327 [MH+]; HRMS (ES+)
calcd. for C23H18NaO2 [MNa+]: 349.1199; found: 349.1196.
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5-Phenyl-1,2,3,4-tetrahydro-xanthen-9-one (196)
194 (100 mg, 0.37 mmol) was dissolved in dioxane (1 mL) and
Pd2(dba)3 (8 mg, 0.009 mmol), Xphos (11 mg, 0.02 mmol),
Cs2CO3 (264 mg, 0.81 mmol) and phenyl boronic acid (135 mg,
1.11 mmol) added according to General Method 2. Workup
followed by column chromatography (10% EtOAc in petroleum ether) gave the title
compound as an off-white solid (86 mg, 84%). m.p. 152 °C; IR (film) 2939, 1624,
1425, 1409, 1156, 758, 698 cm-1; δH (400 MHz, CDCl3) 8.22 (1H, dd, J = 1.7, 7.9,
ArH), 7.65 (1H, dd, J = 1.7, 7.9, ArH), 7.58 (2H, d, J = 7.9, ArH), 7.50-7.45 (2H,
m, ArH), 7.44-7.38 (2H, m, ArH), 2.64-2.57 (4H, m, CH2), 1.89-1.81 (2H, m, CH2),
1.80-1.73 (2H, m, CH2);  δC (100 MHz, CDCl3) 177.9 (C=O), 164.0 (=C), 152.8 (C,
Ar), 136.4 (C, Ar), 134.0 (CH, Ar), 131.1 (C, Ar), 129.6 (CH, Ar), 128.4 (CH, Ar),
127.9 (CH, Ar), 125.2 (CH, Ar), 124.4 (CH, Ar), 123.7 (C, Ar), 118.3 (=C), 28.2
(CH2), 21.9 (CH2), 21.7 (CH2), 21.1 (CH2); MS (ES+) m/z 277 [MH+]; HRMS (ES+)
calcd. for C19H16NaO2 [MNa+]: 299.1043; found: 299.1041.
6-Phenyl-1,2,3,4-tetrahydro-xanthen-9-one (197)
195 (100 mg, 0.37 mmol) was dissolved in dioxane (1
mL) and Pd2(dba)3 (8 mg, 0.009 mmol), Xphos (11 mg,
0.02 mmol), Cs2CO3 (264 mg, 0.81 mmol) and phenyl
boronic acid (135 mg, 1.11 mmol) added according to General Method 2. Workup
followed by column chromatography (10% EtOAc in petroleum ether) gave the title
compound as a white solid (81 mg, 79%). m.p. 143-144 °C; IR (film) 2932, 1636,
1612, 1424, 1152, 754 cm-1; δH (400 MHz, CDCl3) 8.24 (1H, d, J = 7.2, ArH), 7.65
(2H, dd, J = 1.5, 7.2, ArH), 7.59 (2H, dd, J = 1.5, 7.2, ArH), 7.48 (2H, dt, J = 1.5,
7.2, ArH), 7.42 (1H, m, ArH), 2.72-2.66 (2H, m, CH2), 2.64-2.58 (2H, m, CH2),
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1.94-1.84 (2H, m, CH2), 1.82-1.74 (2H, m, CH2); δC (100 MHz, CDCl3) 177.6
(C=O), 164.0 (=C), 156.3 (C, Ar), 146.1 (C, Ar), 139.5 (C, Ar), 129.1 (CH, Ar),
128.6 (CH, Ar), 127.4 (CH, Ar), 126.3 (CH, Ar), 123.6 (CH, Ar), 122.0 (C, Ar),
118.6 (=C), 115.7 (CH), 28.3 (CH2), 22.9 (CH2), 21.8 (CH2), 21.1 (CH2); MS (ES+)
m/z 277 [MH+]; HRMS (ES+) calcd. for C19H16NaO2 [MNa+]: 299.1043; found:
299.1044.
7-Phenylethynyl-1,2,3,4-tetrahydroxanthen-9-one (199)
172 (100 mg, 0.28 mmol) was dissolved in dioxane
(1 mL) and Pd2(dba)3 (6 mg, 0.007 mmol), Xphos (8
mg, 0.02 mmol), Cs2CO3 (199 mg, 0.61 mmol) and
phenylacetylene (0.04 mL, 0.36 mmol) was added according to General Method 2.
Workup followed by column chromatography (10% EtOAc in petroleum ether)
gave the title compound as a yellow solid (56 mg, 67%). m.p. 163-165 °C; IR (film)
3051, 2928, 1633, 1607, 1437, 1307, 1152, 833, 747, 686 cm-1; δH (300 MHz,
CDCl3) 8.36 (1H, d, J = 2.2, ArH), 7.73 (1H, dd, J = 2.2, 8.7, ArH), 7.57-7.52 (2H,
m, ArH), 7.39-7.33 (4H, m, ArH), 2.72-2.65 (2H, m, CH2), 2.62-2.56 (2H, m, CH2),
1.93-1.83 (2H, m, CH2), 1.82-1.73 (2H, m, CH2); δC (100 MHz, CDCl3) 177.1
(C=O), 164.1 (=C), 155.5 (C, Ar), 135.8 (CH, Ar), 131.8 (CH, Ar), 129.3 (CH, Ar),
128.6 (CH, Ar), 128.5 (CH, Ar), 123.2 (C, Ar), 123.0 (C, Ar), 119.9 (C, Ar), 119.0
(=C), 118.1 (CH, Ar), 90.0 (≡C), 88.3 (≡C), 28.3 (CH2), 22.0 (CH2), 21.7 (CH2),
21.1 (CH2); MS (ES+) m/z 301 [MH+]; HRMS (ES+) calcd. for C21H16NaO2
[MNa+]: 323.1043; found: 323.1040.
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7-Styryl-1,2,3,4-tetrahydro-xanthen-9-one (201)
172 (100 mg, 0.28 mmol) was dissolved in dioxane (1
mL) and Pd2(dba)3 (6 mg, 0.07 mmol), Xphos (8 mg,
0.02 mmol), Cs2CO3 (199 mg, 0.61 mmol) and styrene
(0.16 mL, 1.39 mmol) added according to General
Method 2. Workup followed by column chromatography (10% EtOAc in
petroleum ether) gave the title compound as a white solid (39 mg, 46%). m.p. 140-
142 °C; IR (film) 2941, 1627, 1605, 1438, 813, 747, 687, 564 cm-1; δH (300 MHz,
CDCl3) 8.28 (1H, d, J = 2.3, ArH), 7.77 (1H, dd, J = 2.3, 8.8, ArH), 7.53 (2H, d, J =
7.2, ArH), 7.41-7.34 (3H, m, ArH), 7.31-7.25 (1H, m, ArH), 7.16 (2H, s, HC=CH),
2.71-2.56 (4H, m, CH2), 1.93-1.72 (4H, m, CH2); δC (100 MHz, CDCl3) 177.7
(C=O), 163.9 (=C), 155.4 (C, Ar), 137.7 (C, Ar), 134.0 (C, Ar), 130.9 (CH, Ar),
129.7 (=CAr), 128.8 (CH, Ar), 128.0 (CH, Ar), 127.2 (=CAr), 126.7 (CH, Ar),
123.3 (CH, Ar), 118.5 (=C), 118.2 (CH, Ar), 28.3 (CH2), 22.0 (CH2), 21.7 (CH2),
21.1 (CH2); MS (ES+) m/z 305 [MH+]; HRMS (ES+) calcd. for C21H18NaO2
[MNa+]: 325.1199; found: 325.1197.
6-(4-Methoxy-phenylethynyl)-1,2,3,4-tetrahydroxanthen-9-one (203)
195 (100 mg, 0.37 mmol) was dissolved in
dioxane (1 mL) and Pd2(dba)3 (8 mg, 0.009
mmol), Xphos (11 mg, 0.02 mmol), Cs2CO3
(264 mg, 0.81 mmol) and 4-
methoxyphenylacetylene (0.06 mL, 0.48 mmol) added according to General
Method 2. Workup followed by column chromatography (10% EtOAc in
petroleum ether) gave the title compound as a yellow solid (122 mg, 82%). m.p.
139-140 °C; IR (film) 2938, 2209, 1624, 1614, 1603, 1251, 1151, 831 cm-1; δH (300
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MHz, CDCl3) 8.13 (1H, d, J = 8.3, ArH), 7.52-7.46 (3H, m, ArH), 7.43 (1H, dd, J =
1.3, 8.3, ArH), 6.89 (2H, d, J = 8.7, ArH), 3.83 (3H, s, OCH3), 2.69-2.61 (2H, m,
CH2), 2.61-2.53 (2H, m, CH2), 1.92-1.81 (2H, m, CH2), 1.80-1.70 (2H, m, CH2); δC
(100 MHz, CDCl3) 177.2 (C=O), 164.1 (=C), 162.2 (C, Ar), 155.6 (C, Ar), 133.4
(CH, Ar), 128.5 (C, Ar), 127.5 (CH, Ar), 125.7 (CH, Ar), 122.4 (C, Ar), 120.2 (CH,
Ar), 118.8 (=C), 114.6 (CH, Ar), 114.2 (CH, Ar), 93.0 (≡C), 87.1 (≡C), 55.4 (CH3),
28.2 (CH2), 21.9 (CH2), 21.7 (CH2), 21.1 (CH2); MS (ES+) m/z 331 [MH+]; HRMS
(ES+) calcd. for C22H18NaO3 [MNa+]: 353.1148; found: 353.1145.
2,5-Dimethoxy-terephthalic acid dimethyl ester (204)
K2CO3 (37 g, 0.27 mol) and MeI (24 mL, 0.39 mol) were
added to a solution of 211 (8.82 g, 0.039 mol) in acetone
(250 mL). The reaction mixture was stirred at room
temperature for 65 h. The solids were filtered washing with acetone (50 mL) and
the filtrate was concentration in vacuo to give a yellow solid. Trituration with Et2O
and filtration gave the title compound as a white solid (8.28 g, 84%). m.p. 142-143
°C; δH (400 MHz, CDCl3) 7.40 (2H, s, ArH), 3.92 (6H, s, CH3), 3.90 (6H, s, CH3);
δC (100 MHz, CDCl3) 166.1 (C=O), 152.5 (C, Ar), 124.09 (C, Ar), 115.6 (CH, Ar),
56.9 (OCH3), 52.6 (OCH3); MS (ES+) m/z 255 [M+H+]. Data is in accordance with
literature values.212
2,5-Dihydroxy-terephthalic acid dimethyl ester (211)
Dimethyl 2,5-dioxocyclohexane-1,4-dicarboxylate (1 g,
4.39 mmol) was added to AcOH (3 mL) and heated to 80
°C before adding NBS (780 mg, 4.39 mmol) carefully.
After 1 h at 80 °C, the reaction mixture was allowed to cool to room temperature
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and the product was filtered washing with AcOH (2 mL), tBuOMe (2 mL) and H2O
(2 mL). The solid was dried to give the title compound as a yellow solid (852 mg,
86%). m.p. 173-177 °C (lit. m.p 176-177 °C); δH (300 MHz, CDCl3) 10.07 (2H, s,
OH), 7.47 (2H, s, ArH), 3.98 (6H, s, OCH3); δC (100 MHz, CDCl3) 169.6 (C=O),
153.0 (C, Ar), 118.5 (C, Ar), 117.9 (CH, Ar), 52.9 (CH3); MS (ES-) m/z 225 [M-
H+]; HRMS (ES-) calcd. for C10H10O6 [M-H+]: 225.0405; found: 225.0397. Data is
in accordance with literature values.193
2,5-Dimethoxy-terephthalic acid monomethyl ester (222)
KOH (231 g, 4.13 mmol) dissolved in H2O (2 mL) was
added dropwise to a mixture of 204 (1 g, 3.94 mmol) in
MeOH (5 mL) and THF (5 mL). The reaction mixture was
stirred at room temperature for 18 h. The organic solvents were removed in vacuo
and the resulting aqueous phase was extracted with EtOAc (2 x 10 mL) to remove
any remaining starting material. The aqueous phase was then cooled to 0 °C,
acidified using 2M HCl (3mL) and extracted with EtOAc (2 x 20 mL). The organic
phase was separated, dried (MgSO4), filtered and the solvent removed in vacuo. The
resulting solid was purified using column chromatography eluting with 50% EtOAc
in petroleum ether to give the title compound as a white solid (469 mg, 50%). m.p.
145-147 °C (lit. m.p 147-148 °C); IR (film) 2956, 1736, 1709, 1406, 1251, 1209,
1029 cm-1; δH (300 MHz, CDCl3) 10.87 (1H, brs, CO2H), 7.80 (1H, s, ArH), 7.49
(1H, s, ArH), 4.10 (3H, s, CO2CH3), 3.95 (3H, s, OCH3), 3.94 (3H, s, OCH3); δC
(100 MHz, CDCl3) 165.7 (C=O), 164.6 (C=O), 153.6 (C, Ar), 151.2 (C, Ar), 125.5
(C, Ar), 121.3 (C, Ar), 116.8 (CH, Ar), 115.2 (CH, Ar), 57.5 (OCH3), 56.8 (OCH3),
52.8 (CO2CH3); MS (ES-) m/z 239 [M-H+]; HRMS (ES+) calcd. for C11H12NaO6
[MNa+]: 263.0526; found: 263.0525.
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2,5-Dihydroxy-4-hydroxymethyl-benzoic acid methyl ester (224)
To a stirring solution of 211 (3.65 g, 16.15 mmol) in THF
(70 mL) and H2O (11 mL), cooled to 0 °C, was added
NaBH4 (1.83 g, 48.5 mmol). The reaction mixture was
allowed to warm to room temperature and stirred for 1 h before recooling to 0 °C
and quenching with 2M HCl until effervescence ceased (~15 mL). An aqueous
saturated solution of NaHCO3 (20 mL) was added to neutralise the mixture and the
product was extracted with EtOAc (2 x 100 mL). The organic phase was washed
with brine (50 mL), dried (MgSO4), filtered and the solvent removed in vacuo to
give the title compound as an off-white solid (2.2 g, 69%). m.p. 143-145 °C (lit.
m.p 147-148 °C); IR (film) 3424, 1667, 1627, 1438, 1214, 1076, 788 cm-1; δH (300
MHz, CD3OD) 7.17 (1H, s, ArH), 6.95 (1H, s, ArH), 4.63 (2H, s, CH2), 3.91 (3H, s,
CH3); δC (75 MHz, CDCl3) 171.6 (C=O), 156.3 (C, Ar), 147.9 (C, Ar), 139.3 (C,
Ar), 116.4 (CH, Ar), 114.5 (CH, Ar), 111.5 (C, Ar), 60.4 (CH2), 52.6 (OCH3); MS
(ES+) m/z 221 [MNa+]; HRMS (ES+) calcd. for C9H10NaO5 [MNa+]: 221.0420;
found: 221.0423. Data is in accordance with literature values.162
2-Hydroxy-4-hydroxymethyl-5-methoxy-benzoic acid methyl ester (225)
224 (350 mg, 1.77 mmol) was dissolved in acetone (7 mL)
and K2CO3 (1.7 g, 12.37 mmol) was added followed by
MeI (1.1 mL, 17.68 mmol). The reaction mixture was
stirred at room temperature overnight. The solvent was removed in vacuo and
treated with 2M HCl (10 mL) and extracted with DCM (3 x 10 mL). The organic
phase was separated, dried (MgSO4), filtered and the solvent removed in vacuo to
give the title compound as a white solid (128 mg, 34%). m.p. 117-118 °C; IR (film)
2919, 1672, 1203, 1176, 1036, 788, 716 cm-1; δH (300 MHz, CDCl3) 10.43 (1H, s,
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phenolic OH), 7.23 (1H, s, ArH), 6.99 (1H, s, ArH), 4.68 (2H, d, J = 6.6, CH2), 3.97
(3H, s, CH3), 3.84 (3H, s, CH3), 2.29 (1H, t, J = 6.6, CH2OH); δC (150 MHz,
CDCl3) 170.3 (C=O), 156.5 (C, Ar), 149.8 (C, Ar), 138.6 (C, Ar), 117.3 (CH, Ar),
110.6 (C, Ar), 109.4 (CH, Ar), 61.7 (CH2), 55.9 (CH3), 52.4 (CH3); MS (ES+) m/z
213 [MH+]; HRMS (ES+) calcd. for C10H13O5 [MH+]: 213.0757; found: 213.0756.
4-Formyl-2-hydroxy-5-methoxy-benzoic acid methyl ester (226)
225 (128 mg, 0.60 mmol) was dissolved in DCM (10 mL)
and MnO2 (525 mg, 6.04 mmol) was added. The reaction
mixture was stirred at room temperature for 65 h before
filtering through a plug of Celite® washing with DCM (3 x 10 mL). The solvent was
removed in vacuo to give the title compound as a yellow solid (116 mg, 91%). m.p.
139-141 °C; IR (film) 3236, 1677, 1212, 893, 786, 707 cm-1; δH (300 MHz, CDCl3)
10.43 (1H, s, HC=O), 10.25 (1H, s, OH), 7.39 (1H, s, ArH), 7.38 (1H, s, ArH), 3.99
(3H, s, CH3), 3.90 (3H, s, CH3); δC (100 MHz, CDCl3) 189.3 (C=O), 169.6 (C=O),
155.3 (C, Ar), 153.7 (C, Ar), 130.4 (C, Ar), 117.1 (CH, Ar), 117.0 (C, Ar), 112.1
(CH, Ar), 56.3 (CH3), 52.9 (CH3); MS (ES+) m/z 233 [MNa+]; HRMS (ES+) calcd.
for C10H10NaO5 [MNa+]: 233.0420; found: 233.0423.
1-(2,5-Dimethoxy-phenyl)-2-(3-methoxy-phenyl)ethanone (232)
2,5-dimethoxyacetophenone (0.51 mL, 3.2 mmol), 3-
bromoanisole (0.34 mL, 2.67 mmol), Pd(OAc)2 (6 mg,
0.03 mmol), xantphos (31 mg, 0.05 mmol) and NatBuO
(334 mg, 3.48 mmol) were combined in toluene (2.7 mL) and heated to 80 °C
overnight. The reaction mixture was allowed to cool to room temperature and 2M
HCl was added before extracting with Et2O (2 x 10 mL). The organic phase was
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washed with H2O (20 mL), dried (MgSO4), filtered and the solvent removed in
vacuo. The resulting orange oil was purified by column chromatography eluting
with 5% EtOAc in petroleum ether to give the title compound as a colourless oil
(671 mg, 88%). IR (film) 2943, 2834, 1674, 1584, 1490, 1220, 1047, 1018; δH (300
MHz, CDCl3) 7.26-7.18 (2H, m, ArH), 7.03 (1H, dd, J = 3.2, 9.0, ArH), 6.91 (1H,
d, J = 9.0, ArH), 6.85-6.76 (2H, m, ArH), 4.30 (2H, s, CH2), 3.89 (3H, s, CH3), 3.79
(3H, s, CH3), 3.78 (3H, s, CH3); δC (100 MHz, CDCl3) 199.6 (C=O), 159.7 (C, Ar),
153.6 (C, Ar), 153.0 (C, Ar), 136.8 (C, Ar), 129.4 (CH, Ar), 128.4 (C, Ar), 122.2
(CH, Ar), 120.2 (CH, Ar), 115.4 (CH, Ar), 114.4 (CH, Ar), 113.2 (CH, Ar), 112.2
(CH, Ar), 56.1 (CH3), 55.9 (CH3), 55.2 (CH3), 50.2 (CH3); MS (ES+) m/z 287
[MH+]; HRMS (ES+) calcd. for C17H19O4 [MH+]: 287.1278; found: 287.1276.
1-(2,5-Dihydroxy-phenyl)-2-(3-hydroxy-phenyl)ethanone (239)
232 (359 mg, 1.26 mmol) was dissolved in DCM and
cooled to -78 °C. BBr3 (1M in DCM) (4.39 mL, 4.39
mmol) was added cautiously and the reaction mixture was
stirred at -78 °C for 6 h before allowing to warm to room temperature. The reaction
mixture was poured over ice and H2O (30 mL) and extracted with EtOAc (50 mL).
The organic phase was separated, dried (MgSO4), filtered and the solvent removed
in vacuo. The resulting yellow solid was columned eluting with 50% EtOAc in
petroleum ether to give the title compound as a yellow solid (272 mg, 89%). m.p.
170-171 °C; δH (400 MHz, CD3OD) 7.32 (1H, d, J = 3.0, ArH), 7.12 (1H, t, J = 8.0,
ArH), 6.99 (1H, dd, J = 3.0, 9.0, ArH), 6.79 (1H, d, J = 9.0, ArH), 6.74 (1H, d J =
8.0, ArH), 6.73-6.71 (1H, m, ArH), 6.67 (1H, dd, J = 2.4, 8.0, ArH), 4.19 (2H, s,
CH2); δC (100 MHz, CDCl3) 205.5 (C=O), 158.7 (C, Ar), 157.1 (C, Ar), 150.5 (C,
Ar), 137.4 (C, Ar), 130.7 (CH, Ar), 126.0 (CH, Ar), 121.6 (CH, Ar), 120.1 (C, Ar),
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119.7 (CH, Ar), 117.2 (CH, Ar), 116.3 (CH, Ar), 114.9 (CH, Ar), 46.2 (CH2). MS
(ES+) m/z 267 [M+Na+]; HRMS (ES+) calcd. for C14H12NaO4 [M+Na+]: 267.0628;
found: 267.0627.
2-[1-Hydroxy-2-(3-hydroxy-phenyl)ethyl]benzene-1,4-diol (246)
239 (100 mg, 0.41 mmol) was dissolved in a mixture of
THF (2 mL) and H2O (0.3 mL) and cooled to 0 °C.
NaBH4 (46 mg, 1.23 mmol) added and once the
effervescence had ceased, the reaction mixture was allowed to warm to room
temperature for 10 min. The mixture was then recooled to 0 °C and was quenched
with 2M HCl (5 mL) and was extracted with EtOAc (2 x 5 mL). The organic phase
was separated, dried (MgSO4), filtered and the solvent removed in vacuo to give the
title compound as an orange oil (54 mg, 53 %). δH (400 MHz, CD3OD) 7.05 (1H, t,
J = 8.0, ArH), 6.72-6.67 (3H, m, ArH), 6.63-6.58 (2H, m, ArH), 6.52 (1H, dd, J =
3.0, 8.6, ArH), 5.08 (1H, dd, J = 4.6, 8.4, CHOH), 3.00 (1H, dd, J = 4.6, 13.6,
CHH), 2.80 (1H, dd, J = 8.4, 13.6, CHH); δC (100 MHz, CDCl3) 158.0 (C, Ar),
151.0 (C, Ar), 148.4 (C, Ar), 142.1 (C, Ar), 132.6 (C, Ar), 129.9 (CH, Ar), 121.9
(CH, Ar), 117.4 (CH, Ar), 116.9 (CH, Ar), 115.2 (CH, Ar), 114.4 (CH, Ar), 113.9
(CH, Ar), 72.5 (CHOH), 45.2 (CH2); MS (ES-) m/z 245 [M-H+]; HRMS (ES+)
calcd. for C14H14NaO4 [MNa+]: 269.0784; found: 269.0783
1-(2-Hydroxy-5-methoxy-phenyl)-2-(3-methoxy-phenyl)ethanone (248)
Compound 232 (4 g, 13.99 mmol) was dissolved in
DCM (100 mL) and cooled to -78 °C. BBr3 (1M in
DCM) (16.78 mL, 16.78 mmol) was added and the
reaction mixture was stirred at -78 °C for 1 h before warming to room temperature.
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The mixture was subsequently poured over ice and H2O (100 mL) and extracted
with EtOAc (2 x 100 mL). The organic phase was separated, dried (MgSO4),
filtered and the solvent removed in vacuo. The resulting orange oil was purified by
column chromatography eluting with 10% EtOAc in petroleum ether to give the
title compound as a yellow oil which solidified on standing at room temperature
(3.42 g, 90%). m.p. 48-49 °C; IR (film) 2956, 1592, 1485, 1258, 1228, 1040, 775
cm-1; δH (400 MHz, CDCl3) 11.82 (1H, s, OH), 7.31-7.25 (2H, m, ArH), 7.11 (1H,
dd, J = 3.0, 9.0, ArH), 6.93 (1H, d, J = 9.2, ArH), 6.89-6.81 (3H, m, ArH), 4.25
(2H, s, CH2), 3.80 (3H, s, OCH3), 3.78 (3H, s, OCH3); δC (100 MHz, CDCl3) 203.4
(C=O), 160.0 (C, Ar), 157.4 (C, Ar), 151.8 (C, Ar), 135.5 (C, Ar), 129.9 (CH, Ar),
124.6 (CH, Ar), 121.8 (CH, Ar), 119.6 (CH, Ar), 118.6 (C, Ar), 115.2 (CH, Ar),
113.2 (CH, Ar), 112.7 (CH, Ar), 56.0 (CH3), 55.6 (CH3), 45.6 (CH2); MS (ES-) m/z
271 [M-H+]; HRMS (ES-) calcd. for C16H15O4 [M-H+]: 271.0976; found: 271.0982.
6-Methoxy-4-(3-methoxy-benzyl)-4H-benzo[1,3]dioxine (250)
249 (200 mg, 0.73 mmol) was dissolved in DMF and
cooled to 0 °C. NaH (60% in mineral oil) (73 mg, 1.8
mmol) was added and the reaction mixture was allowed
to warm to room temperature before adding bromochloromethane (0.07 mL, 1.09
mmol). Stirred at room temperature overnight and then quenched with an aqueous
saturated solution of NH4Cl (10 mL). The product was extracted with EtOAc (2 x
10 mL), washed with H2O (10 mL), dried (MgSO4), filtered and the solvent
removed in vacuo. The resulting oil was purified by column chromatography
eluting with 10% EtOAc in petroleum ether to give the title compound as a
colourless oil (65 mg, 31%). IR (film) 3001, 2916, 2849, 2834, 1601, 1584, 1497,
1227, 1006 cm-1; δH (300 MHz, CDCl3) 7.73-7.67 (1H, m, ArH), 7.37-7.17 (4H, m,
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ArH), 7.01 (1H, d, J = 2.8, ArH), 5.70 (1H, d, J = 5.8, acetal CHH), 5.61 (1H, dd, J
= 4.1, 8.9, CHO), 5.52 (1H, d, J = 5.8, acetal CHH), 4.25 (3H, s, OCH3), 4.18 (3H,
s, OCH3), 3.64 (1H, dd, J = 4.1, 14.3, CHH), 3.51 (1H, dd, J = 8.9, 14.3, CHH); δC
(100 MHz, CDCl3) 159.7 (C, Ar), 154.0 (C, Ar), 147.0 (C, Ar), 139.4 (C, Ar), 129.3
(CH, Ar), 125.4 (C, Ar), 121.9 (CH, Ar), 117.9 (CH, Ar), 115.4 (CH, Ar), 114.2
(CH, Ar), 112.1 (CH, Ar), 110.5 (CH, Ar), 89.4 (acetal CH2), 75.6 (CHO), 55.8
(CH3), 55.3 (CH3), 42.4 (CH2); MS (ES+) m/z 309 [MNa+]; HRMS (ES+) calcd. for
C17H18NaO4 [MNa+]: 309.1097; found: 309.1098.
2-[1-Hydroxy-2-(3-methoxy-phenyl)ethyl]-4-methoxy-phenol (251)
Using Will’s catalyst: The tethered catalyst (253) (2.3
mg, 0.004 mmol) was stirred at 28 °C for 30 min in a 5:2
mixture of formic acid and NEt3 (0.19 mL) before
adding ketone 232 (100 mg, 0.37 mmol). Further 5:2 formic acid:NEt3 mixture
(0.19 mL) was added to aid stirring and solubility. The reaction mixture was stirred
at 28 °C for 24 h before filtering through a plug of silica washing with EtOAc (10
mL). The solvent was then removed in vacuo and the resulting residue was purified
by column chromatography eluting with 10% EtOAc in petroleum ether to give the
title compound as a colourless oil (77 mg, 76%, 93% ee). [α]D
24 -9.2 (c1 in CHCl3).
IR (film) 3353, 1585, 1490, 1257, 1151, 1036, 755 cm-1; δH (400 MHz, CDCl3) 7.60
(1H, brs, OH), 7.26 (1H, t, J = 7.7, ArH), 6.85-6.80 (3H, m, ArH), 6.76-6.74 (1H,
m, ArH), 6.73 (1H, d, J = 3.0, ArH), 6.50 (1H, d, J = 3.0, ArH), 4.95 (1H, t, J = 7.0,
CHOH), 3.79 (3H, s, OCH3), 3.71 (3H, s, OCH3), 3.08 (2H, d, J = 7.0, CH2), 3.00
(1H, brs, OH); δC (100 MHz, CDCl3) 159.9 (C, Ar), 153.0 (C, Ar), 149.2 (C, Ar),
139.0 (C, Ar), 129.8 (CH, Ar), 127.4 (C, Ar), 121.9 (CH, Ar), 119.7 (CH, Ar),
117.8 (CH, Ar), 115.2 (CH, Ar), 114.2 (CH, Ar), 112.9 (CH, Ar), 112.5 (CH, Ar),
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76.5 (CHOH), 55.9 (OCH3), 55.3 (OCH3), 44.3 (CH2); MS (ES-) m/z 273 [M-H+];
HRMS (ES+) calcd. for C16H18NaO4 [MNa+]: 297.1097; found: 297.1093.
Using Noyori’s catalyst: (p-cymene)ruthenium(II)chloride dimer (2.3 mg, 0.004
mmol) and (R,R)-TsDPEN (1 mg, 0.002 mmol) was stirred at 28 °C for 30 min in a
5:2 mixture of formic acid and NEt3 (0.19 mL) before adding ketone 232 (100 mg,
0.37 mmol). Further 5:2 formic acid:NEt3 mixture (0.19 mL) was added to aid
stirring and solubility. The reaction was carried out, worked up and purified as
above to provide a colourless oil (91 mg, 79%, 91% ee). Data as above.
2,5-Dibromo-3,6-dimethoxy-terephthalic acid dimethyl ester (255)
Dimethyl 2,5-dioxocyclohexane-1,4-dicarboxylate (1 g,
4.39 mmol) in AcOH (3 mL) was heated to 70 °C and
NBS (869 mg, 4.88 mmol) was added carefully. The
reaction mixture was heated to 90 °C for 40 min and then cooled to 60 °C for the
addition of the remaining NBS (2.54 g, 14.27 mmol). The temperature was raised to
80 °C for 1 h and then cooled to 10 °C. The solids were filtered washing with
AcOH (5 mL) and H2O (5 mL). This material was then dissolved in a mixture of
DCM (5.6 mL), MeOH (1.9 mL), AcOH (0.06 mL) and H2O (0.9 mL) and was
cooled to 0 °C. Na2S2O4 (847 mg in 4 mL H2O) was then added and the reaction
mixture stirred at room temperature for 30 min. The organic solvents were removed
in vacuo and the resulting suspension was filtered at 0 °C washing with ice-cold
H2O (10 mL). K2CO3 (2.08 g, 15.1 mmol) and MeI (0.56 mL, 9.03 mmol) were
added to a suspension of this solid (578 mg, 1.51 mmol) in acetone (11 mL). The
reaction mixture was stirred at room temperature for 48 h before filtering the
insoluble material washing with acetone (3 x 20 mL). The filtrate was concentrated
in vacuo and the resultant residue was purified by column chromatography eluting
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with 10% EtOAc in petroleum ether to give the title compound as a white solid (275
mg, 17% over 3 steps). m.p. 152 °C; IR (film) 2946, 1726, 1438, 1375, 1256, 1007
cm-1; δH (400 MHz, CDCl3) 3.98 (6H, s, CH3), 3.88 (6H, s, CH3); δC (100 MHz,
CDCl3) 164.9 (2C=O), 151.1 (C, 2Ar), 134.1 (C, 2Ar), 114.0 (C, 2Ar), 62.8
(2CO2CH3), 53.2 (2CH3); MS (ES+) m/z 433 [MNa+, 79Br,79Br], 435 [MNa+,
79Br,81Br], 437 [MNa+, 81Br,81Br]; HRMS (ES+) calcd. for C12H12Br2NaO6 [MNa+,
79Br, 81Br]: 434.8873; found 434.8875.
2,5-Dibromo-3,6-dimethoxy-terephthalic acid monomethyl ester (256)
Diester 255 (500 mg, 1.21 mmol) was dissolved in dioxane
(5 mL) and 1M NaOH (1.21 mL) was added. The reaction
mixture was heated to reflux overnight before allowing to
cool to room temperature. H2O (20 mL) was added and extracted with DCM (10
mL) to remove any remaining starting material. 2M HCl was added to acidify the
aqueous phase and extracted with DCM (2 x 20 mL). Dried (MgSO4), filtered and
the solvent removed in vacuo. The resulting yellow solid was purified using column
chromatography eluting with 100% EtOAc to give the title compound as a white
solid (192 mg, 40%). IR (film) 3024, 2945, 1743, 1691, 1378, 1283, 1007 cm-1; δH
(300 MHz, CDCl3) 8.28 (1H, s, CO2H), 3.99 (3H, s, OCH3), 3.95 (3H, s, OCH3),
3.90 (3H, s, OCH3); δC (100 MHz, CDCl3) 168.6 (C=O), 165.1 (C=O), 151.3 (C,
Ar), 151.2 (C, Ar), 134.4 (C, Ar), 133.4 (C, Ar), 114.2 (C, Ar), 113.8 (C, Ar), 63.1
(CH3), 53.4 (CH3), 31.1 (CH3); MS (ES+) m/z 419 [MNa+, 79Br,79Br], 421 [MNa+,
79Br,81Br], 423 [MNa+, 81Br,81Br]; HRMS (ES+) calcd. for C12H12Br2NaO6 [MNa+,
79Br, 81Br]: 420.8717; found 420.8719.
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2,5-Dibromo-4-chlorocarbonyl-3,6-dimethoxy-benzoic acid methyl ester (257)
256 (500 mg, 2.08 mmol) dissolved in SOCl2 (3 mL, 41.7
mmol) and heated to reflux for 3 h. The reaction mixture was
allowed to cool to room temperature and excess SOCl2
removed in vacuo. The resulting solid was triturated with hexane and filtered off to
give the title compound as a pale yellow solid (340 mg, 63%). IR (film) 2946, 1775,
1730, 1374, 1253, 1009 cm-1; δH (500 MHz, CDCl3) 4.00 (3H, s, OCH3), 3.95 (3H,
s, OCH3), 3.91 (3H, s, CH3); δC (125 MHz, CDCl3) 165.1 (C=O), 164.7 (C=O),
151.5 (C, Ar), 149.8 (C, Ar), 137.6 (C, Ar), 135.0 (C, Ar), 114.3 (C, Ar), 112.0 (C,
Ar), 63.3 (CH3), 63.1 (CH3), 53.4 (CH3).
2,5-Dibromo-3,6-dimethoxy-terephthalic acid 1-cyclohex-1-enyl ester 4-methyl
ester (263)
TMS silyl enol ether (329 mg, 1.93 mmol) was
dissolved in THF and cooled to -78 °C. MeLi (1.6 M
in Et2O) (1.32 mL, 2.13 mmol) was added and the
reaction mixture was stirred at -78 °C for 1 h and then at room temperature for 1 h.
It was then recooled to -78 °C and acid chloride 257 (500 mg, 1.93 mmol) was
added and the mixture stirred at -78 °C for 1 h before allowing to warm to room
temperature overnight. 2M HCl (10 mL) was added and extracted with EtOAc (2 x
20 mL) washing with H2O (20 mL). The organic phase was dried (MgSO4), filtered
and the solvent removed in vacuo. The resulting oil was purified by column
chromatography eluting with 5% EtOAc in petroleum ether to give the title
compound as a white solid (125 mg, 14%). m.p. 116-117 °C; IR (film) 2936, 1737,
1378, 1227, 1010, 589 cm-1; δH (400 MHz, CDCl3) 5.61 (1H, m, CH), 3.98 (3H, s,
CO2CH3), 3.91 (3H, s, OCH3), 3.89 (3H, s, OCH3), 2.37-2.31 (2H, m, CH2), 2.22-
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2.15 (2H, m, CH2), 1.86-1.78 (2H, m, CH2), 1.70-1.62 (2H, m, CH2); δC (100 MHz,
CDCl3) 165.0 (C=O), 162.9 (C=O), 151.3 (C, Ar), 151.2 (C, Ar), 148.6 (C, Ar),
134.2 (C, Ar), 134.0 (C, Ar), 115.2 (CH), 114.1 (C, Ar), 114.0 (C, Ar), 62.9
(OCH3), 53.3 (CO2CH3), 26.7 (CH2), 23.8 (CH2), 23.8 (CH2), 22.7 (CH2), 21.7
(CH2); MS (ES+) m/z 499 [MNa+, 79Br,79Br], 501 [MNa+, 79Br,81Br], 503 [MNa+,
81Br,81Br]; HRMS (ES+) calcd. for C17H18Br2NaO6 [MNa+, 79Br, 81Br]: 500.9343;
found 500.9344.
Biological experimental data
Fermentation of Amycolatopsis regifaucium
Amycolatopsis regifaucium bacteria grown on GYM agar was inoculated into a 500
mL Erlenmeyer flask containing 100 mL of liquid (pre-seed) culture medium
[galactose 2% (w/v), dextrin 2% (w/v), Bactosoytone (Difco) 1% (w/v), corn steep
liquor 0.5% (w/v), (NH4)2SO4 0.2%, CaCO3 0.2%, pH 7.4]. It was cultured on a
rotary shaker (180 rpm) at 30°C for 3 days. 1 mL of this seed culture was inoculated
into 100 mL of production medium (prepared by adding glycerol 1% (v/v) to the
seed culture medium). The production medium was shaken on the rotary shaker at
37°C for 5 days. The culture was centrifuged and the supernatant separated and
adjusted to pH 2 using 6M HCl before extracting with butyl acetate (5 x 100mL).
Dried (MgSO4), filtered and solvent removed in vacuo to give an orange residue.
Preparation of GYM medium
Glucose (1.6 g), yeast extract (1.6 g), malt extract (4 g) and CaCO3 (0.8 g) was
added to distilled water (400 mL) and adjusted to pH 7.2 using 2M NaOH. Agar
(4.8 g) was added and the mixture autoclaved (120°C). The mixture was then
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melted under microwave irradiation (low heat, 5 min). 25 mL of the resulting liquid
was then added to each of 4 petri dishes and left at room temperature to set.
Preparation of GPHF medium
Glucose (1.0 g), peptone from casein (500 mg), yeast extract (500 mg), beef extract
(500 mg) and CaCl.2H2O (74 mg) were added to distilled H2O (100 mL) and
adjusted to pH 7.2 using 2M NaOH. Agar (4.8 g) was added and the mixture
autoclaved (120 °C). The mixture was then melted under microwave irradiation
(low heat, 5 min). 25 mL of the resulting liquid was then added to each of 4 petri
dishes and left at room temperature to set.
Cell culture
PANC-1 cells established from a human Caucasian pancreatic carcinoma were
obtained from the European Collection of Cell Cultures (Porton Down, UK) and
maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
20% (v/v) foetal bovine serum, 2 nM glutamine and 0.1% (v/v) gentamicin. The
medium was routinely changed every 3 days and cells were passaged by
trypsinisation (using 0.2 mg/mL trypsin solution) at approximately 80% confluence.
Nutrient deprived medium (NDM) was prepared as follows: CaCl2 (1M) (0.6 mL),
Fe(NO3)3.9H2O (0.5 mg), KCl (200 mg), MgSO4.7H2O (100 mg), NaCl (3.2 g),
NaHCO3 (350 mg), NaH2PO4 (62.5 mg), phenol red (7.5mg), 1M HEPES buffer
(12.5 mL) and MEM vitamin solution (5 mL) (Lonza, UK) were dissolved in
doubly distilled H2O (final volume 500 mL). The pH was adjusted to 7.2 using an
aqueous saturated solution of NaHCO3. The medium was sterile filtered and stored
at - 4°C.
Chapter 5: Experimental
___________________________________________________________________________________________________________________
___________________________________________________________________
206
Trypan blue assay
PANC-1 cells were seeded in 6 x 6 well plates and incubated in fresh DMEM (2
mL per well) at 37 °C under a 5% CO2 / 95% air atmosphere until confluent. Serial
dilutions of kigamicin C in both DMEM and NDM were prepared at 0, 0.001, 0.01,
0.1, and 10µg/mL and a control set of serial dilutions also prepared containing
DMSO in NDM at the quantities used above. DMSO was used to dissolve the
kigamicin C and therefore this is the carrier control. DMEM was removed from the
wells and the cells washed with PBS buffer before adding the serial dilutions to the
wells. Everything was carried out in duplicate. After 24 h incubation at 37 °C under
5% CO2, the supernatant from each well was removed and set aside. 2 mL trypsin
(0.2 mg/mL) was added to each well and incubated at 37 °C under 5% CO2 / 95%
air atmosphere for 5 min. The trypsinised cells were added to the supernatant
removed from the same well. The combined mixture was then centrifuged at 200g
for 5 min and the cells resuspended in 50 µL DMEM. 10 µL of cell suspension was
then added to 90µL trypan blue dye and left at room temperature for 3 min after
which time live and dead cells were counted under the microscope using a
haemocytometer.
WST-1 assay
Cell viability was assayed by determination of formazan levels resulting from the
metabolism of NADH to NAD+ using assay kits from Roche Diagnostics Ltd
(Burgess Hill, UK). Assays were performed according to the manufacturer’s
instructions.
Cells were seeded in 96 well plates (1 x 104 per well) and incubated in fresh
DMEM for 24 h at 37 °C under 5% CO2 / 95% air atmosphere. In order to seed the
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plates at the correct concentration, cells were trypsinised and centrifuged before
resuspending them in fresh medium (10 mL). An aliquot of cell suspension was
diluted (100 µL of cell suspension added to 100 µL of medium) before counting
cells using a haemocytometer. Once the concentration of cells per mL was known,
the dilution factor could be calculated based on total number of cells and total
volume of medium required.
Serial dilutions of kigamicin C in both DMEM and NDM were prepared at 0, 0.001,
0.01, 0.1, and 10µg/mL. Blank controls (containing only media) and low controls
(containing untreated cells) were included on each plate. DMEM was removed from
the wells and the cells were washed with warm PBS buffer before adding the serial
dilutions (100µL per well). Each concentration was assayed in quadruplicate. After
24 h incubation at 37 °C under a 5% CO2 / 95% air atmosphere, WST-1 reagent
(Roche Diagnostics) was added to each well (10 µL per well) and the plate
incubated at 37°C under a 5% CO2 / 95% air atmosphere for 1 h. The absorbance
was then measured at 490 nm.
Lactate Dehydrogenase assay (LDH)
Cell death was assayed by determination of cellular release of LDH using assay kits
from Roche Diagnostics Ltd (Burgess Hill, UK). Assays were performed according
to the manufacturer’s instructions.
Briefly, cells were seeded in 96 well plates (3 x 104 per well) and incubated in fresh
DMEM for 24 h at 37 °C under 5% CO2 / 95% air atmosphere. Serial dilutions of
the compound to be tested, in both DMEM and NDM were prepared at 0, 0.001,
0.01, 0.1, 1.0, 10 and 100 µg/mL. Blank controls (containing only media), low
Chapter 5: Experimental
___________________________________________________________________________________________________________________
___________________________________________________________________
208
controls (containing untreated cells) and high controls (containing cells lysed with
2% (v/v) Triton X to determine maximum cellular LDH levels) were included on
each plate. DMEM was removed from the wells and the cells washed with warm
PBS before adding the serial dilutions (100 µL per well) of the compound to be
tested. Each concentration was assayed in triplicate. After 24 h incubation at 37 °C
under a 5% CO2 / 95% air atmosphere, the plate was centrifuged and 80 µL of
supernatant from each well was transferred to a new 96 well plate. The LDH assay
catalyst (diaphorase and NAD+) and dye solution (iodotetrazolium chloride and
sodium lactate) were combined and 80 µL of this reagent mix was added to each
well. After 30 min at room temperature in the dark, the absorbance was measured at
490 nm. All experiments were carried out on at least three separate occasions.
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X-ray structure of 105:
Solid state structure of 105 with atom labelling and disorder in the cyclohexyl ring
removed for clarity
Depiction of solid state structure of 105 with atom labelling showing the disorder in
the cyclohexyl ring.
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Graphs showing results of the LDH assay
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103 at Intermediate Concentrations
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